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 Selenocysteine (Sec), the 21st proteogenic amino acid, was first identified in 1976 
by Thressa Stadtman. In proteins, Sec replaces the far more common sulfur-containing 
amino acid cysteine (Cys). A key question since Stadtman’s discovery is: Why does Sec 
replace Cys? This question is especially relevant since Cys-orthologs of Sec-enzymes 
catalyze the identical reaction with only slightly reduced efficiency, and incorporation of 
Sec into a protein is much more complicated and bioenergetically costly compared to Cys. 
The study of selenoproteins is very difficult because Sec is incorporated into proteins by 
recoding a UGA stop codon as a sense codon. Production of recombinant selenoproteins 
involves reconstituting the recoding machinery. Alternatively, selenoproteins can be 
produced using a combination of recombinant DNA technology and peptide synthesis. 
While the development of solid phase peptide synthesis has provided a synthetic route for 
studying Sec, the Sec side chain requires the use of sturdy protecting groups (PGs) during 
synthesis. 
 
Work herein first addresses complications associated with Sec and Cys PGs, which 
until now have required harsh conditions for removal. My work has developed facile new 
methods for the deprotection of Sec and Cys residues. For Sec, we found that the use of 
DTNP to remove various PGs with subsequent ascorbolysis results in a Sec-selenol. 
Likewise, we developed 2,2’-dipyridyl diselenide (PySeSePy) to deprotect Cys, which can 
be used with subsequent ascorbolysis to provide a Cys-thiol. Notably, we found the 
ascorbolysis step to be chemoselective; ascorbate can reduce a selenosulfide bond, but not 
a formed disulfide bond. We harnessed this chemoselectivity for the synthesis of peptides 
that contain multiple disulfide bonds, which we demonstrate by synthesizing guanylin and 
tachyplesin-1 using PySeSePy as a chemical tool. 
 
Another chemical tool that we utilize to explore selenoprotein chemistry is alpha-
methyl selenocysteine (αMe)Sec. This unique amino acid has a methyl group in place of 
its α-H. We found that a peptide containing (αMe)Sec (compared to a Sec-peptide control), 
showed enhanced stability when incubated in oxygenated buffer for prolonged periods of 
time. We also utilized our (αMe)Sec-peptide as a glutathione peroxidase mimic to reduce 
peroxides, and postulate that this peptide could serve as a therapeutic in times of high 
oxidative stress.  
 
Finally, it is now commonly accepted in the field that selenoproteins evolved to 
resist oxidative stress. Herein, we expand this hypothesis: Sec replaces Cys in proteins to 
resist all types of electrophilic stress. We found that when Sec residues are alkylated by 
reactive biological electrophiles (such as acrolein), the formed adduct can be reversed. 
There are many potential mechanisms of reversal, but we provide evidence supporting a 
selenoxide elimination mechanism using a mutant form of thioredoxin reductase that 
contains (αMe)Sec in place of the native Sec residue at the C-terminal active site. Taken 
together, the works described in this dissertation expand the chemical toolbox for the study 
of Se-containing biomolecules and provides new hypotheses for the chemical role of Se in 
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CHAPTER 1: INTRODUCTION TO SELENOCYSTEINE AND CYSTEINE IN 
PEPTIDES AND PROTEINS 
 
1.1 The chemistry of selenocysteine and cysteine 
Cysteine (Cys) and selenocysteine (Sec) are proteogenic amino acids (AAs) whose 
side chains contain sulfur and selenium, respectively. On the periodic table, sulfur (S) and 
selenium (Se) are both group 16 elements and they have very similar physical and chemical 
properties, but there are also significant differences. Therefore, Cys and Sec have very 
similar physical and chemical properties as well. Despite this, the way in which the two 
AAs are incorporated into proteins is significantly different, which is described in detail in 
Section 1.2. As a consequence, there is a large difference in the frequency in which Cys 
vs. Sec residues are found in the human proteome; there exists only 35 Sec residues 
distributed among 25 proteins compared to ~214,000 Cys residues which are widely 
distributed among proteins1, 2. Below is a discussion of the chemical ways in which Cys 
and Sec are similar and different, and how these properties might explain what biochemical 
advantages Sec has over Cys.  
 
1.1.1 Similarities between sulfur and selenium 
Perhaps the most important similarity that allows Sec to replace Cys in some 
proteins is that the AAs have nearly identical structures, as displayed in Figure 1.1. 
Additionally, both the sulfur and selenium atoms in the side chains of Cys and Sec can 
adopt a large range of oxidation states (-2 to +6) which allows both AAs to adopt a plethora 
of chemically unique forms and functional group types3. In proteins, Cys and Sec are 
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subjected to alkylation by electrophiles and oxidation by reactive oxygen and nitrogen 
species, leading to post translationally modified forms of these unique AAs that can exhibit 
significantly altered biochemical functions4. 
 
Figure 1.1: Structures of Cys and Sec 
AAs. The pKa of the side chain thiol 
and selenol moieties are displayed. For 
Cys and Sec, and many sulfur and 
selenium compounds, the substantially 
lower basicity of the selenolate versus 






1.1.2 Differences between sulfur and selenium 
As displayed in Figure 1.1, Sec has a much lower pKa than Cys and is deprotonated 
(in the reactive selenolate form) at physiological pH while Cys is largely protonated (in the 
thiol form). Additionally, Sec has a much lower redox potential than Cys. When they form 
hypervalent compounds, S-X bonds are weaker than Se-X bonds, and this ability to tolerate 
hypervalency contributes to Sec being a better electrophile than Cys5. For example, when 
nucleophiles attack the Se or S atom in an SN2 reaction, a hypervalent intermediate forms 
before reaching the desired product. The hypervalent Se transition state would be more 
stable than the hypervalent S transition state5. Similarly, the Se radical is more stable than 
the S radical6.  In 2014, Koppenol and co-workers showed that when a thiyl radical is 
formed in a peptide, Cα−H abstraction is greatly favored, while the same reaction of a 
selanyl radical is slow5, 6. This has very important implications in protein chemistry as the 




Perhaps the most important difference between Sec and Cys is the larger size of the 
side chain Se atom of Sec (115 ppm) compared to the side chain S atom of Cys (100 ppm)5. 
As a result of their size difference, selenium is much “softer” and more polarizable than 
sulfur. The increased polarizability of the Se atom makes it both a better nucleophile and a 
better electrophile than sulfur. The larger size of Se also means that the Se-X bond (where 
X is carbon, oxygen, or hydrogen) is longer and therefore, weaker than the S-X bond. The 
increased lability of the Se-X bond is very important for much of the work in this 
dissertation; it might explain the ability of Sec-proteins to reverse oxidative and 
electrophilic modifications while Cys-proteins cannot. The ability of Sec-proteins to 
reverse post-translational modifications, and the biological consequences of this, are 
discussed in greater detail in Chapter 4. 
 
1.2 The role of selenium in proteins 
Selenium, a rare chemical element, was discovered in 1817 by Jöns Jacob Berzelius 
and received its name based on: Σεληνή, “moon” (goddess)5. Like the moon, selenium (Se) 
has two faces since it is both toxic to all organisms and essential to many bacteria and 
animal species5. Se is also two-faced in its chemical reactivity since it is both a strong 
nucleophile and potent electrophile. In the past ~80 years, scientists have discovered that 
Se has replaced S in several biological molecules.  
Selenium was first discovered as a nutritional factor in prokaryotes in 1954, then 
eukaryotes in 1957, and selenocysteine was ultimately identified as the organoselenium 
moiety present in proteins in 1976 by Stadtman and coworkers8, 9. 10 years later, it was 
reported that genes to express Sec-proteins contain in-frame TGA termination codons, 
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which allowed researchers to name Sec the 21st proteogenic amino acid9. Since this 
discovery, the role of Sec in proteins has been debated. 
At the foundation of this debate lies the costly process for incorporating Sec into 
proteins, which is described in detail in previous publications9, 10. Briefly, Sec is encoded 
by UGA, which is typically a stop codon. UGA must be recoded as a sense codon for Sec 
incorporation into proteins, and this recoding process requires numerous accessory proteins 
and a special structural element in the 3′-untranslated region of the mRNA. For the cell to 
provide the complicated apparatus for UGA recoding, one can assume it would require 
considerably more energy to insert Sec into a protein compared to Cys, which requires ~25 
mol ATP per residue5. Further complicating Sec incorporation is the geological distribution 
of selenium in the Earth’s crust which is largely uneven; there are selenium deficient areas 
in China, New Zealand, and Finland, meaning mammals there would have poor access to 
the essential nutrient. Additionally, sulfur is much more abundant relative to selenium. This 
ratio is estimated to be as low as 6000:1175 and as high as 55,500:15. 
Considering the complications involved with Sec incorporation into proteins, the 
question of “why did nature chose selenium?” frequently arises when studying 
selenoproteins5. Often, there are Cys-orthologs of Sec-proteins that can catalyze the same 
reactions. Therefore, there must be a critical reason for Sec to replace Cys in some cases; 
Sec must confer a significant advantage to proteins to justify its incorporation. 
It was previously thought that Sec replaced Cys in selenoenzymes as a chemical 
necessity; that is, the reaction catalyzed by these enzymes would be much faster with 
selenium at the C-terminus active site than sulfur11. However, this was found to be incorrect 
when Kanzok and coworkers determined that the rate of E. coli Trx reduction by human 
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(Sec-containing) TrxR was only about ~3 fold higher than the rate of E. coli Trx reduction 
by Drosophila melanogaster (Cys-containing) TrxR12 (DmTrxR). The authors determined 
that “these data speak against the proposition that selenocysteine in the COOH-terminal 
Cys-X sequence of high Mr TrxRs is a chemical necessity.”
12 Thus, it can be concluded 
that the presence of Sec in mTrxR is not confined to a purely catalytic role. 
 
1.2.1 Selenoproteins resist oxidative inactivation 
One hypothesis, first proposed by Chaudiere in 199213 and strongly revived by the 
Hondal lab, is that Sec replaces Cys to resist oxidative stress14, 15. The ability of mammalian 
thioredoxin reductase (mTrxR)  to resist oxidative stress was strongly demonstrated by 
Snider and coworkers in 2013 who showed a direct comparison of the abilities of mTrxR 
and a Cys-ortholog (DmTrxR) to resist inactivation by oxidation from a variety of oxidants 
including H2O2, hydroxyl radical, peroxynitrite, hypochlorous acid, hypobromous acid, 
and hypothiocyanous acid. Their in vitro results showed that Sec-containing TrxR enzymes 
are far superior to Cys-orthologs in resisting inactivation by oxidation14.  
Additionally, in vivo evidence from Conrad and Coworkers provides strong support 
for Chaudiere’s hypothesis. Using mouse embryonic fibroblast cells, they found that cell 
lines that only expressed Cys-contaning GPX underwent peroxide induced ferroptosis, 
while wild type cells expressing Sec-GPX did not16. Conrad and coworkers also provided 
mechanistic support via mass spectrometric (MS) analysis; MS analysis showed that for 
the Cys-mutant GPX, the active site Cys residue was overoxidized to both the Cys-sulfinic 
and Cys-sulfonic acid forms16. In contrast, previous works showed that Sec-containing 
GPX avoids inactivation because the selenenic acid is protected from further oxidation by 
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rapid attack by a backbone amide nitrogen to form a cyclic selenenylamide17. The 
selenenylamide is then reduced by GSH to restore the active selenol form of Sec-GPX17. 
Further evidence supporting the hypothesis that Sec in proteins confers resistance 
to permanent oxidation is provided from numerous studies conducted using [NiFeSe]-
hydrogenases and selenosubtilisin. A thorough review of these important studies, which 
undoubtably advance and refine this hypothesis, is provided by Hondal and Maroney15.  
 
1.2.2 Selenoproteins resist electrophilic inactivation 
A new hypothesis that we explore in Chapter 4 expands upon the idea that Sec has 
evolved in enzymes to resist oxidative stress. Ground-state oxygen atoms, which are 
diradicals, behave as distinctly electrophilic reagents18. However, oxygen is not the only 
biological electrophile that Sec-enzymes encounter in vivo.  Indeed, there are many small 
molecule, biological electrophiles that have previously been shown to interact with Sec-
enzymes, including Sec-TrxRs. Due to their high reactivity, they can be considered 
biological reactive electrophilic species (RES), which in cells, react with intracellular 
nucleophilic substrates including DNA, lipids, and proteins. In proteins, Cys and Sec 
residues are the most nucleophilic, followed by His and Lys, and the N-terminal amine, 
making these sites targets for RES alkylation. 
It has been proven that selenoproteins can be alkylated by RES at the highly 
nucleophilic Sec residue, which causes a loss of enzyme function19-21. For example, in the 
case of mTrxR, the enzyme would no longer be able to reduce Trx, which would be 
detrimental to numerous cellular functions. However, there are many mechanisms, both 
enzymatic and chemical, by which the formed Sec-adduct could be reversed, which would 
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restore protein function. Though reversal of a formed Cys-RES adduct could also be 
possible, we predict Cys-RES reversal would be very slow by chemical mechanisms. 
Currently, we can find only two examples in the literature that suggest Cys-alkylation could 
be chemically reversible, though neither study uses proteins; both studies are completed 
using peptide models22 or polymer-supported thiols23. These studies are examined in 
greater detail in Chapter 4. 
Thus, Sec-enzymes would have an advantage over their Cys-orthologs in that they 
could readily restore activity after RES-alkylation by non-enzymatic mechanisms. In 
recent years, fragments of in vivo evidence in support of this hypothesis have emerged24-
26, however none tell the full story. Perhaps the strongest example comes from Randall and 
coworkers who showed that acrolein rapidly inactivates Sec-TrxR in human bronchiolar 
epithelial cells, but this activity can be recovered after 4-8 h by a mechanism depending on 
the presence of cellular glutathione and Trx. Their reported loss and subsequent recovery 
of Sec-TrxR activity corresponds with reversal of the formed protein–acrolein adduct.27 
However, there is no mechanistic or in vitro evidence provided in this study, and 
mechanisms for such reversal remain elusive. In this dissertation, we provide evidence of 
a selenoxide elimination mechanism for which Sec-RES Michael adducts can be reversed 
and propose that this one reason why nature chose selenium.  
 
1.3 Human selenoproteins 
There are currently 25 known human proteins, summarized in Table 1.1. Each 
selenoprotein contains one Sec residue except for iodothyronine deodinase 2 (which has 
two Sec residues), and selenoprotein P (which has 10 Sec residues).  
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Table 1.1: Human selenoproteome with abbreviations, Sec-location, size, and reported 
functions specified. Adapted from Labunskyy et al., 2014.28 Nomenclature for the TrxR 
family follows recommendations from Arnér, 2009.29 
 
Selenoprotein Abbrv. Sec location                   
(AA residue #) 
Size                                  
(# AA) 
Function 
15 kDa selenoprotein Sep15 93 162 Putative role in quality control of 
protein folding in the ER 
Glutathione peroxidase 1 GPX-1 47 201 Cytosolic glutathione 
peroxidase 
Glutathione peroxidase 2 GPX-2 40 190 Gastrointestinal glutathione 
peroxidase 
Glutathione peroxidase 3 GPX-3 73 226 Plasma glutathione peroxidase 
Glutathione peroxidase 4 GPX-4 73 197 Phospholipid hydroperoxide 
glutathione peroxidase 
Glutathione peroxidase 6 GPX-6 73 221 Olfactory glutathione 
peroxidase 
Iodothyronine deodinase 1 DIO1 126 249 Thyroid hormone-activating DIO 
Iodothyronine deodinase 2 DIO2 133, 266 273 Tissue-specific thyroid 
hormone-activating DIO 








SPS2 60 448 Involved in the synthesis of 
selenoproteins 
Selenoprotein H SelH 38 116 Unknown 
Selenoprotein I SelI 387 397 Unknown 
Selenoprotein K SelK 92 94 Putative role in quality control of 
protein folding in the ER 
Selenoprotein M SelM 48 145 Unknown 
Selenoprotein N SelN 428 556 Putative role in quality control of 
protein folding in the ER 
Selenoprotein O SelO 667 669 Unknown 
Selenoprotein P SelP 59, 300, 318, 330, 
345, 352, 367, 
369, 376, 378 
381 Se transport 
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Selenoprotein S SelS 188 189 Putative role in quality control of 
protein folding in the ER 
Selenoprotein T SelT 36 182 Unknown 
Selenoprotein V SelV 273 346 Unknown 
Selenoprotein W SelW 13 87 Unknown 
Thioredoxin reductase 1 TrxR-1 498 499 Reduction of cytosolic 
thioredoxin 
Thioredoxin reductase 2 TrxR-2 522 523 Mitochondrial-specific reduction 
of thioredoxin  
Thioredoxin reductase 3  TrxR-3, 
TGR 
655 656 Testis-specific reduction of 
thioredoxin and glutaredoxin 
 
The most well studied selenoproteins are the glutathione peroxidase (GPX) and 
TrxR families of enzymes. In this dissertation, the primary focus is TrxR-2, mitochondrial 
TrxR. Examination of each human selenoprotein is beyond the scope of this dissertation. 
However, Sections 1.3.1-1.3.2 discuss two popular selenoproteins that are the key to works 
described herein. 
 
1.3.1 Glutathione peroxidase 
Glutathione peroxidase (GPX) is a widespread protein superfamily of eight 
enzymes found in many organisms throughout all kingdoms of life30. Vertebrate GPX is an 
enzyme that catalyzes the reduction of H2O2, organohydroperoxides, and lipid 
hydroperoxides13, 31. Multiple forms of the enzyme contain the rare AA Sec30, 32. The GPX 
catalytic cycle proceeds by nucleophilic attack of the selenolate on to the peroxyl oxygen 
of the substrate resulting in  a selenenic acid intermediate, that is subsequently reduced 
back to the selenolate by two equivalents of glutathione (Figure 1.2). 32  
When concentrations of H2O2 are elevated, such as during reoxygenation after a 
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period of ischemia, GPX can become overwhelmed and does not reduce H2O2 fast enough 
to prevent reperfusion injury.33 Additionally, since it plays a major role in antioxidant 
defense, deficiencies in GPX have been linked to the pathogenesis of many diseases 
including diabetes, cancer, obesity, Alzheimer disease and Parkinson’s disease. Thus, it is 
desirable to design a small molecule GPX mimic that can serve a therapeutic function for 
situations of high oxidative stress, or for long term antioxidant defense.34 In Chapter 3, 
work regarding the design of novel GPX mimics is presented and discussed. 
 
 
Figure 1.2: Catalytic cycle of GPX. The selenol of Sec first reduces oxidants resulting in 
a selenenic acid intermediate, which is then reduced by one equivalent of GSH forming the 
GPX-Sec-glutathione adduct. A second equivalent of GSH regenerates the enzyme by 
restoring the reduced selenol, forming oxidized glutathione (GSSG) as a byproduct. GSSG 
is then reduced by glutathione reductase (GR) in the presence of NADPH. 
 
 
1.3.2 Thioredoxin reductase 
Thioredoxin reductase (TrxR) is a NADPH dependent pyridine nucleotide-
disulphide oxidoreductase whose canonical function is to reduce the small protein, 
thioredoxin (Trx)29. TrxR, NADPH, and Trx comprise the thioredoxin system which is a 
vital antioxidant system responsible for maintaining redox homeostasis in the cell by 
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providing essential reducing equivalents to a number of important cellular targets, as 




Figure 1.3: Thioredoxin system. Once Trx is reduced by TrxR, it goes on to provide 
reducing equivalents to numerous cellular substrates including (but not limited to): (i.) 
peroxiredoxins (Prx), a ubiquitous family of antioxidants that controls cytokine-induced 
peroxide levels and mediates signal transduction; (ii.) tumor protein 53 (p53), which 
regulates the cell cycle and hence functions as a tumor suppressor; (iii.) ribonucleotide 
reductase (RNR), which catalyzes the formation of deoxyribonucleotides from 
ribonucleotides, a process vital for DNA synthesis; and (iv.) methionine-sulfoxide 
reductase 1 (MsrB1), which reduces methionine (R)-sulfoxide back to methionine, 
ultimately repairing oxidized Met residues.35, 36  
 
After the discovery of TrxR in 1964 by Laurent and coworkers37, much work has 
been done to study this vital enzyme. There are two classes of TrxRs that differ by size and 
the number of redox centers present in the enzyme38. The lower molecular weight (Mr) 
TrxRs have two redox centers: a flavin adenine dinucleotide (FAD) and an N-terminal 
12 
 
disulfide redox center. Bacteria, plants, archaea, and most unicellular eukaryotes utilize 
this low Mr form of TrxR
38.  
In contrast, higher Mr TrxRs have three redox centers: a flavin adenine dinucleotide 
(FAD), an N-terminal disulfide redox center, and an additional C-terminal redox center38. 
This C-terminal redox center is highly conserved among species and contains one of three 
motifs, depending on the organism for which it is found. The three possible motifs are as 
follows: (i.) a disulfide redox center with sequence: Xaa-Cys
1-Cys2-Xaa, or (ii.) a 
selenosulfide redox center with sequence: Xaa-Cys-Sec-Xaa (Sec-TrxRs) or, (iii.) a disulfide 
redox center with the sequence: Gly-Cys1-Gly-Gly-Gly-Lys-Cys2-Gly38. 
There are three isoforms of mammalian TrxR (mTrxR, EC 1.8.1.9): (i.) mTrxR-1, 
the most common form of the enzyme, mainly cytosolic and found in most tissues; (ii.) 
mTrxR-2, a predominantly mitochondrial protein that is commonly expressed at lower 
levels than TrxR-1 in most tissues; and (iii.) mTrxR-3, also frequently known as TGR, is 
mainly expressed in testis (male germ cells)29. TGR is a TrxR-glutathione reductase hybrid 
enzyme that possesses an N-terminal glutaredoxin-domain in addition to a C-terminal Sec-
containing redox center39.  
Mammalian TrxRs are highly homologous to glutathione reductases (GRs) and 
lipoamide dehydrogenase (LipDH), and the overall fold of mTrxR resembles other 
homodimeric pyridine nucleotide disulphide oxidoreductases39. Human TrxR1 and 
glutathione reductase (GR) share a high active site residue similarity at the cofactor and 
substrate binding sites, as well as a similar reaction mechanism39. In Sec-mTrxRs, the 8 
membered selenosulfide ring acts as an internal substrate that receives electrons from the 
N-terminal disulfide once it is reduced by NADPH. In contrast, GR is essentially a 
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truncated form of mTrxR that do not contain the flexible C-terminal tail. Instead, GR 
reduces an external substrate, oxidized glutathione (GSSG)38. 
All higher Mr TrxRs function as head to tail homodimers, and each subunit contains 
a binding domain for FAD and NADPH, an interface domain, and a discrete active center38. 
Both subunits are absolutely required for normal catalysis during a single catalytic cycle 
due to the interactions between the C-term of one subunit with the N-term of the other29. 
The full catalytic mechanism of TrxR is given in Figure 1.4. 
The mTrxRs have a wide substrate scope that arises from the fact that substrates 
may be reduced both by the easily accessible C-terminal selenolthiol motif of the NADPH-
reduced enzyme, and some low-molecular weight substrates can also be reduced directly 
by the N-terminal redox center of the enzyme29. Lipoic acid, selenocystine, and Ellman’s 
reagent are examples of small molecule substrates that can be reduced directly by the N-
terminal redox active disulfide of mTrxRs40, 41. Trx contain two vicinal cysteines in a 
CXXC motif that are key to the ability of Trx to reduce other proteins. Upon reduction of 
other proteins, the vicinal Cys resdues of Trx are left in a disulfide that is subsequently 
reduced by mTrxR, returing Trx to its active form (Figure 1.4)29. 
Several Pfam domains (described by The European Bioinformatics Institute 
(EMBL-EBI)) present in mTrxR1 include: a pyridine nucleotide-disulphide oxidoreductase 
domain, pyridine nucleotide-disulphide oxidoreductase dimerisation domain, and 
nucleotide phosphate-binding region. Its substrate, thioredoxin, contains a glutaredoxin 
domain42, 43. CATH database classifies mTrxR1 as an “Alpha Beta” protein, with 3-
Layer(ββα) Sandwich architecture, and a FAD/NAD(P)-binding domain. It also contains 
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an enolase-like domain and is considered a member of the glutaredoxin homologous 
superfamily44, 45.  
 
 
Figure 1.4: Catalytic mechanism of high Mr Sec-TrxRs. (Top): First, exogenous 
NADPH donates a hydride to reduce a bound flavin. The reduced flavin next reduces the 
conserved N-terminal disulfide redox center. Once reduced, one of the Cys-thiols forms 
a charge transfer complex with the flavin, and the other Cys-thiol goes on to reduce the 
8-membered selenosulfide ring of the Cys-Sec dyad that is attached to the enzyme 
through a flexible peptide linker on the opposite subunit. (Bottom): Once the C-terminal 
selenosulfide is reduced, the Sec-selenol reduces the disulfide bond of Trx, forming a 
senosulfide bonded intermediate. This intermediate is then “resolved” by the C-term 
Cys, which is adjacent to Sec. This results in the formation of a rare 8-membered 
selenosulfide ring, which is often thought to be the resting state. 
 
Currently, there are no crystal structures of the flexible C-terminal redox center of 
mTrxR without substrate present. However, crystal structures of mTrxR1 bound to Trx 
have been solved (PDB: 3QFA and 3QFB). The first crystal structure of Type 1 mTrxR in 
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complex with its Trx substrate was solved by Karin Fritz-Wolf, et al. in 2011 and gave 
much information into structural details of the enzyme39. The N-terminally located redox 
active disulfide (Cys59-Cys64) is buried in the protein, whereas the second, C-terminally 
located redox active selenosulfide (Cys497-Sec498) is positioned on a flexible, highly 
accessible C-terminal tail of the other subunit39. Complex formation of mTrxR-1 with Trx 
involves the generation of an intermolecular disulfide bond between the catalytic residues 
Cys32 of Trx and Sec498 of mTrxR-1, which is stabilized by several other interactions, 
including hydrogen bonding, hydrophobic packing, and electrostatic interactions. All 
residues involved in forming the intermediate are highly conserved in mammals39. It is 
important to note in this crystal structure the penultimate Sec residues (one on each 
monomer) were mutated to Cys residues and the resolving Cys residue was mutated to 
alanine to keep Trx bound. 
Like other selenoproteins, the role of Sec in high Mr TrxRs is not fully understood. 
The hypotheses that selenoproteins can resist oxidative and electrophilic stress better than 
their Cys orthologs apply to Sec-TrxRs. In fact, Sec and Cys TrxRs have served as model 
enzymes for many of these studies7, 14, 15, 38. One hypothesis that is somewhat unique to 
Sec-TrxRs is that Sec accelerates thiol disulfide exchange reactions in enzymes, thus 
conferring a kinetic advantage38. This hypothesis is particularly well suited for Sec-TrxRs, 
which undergo three thiol disulfide exchange reactions involving selenium in a single 
catalytic cycle. Sec can accelerate thiol disulfide exchange reactions in three different 
ways. First, Sec can enhance the rate of the enzyme by being a better nucleophile than Cys 
(see Figure 1.5)38. This is a reasonable hypothesis considering the lower pKa of Sec (pKa 
~ 5.3) compared to Cys (pKa ~ 8.3); Sec would be deprotonated at a much lower pH 
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(especially at physiological pH), making it a reactive nucleophile5, 38, 46. Second, Sec is a 
better leaving group than Cys, and this accelerates the exchange reaction (see Figure 1.5). 
Because the acidity of a selenol is ~1000 times greater than a thiol, the selenol that results 
after the X-Se bond is broken will be significantly more stable than the corresponding thiol 
when an X-S bond is broken, which makes selenols superior leaving groups38. Third, Sec 
is a better electrophile than Cys and this greater electrophilicity accelerates the reaction 
(see Figure 1.5)38. The Hondal research group has provided much evidence supporting the 







Figure 1.5: Selenium replaces sulfur in enzymes that utilize thiol/disulfide exchange 
reactions. Adapted from Hondal, et al., 201138. This reaction can be accelerated by 
selenium in three different ways. (A) Since Se is a better nucleophile than S, nucleophilic 
attack is faster. (B) Thiol/disulfide exchange can also be accelerated by the center atom 
(Xc) being a good electrophile. (C) Last, the reaction is also sensitive to leaving group 
ability, which is largely determined by the pKa of XLg. While Se accelerates 
thiol/disulfide exchange reactions by all of the ways shown above, it accelerates the 
reaction up 104-fold faster by being a better electrophile.  
 
Because mTrxRs depend heavily on Sec to reduce Trx, disorders arise when the 
Sec residue is compromised. Sec can be bound by naturally or chemically occurring 
compounds rendering Sec-TrxRs inactive, leading to inactive Trx, and multiple diseases. 
Some natural compounds that inhibit mTrxR include: curcumin and curcumin analogs, 
quinones, flavonoids, 4-HNE (4-hydroxy-2-nonenal) and other endogenous lipid 
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electrophiles, and mercury, gold,  and other metal ions29. This topic is discussed in further 
detail in Chapter 4. 
 
1.4 Methods to obtain selenoproteins for study 
Currently, there are several unanswered questions surrounding many aspects of 
selenoproteins. The largest barrier in studying mammalian selenoproteins is that it is very 
difficult to obtain them in high yield and purity using traditional recombinant protein 
expression techniques. We currently have only snapshots of individual players that are 
involved in determining the mRNA stability and translational efficiency of each 
selenoprotein mRNA. We also have only vague notions about how they assemble on each 
mRNA inside the cell to allow regulated selenoprotein mRNA maturation and 
selenoprotein synthesis48. The lack of knowledge in this area makes it nearly impossible to 
replicate the necessary cellular machinery. Further complicating the matter, it is evident 
that selenoproteins have evolved their own unique mRNA features that fine-tune 
expression in various in vivo conditions, making it hard to express selenoproteins 
originating from one species in a separate vector48. Recombinant protein expression and 
purification in E. coli is the most common method used by biochemists to obtain usable 
quantities of proteins of interest since E. coli is relatively inexpensive, robust, and 
reproduces quickly. However, as eluded to above, there are many challenges associated 
with recombinant eukaryotic selenoprotein expression in E.coli. 
One challenge lies in the fact that the SECIS binding mRNA structural loop of E. 
coli is significantly different in both sequence and location compared to the archaeal or 
eukaryotic elements48, 49. SECIS elements are critical as Sec incorporation depends on 
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RNA-binding proteins that bind to them. These variations between species’ SECIS 
elements, and their associated RNA-binding proteins are problematic and typically result 
in unwanted AA changes when archaeal or eukaryotic selenoproteins are expressed in E. 
coli.49 Therefore, the natural Sec incorporation machinery of E. coli cannot be exploited 
without manipulation to produce selenoproteins. This is described in detail in a recent 
review by Fu and coworkers49.  
To circumvent the above described problems, efforts have been made towards 
engineering components of the insertion machinery to be more suitable in E. coli systems49. 
For example, a few studies have engineered the E. coli tRNASec or tRNASec and elongation 
factor Tu (ET-Tu) together, allowing the resultant tRNASec to be recognized by EF-Tu 
directly50-52. While this approach is mostly successful, it still relies on conversion of Ser to 
Sec on the engineered tRNASec. Since the tRNASec is a mutant engineered component, the 
conversion efficiency is decreased, ultimately resulting in misincorporation of Ser instead 
of the desired Sec50-52.  
Another method that has been explored, which involves expansion of the genetic 
code using an orthogonal tRNA/synthetase pair, has the potential to site-specifically 
incorporate Sec while completely avoiding Sec-dedicated incorporation components52-55. 
One example from Rakauskaite and coworkers utilizes an orthogonal tRNALeu/CmnRS pair 
to incorporate a photocaged Sec analog into a protein in yeast.55 The photocaged Sec analog 
was then converted into Sec through photolysis. However, photolysis to generate Sec 
resulted in an unwanted >15% conversion of Sec to dehydroalanine (DHA)56. To date, 
there have been no native selenoproteins prepared with the photocaged analog approach52. 
A second example in which genetic code expansion was exploited comes from Liu and 
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coworkers who evolved an orthogonal tRNAPyl/ASecRS pair to genetically incorporate a 
Sec analog with a small allyl protecting group in E. coli, which reportedly does not rely on 
any Sec-dedicated incorporation components. Following incorporation, the allyl protected 
Sec was deprotected using a facile palladium-mediated cleavage under mild biocompatible 




Figure 1.6 (adapted from 
Eckenroth et al.57): Cleavage of 
mTrxR-intein fusion construct by 
addition of tripeptide and thiol. 
Previous work from our group 
constructed a fusion protein that 
consists of mouse thioredoxin 
reductase-2 (mTrxR-2, pink sphere), 
intein, and a chitin binding domain 
peptide (CBD). The CBD binds 
tightly to chitin-agarose resin (grey 
sphere), and this affinity is used for 
purification of the fusion protein. 
The fusion protein was made such 
that glycine 487 of mTrxR-2 is the 
AA at the junction between mTrxR-
2 and the intein (blue sphere) 
through a thioester linkage. Addition 
of a cleavage buffer containing thiol 
and H-CUG-OH (which are the final 
three AAs in the protein sequence) 
initiates an N → S acyl transfer, with 
subsequent cleavage of full length 
mTrxR-CUG from the column. 
 
 One general problem with this type of method is that the Sec analogs 
utilized are noticeably bulkier than native Sec, and may not fit well in buried Sec sites in 
native selenoproteins, which may interfere with protein folding52. Additionally, genetic 
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code expansion is complicated; it involves sophisticated microbiology and biological 
engineering techniques which are simply not accessible for many laboratories.  
Protein semi-synthesis, championed by the Raines group in 2002, has allowed 
biochemists to obtain eukaryotic selenoproteins in high yields and purity58. Protein semi-
synthesis, defined as the assembly of a protein from a combination of synthetic and 
recombinant fragments—is an expanding field of chemical biology that has impacted many 
areas in the life sciences59. Using synthesis as the primary method works particularly well 
for relatively small selenoproteins (up to 200 AAs) and can yield homogenous product in 
milligram quantities49. Recently, Dery and coworkers reported the first total chemical 
synthesis of human selenoproteins M and W60.  
Expressed protein ligation works particularly well for Sec-containing mTrxRs. In 
mTrxR, Sec is the penultimate residue of the AA sequence and it is adjacent to a Cys 
residue, which can undergo native chemical ligation with the expressed portion of the 
enzyme, as depicted in Figure 1.6. Here, only the short peptide H-Cys-Sec-Gly-OH, which 
corresponds to the C-terminus of the enzyme, needs to be synthesized using solid phase 
peptide synthesis (SPPS) while a majority of the protein (487 residues) can be expressed 
and purified in E. coli. Our research group has used this method to make mTrxR-CUG 
(wild type), along with a myriad of mTrxR mutants where the C-terminal synthetic peptide 
is mutated with both natural and non-natural AAs to enable detailed mechanistic studies7, 




1.5 Solid phase peptide synthesis 
Solid phase peptide synthesis (SPPS), which is crucial for producing semi-synthetic 
enzymes (including selenoproteins), is a method for synthesizing peptides in high yield and 
purity that was first developed by Merrifield in 196363. Utilizing a solid support for 
synthesis enables high yield because unreacted reagents are easily washed away after each 
synthetic step without a need for column purification. Furthermore, introduction of 
coupling reagents and optimization of each synthetic step during SPPS has allowed nearly 
100% yield for each step which allows for peptides to be made in very high final yield 
despite the many steps required for synthesis.  
Briefly, the process for SPPS goes as follows. The C-terminus AA of the desired 
sequence is coupled directly to a solid support using Nα-protected AAs. Protecting group 
chemistry is explained in more detail in Section 1.5.1.  Next, any unreacted AA or coupling 
reagent is washed away from the solid support, followed by a deprotection step where the 
Nα-protecting group is removed. The next AA in the desired sequence is then activated at 
the carboxylic acid using a coupling reagent, and the Nα acts as a nucleophile to form an 
amide bond, resulting in a dipeptide on the resin. Any unreacted AA is washed away, and 
deprotection and coupling steps are repeated until the desired sequence has been achieved. 
The peptide is then cleaved from the resin using either acid (typically trifluoroacetic acid 
(TFA)), or saponification, depending on the resin/ Nα-protecting group strategy utilized. 
Thorough descriptions of the various resins, Nα-protecting groups, and coupling reagents 





1.5.1 Amino acid protecting groups 
SPPS relies heavily on AA protecting groups. As discussed in Section 1.2, a Nα-
protecting group is imperative to prevent self-coupling of an AA during coupling steps. 
Common Nα-protecting groups are acid-labile tert-Butyloxycarbonyl (Boc), and base-labile 
fluorenylmethoxycarbonyl (Fmoc).   
Additionally, AAs with reactive side chains must be protected during synthesis to 
avoid unwanted side reactions. A suitable protecting group should have the following  
characteristics: (i) it is easily introduced into the functional group; (ii) it is stable to a broad 
range of reaction conditions; and (iii) it is safely removed at the end of a synthetic process 
when the functional group requires manipulation. A fourth characteristic that is desirable 
but not always attainable is orthogonality. 
Cys and Sec chemistry is diverse and versatile due to the highly reactive thiol and 
selenol functional groups their respective side chains. Thus, Cys and Sec residues must 
remain protected during SPPS to prevent numerous side reactions. Common Cys protecting 
groups include trityl (Trt)68, acetamidomethyl (Acm)69, tert-butyl (But)70, benzyl (Bzl)71, 
and p-methoxybenzyl (Mob)72, 73. These PGs are displayed in Table 1.2. These same 
protecting groups exist for Sec, except for Trt which is too labile to be a suitable Sec 
protecting group.   
During Fmoc-SPPS, trifluoroacetic acid (TFA) is commonly used to cleave the 
peptide from resin, and Trt is removed from Cys residues during this step. Thus, peptides 
synthesized using Fmoc-Cys(Trt)-OH are left with reactive thiol functionality upon resin 
cleavage and Cys residues are not protected for future applications. In contrast, the Acm, 
But, Mob, and Bzl groups are difficult to remove and require harsh conditions. Mob, Bzl, 
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and But are typically removed by hydrofluoric acid and scavengers, or by mercuric 
trifluoroacetate74. Acm is typically removed by oxidative treatment with iodine, which 
often results in mixed disulfide bonds75. All the above-mentioned methods for protecting 
group removal are challenging and require use of toxic reagents. Thus, gentler methods of 
Sec and Cys protecting group removal is desirable.  
 
Table 1.2: Common Cys protecting groups and their reported conditions for removal. 
All the same protecting groups also exist for Sec and require similar deprotection condition. 
 
Protecting group p-Methoxybenzyl Acetamidomethyl Tert-butyl 






HF at 0 °C & 
scavengers; or 
triflic acid; or Hg (II) 
acetate in TFA. 
Iodine oxidation; or 
Hg (II) & silver 
triflate. 
HF at 20 °C; or 
triflic acid & 
scavengers; or Hg 
(II) acetate in TFA. 
 
We have developed new deprotection schemes for Cys and Sec residues using mild 
reagents such as triisopropylsilane (TIS), pyridyl diselenide, and ascorbate. Among other 
applications, this work has allowed us to synthesize the fully deprotected H-Cys-Sec-Gly-
OH tripeptide for use in protein semi-synthesis using biocompatible reagents. These works 





1.5.2 Applications of Sec- and Cys- containing peptides 
 Cys and Sec chemistry is intriguing and versatile due to the high reactivity of their 
side chains. The thiol (SH) of Cys and selenol (SeH) functionality of Sec are very 
susceptible to oxidation and can readily form stable dimers (disulfide or diselenide bonds), 
which play important roles in protein tertiary structure. Cys and Sec are also quite 
nucleophilic and react readily with electrophilic molecules to form a variety of thiol-linked 
derivatives (e.g. thioethers, thioesters, and thioacetals)76. Thus, Cys and Sec side chains are 
common sites for various biological coupling and conjugation reactions, including 
palmitoylation, isoprenylation, and thiol-disulfide exchange76.  
 The modification of AA residues in proteins are called post-translational 
modifications, which are essential for a myriad of essential processes including cell growth, 
repair and death, as well as modulation of macromolecular functions. The ability to mimic 
these processes outside of an in vivo environment allows researchers to mimic nature, 
explore biosynthetic pathways, manipulate and decipher natural protein function, and to 
attach affinity or fluorescent tags for imaging77. Cys and Sec provide reactive handles for 
chemical modifications in peptides that have the potential to advance the understanding of 
PTMs and their biological consequences. 
 Additionally, peptide chemists have exploited Cys chemistry for a variety of 
applications and biotechnologies. For example, Cys is also the site of “peptide stapling” 
which allows peptide chemists to make peptides of desired, cyclic structures bound by a 
staple. Stapled peptides have enhanced biophysical properties such as conformational and 
proteolytic stability, cellular uptake and elevated binding affinity, varying topology, and 
specificity for their biological targets78. Currently, there are limited methods available to 
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achieve stapled peptides, but promising Cys-based strategies have been recently developed 
thanks to facile access from Cys functionalized peptide precursors78.  
Importantly, many peptide therapeutics contain multiple disulfide bonds79. 
Disulfide bonds in peptides and proteins provide enhanced stability. There are many 
examples of bioactive, disulfide rich peptides and proteins such as the insulin 
superfamily80, 81, conotoxins82, 83, guanylin84, 85, designed peptide therapeutics79, apamin 
and analogs8,9, sarafatoxin10, cyclotides11,12, defensins13, elafin14, and atracotoxins15, 16, 
whose biological activity relies heavily on proper disulfide connectivity. Synthesis of these 
bioactive peptides and therapeutics relies upon methods for oxidative refolding or 
regioselective disulfide bond formation.17,18 Though many methods have been developed 
for regioselective disulfide bond formation, many of these methods suffer from a lack of 
orthogonality between pairs of protected cysteine (Cys) residues, efficiency, and high 
yields.19, 20 
The multiple disulfide bonds present in these peptides confer enhanced chemical, 
biophysical, and metabolic stability83, 86. Chemical synthesis of these peptides is essential 
as it provides a source of the peptide/protein that could not otherwise be obtained by other 
methods, and allows for investigation of their structure−activity relationships 86, 87. Though 
there are several established Cys protection and activation strategies, applying these in a 
chemoselective and orthogonal fashion to peptides containing multiple disulfide bonds 
remains a challenge86-88. Chapter 2 of this dissertation focuses on improving these 
strategies by developing highly specific methods for regioselective disulfide bond 




1.6 Conclusions and Introductory Remarks 
The biological role of selenium is intriguing. Selenoproteins, while energetically 
costly to synthesize, play very important physiological roles. One such example is 
thioredoxin reductase (TrxR), which is directly responsible for maintaining redox 
homeostasis in the cell. Though it is now widely accepted that higher molecular weight 
TrxRs have evolved to use selenium to resist oxidative inactivation, it is highly possible 
that the chemical role of Sec is much more expansive than currently realized.  
One aim of this work was to explore the role of selenium in mammalian TrxR 
(mTrxR), which we propose has evolved to resist inactivation from reactive electrophilic 
species such as acrolein. Along the way, we developed chemical tools to make the study 
of this selenoprotein, and others, more accessible. Specifically, we focused on improving 
methods for the chemical synthesis of peptides that contain Cys and Sec residues. One 
large barrier in working with Cys and Sec-containing peptides is that the chemical 
reactivity of their sidechains must be masked with sturdy protecting groups during 
synthesis. However, subsequent removal of these protecting groups has required use of 
harsh conditions that are not biocompatible for protein semi-synthesis without purification.  
Thus, we saw a great need to develop methods for Cys and Sec deprotection that 
are facile, non-toxic, and chemoselective. Herein, we describe three deprotection schemes 
that provide either free Sec-selenols/Cys-thiols, or peptide disulfide bonds when more than 
one Cys-residue is deprotected at the same time. We also describe a new chemoselective 
tool, 2,2’-dipyridyl diselenide, that works as a disulfide bond forming reagent in the 
synthesis of peptides that already have one disulfide bond formed.  
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Another tool to explore the role of selenium in proteins is alpha-methyl 
selenocysteine ((αMe)Sec) since this unique AA is resistant to β-syn elimination that 
results from either over-oxidation or RES alkylation of Sec. By incorporating (αMe)Sec 
into TrxR, we were able to conduct in vitro mechanistic studies in which interpretation of 
the data was unambiguous as a result. Additionally, we found that incorporation of 
(αMe)Sec into a peptide allowed the peptide to redox cycle and convert hydrogen peroxide 
to water. These redox properties make our (αMe)Sec-peptide a GPX mimic that has 
therapeutic potential.  
Finally, we envision that the chemical tools, methods, and concepts that we have 
developed herein will have applications and implications reaching far beyond protein 
chemistry, and the potential of this work is described. 
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CHAPTER 2: STRATEGIES FOR CYS AND SEC DEPROTECTION AND 
CHEMOSELECTIVE DISULFIDE BOND FORMATION 
 
2.0 OVERVIEW 
To overcome the challenges associated with Cys and Sec protecting group 
chemistry described in Section 1.5.1, the Hondal lab previously reported on a method for 
the facile removal of 4-methoxybenzyl (Mob) and acetamidomethyl (Acm) protecting 
groups from Cys and Sec using 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved in 
trifluoroacetic acid (TFA) (DTNP/TFA), with or without thioanisole. The use of this 
reaction mixture removes the protecting group and replaces it with a 2-thio(5-nitropyridyl) 
(5-Npys) group. This results in either a mixed selenosulfide bond or disulfide bond 
(depending on the use of Sec or Cys), which can subsequently be reduced by thiolysis. A 
major disadvantage of thiolysis is that excess thiol must be used to drive the reaction to 
completion and then removed before using the Cys- or Sec-containing peptide in further 
applications. Here, we report a further advancement of this method as we have found that 
ascorbate at pH 4.5 and 22 °C will reduce the Sec-selenosulfide to the selenol. Ascorbolysis 
of the mixed disulfide between Cys and 5-Npys is much less efficient but can be 
accomplished at higher concentrations of ascorbate at pH 7 and 37 °C with extended 
reaction times.  
To improve upon the methods for Cys deprotection, we decided to switch the 
position of sulfur and selenium in the selenosulfide bond to be reduced by ascorbolysis. 
This was accomplished by using 2,2´-dipyridyl diselenide (PySeSePy) in place of DTNP 
in the deprotection scheme for Cys peptides. Here, we show the utilization of PySeSePy as 
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a chemical tool for the removal of Cys-protecting groups and regioselective formation of 
disulfide bonds in peptides. We found that peptides containing either Cys(Mob) or 
Cys(Acm) groups treated with PySeSePy in TFA (with or without triisopropylsilane (TIS)) 
were converted to Cys-S–SePy adducts at 37 °C and various incubation times. This novel 
Cys-S–SePy adduct is able to be chemoselectively reduced by five-fold excess ascorbate 
at pH 4.5, a condition which should spare already installed peptide disulfide bonds from 
reduction.  
We applied our new chemistry to the iodine-free synthesis of the human intestinal 
hormone guanylin, which contains two disulfide bonds. While we originally envisioned 
using ascorbate to chemoselectively reduce one of the formed Cys-S–SePy adducts to 
catalyze disulfide bond formation, we found that when pairs of Cys(Acm) residues were 
treated with PySeSePy in TFA, the second disulfide bond formed spontaneously. 
Spontaneous formation of the second disulfide is most likely driven by the formation of 
the thermodynamically favored diselenide (PySeSePy) from the two Cys-S–SePy adducts.  
Notably, TIS was needed for complete deprotection of Cys(Acm) by PySeSePy. 
TIS, a hindered hydrosilane, has long been utilized as a cation scavenger for the removal 
of AA protecting groups during peptide synthesis. However, its ability to actively remove 
Cys-S-protecting groups by serving as a reductant has largely been mischaracterized by the 
peptide community. Here, we provide strong evidence that TIS can act as a reducing agent 
to facilitate the removal of acetamidomethyl (Acm), 4-methoxybenzyl (Mob), and tert-
butyl (But) protecting groups from cysteine (Cys) residues in the presence of trifluoroacetic 
acid (TFA) at 37 °C.  
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Unexpectedly, we found that TIS promoted disulfide formation in addition to aiding 
in the removal of the protecting group. We also tested other common scavengers under 
these reaction conditions and found that thioanisole and triethylsilane were similarly 
effective as TIS in enhancing deprotection and catalyzing disulfide formation. Our findings 
show that careful consideration should be given to the type of scavenger used when it is 
desirable to preserve the Cys-protecting group.  
In all, we present three new Sec and Cys deprotection schemes in this chapter: (i.) 
the ascorbolysis of Sec(5-Npys) adducts, (ii.) the conversion of Cys(Mob) or Cys(Acm) to 
Cys-S–SePy adducts with subsequent ascorbolysis, and (iii.) the reduction of Cys-S-
protecting groups by TIS. These schemes can be used to produce free Cys-thiols and Sec-
selenols in situ, or can be used for chemoselective disulfide bond formation. 
We envision that our improved deprotection methods will allow for in situ reactions 
with alkylating agents and electrophiles without the need for further purification, as well 
as a number of other applications. We have also developed a one-pot method for 
concomitant deprotection and disulfide bond formation of Cys(Acm) pairs in the presence 
of an existing disulfide bond.  This chemoselective reduction by ascorbate will undoubtedly 
find utility in numerous biotechnological applications. Finally, our results raise the 
possibility of using TIS in orthogonal deprotection strategies of Cys-protecting groups 
following peptide synthesis as TIS can be viewed as a potential deprotection agent instead 




2.1 Removal of the 5-Npys protecting group from Sec and Cys by ascorbolysis 
 The Hondal research group recently reported a method for the facile removal of 4-
methoxybenzyl (Mob) and acetamidomethyl (Acm) protecting groups from cysteine (Cys) 
and selenocysteine (Sec) using 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved in TFA 
(DTNP/TFA), with or without thioanisole as shown in Figure 2.189, 90. Prior to the 
development of this method, removal of these protecting groups required harsh conditions, 
as described in Chapter 165, 91. DTNP can be added to all standard cleavage cocktails that 
are used to cleave the peptide from the solid support in Fmoc solid-phase peptide synthesis 
(SPPS) with simultaneous removal of the protecting group from Cys or Sec. 
 
Figure 2.1: Deprotection of Sec-Se(protecting group) using DTNP in a 
TFA/thioanisole/H2O cleavage cocktail, followed by thiolysis. Deprotection of Cys(Mob) 
works similarly. Figure is adapted from Harris et al.89  
 
 However, one limitation of this method is that it requires the use of excess thiol in 
a subsequent step to remove the 5-Npys group from Sec or Cys. In both cases, but 
especially for Sec, a very large excess of thiol must be added in order to ensure that thiolysis 
results in production of a free Cys-thiol or free Sec-selenol. In many cases a mixture of free 
thiol/selenol and mixed disulfide/selenosulfide peptide results90. Another drawback of 




 We hypothesized that a modification to our earlier method could replace thiolysis 
of the mixed disulfide/selenosulfide bond in Figure 2.1 with ascorbolysis as shown in 
Figure 2.2. It is known that ascorbate will reduce reactive disulfide bonds such as DTNP 
and 5,5'-dithio-bis(2-nitrobenzoic acid (better known as DTNB), with a lesser ability to 
reduce cystine and disulfide bonds with similar reactivity92, 93. Ascorbate has also been 
used for the specific reduction of S-nitrosothiols in the biotin switch assay94, 95.  
 
Figure 2.2: Deprotection of Sec-Se(protecting group) using DTNP in a 
TFA/thioanisole/H2O cleavage cocktail, followed by ascorbolysis. 
 
 We envision that ascorbolysis will allow for in situ reactions with alkylating agents 
and electrophiles without the need for further purification, as well as a number of other 
applications. Another advantage of using ascorbate to reduce the selenosulfide in Figure 
2.2 is that excess ascorbate in solution helps quench dissolved oxygen in the sample, 
thereby keeping the selenol in a reduced form. Another area where we envision this 
ascorbate chemistry to be useful is in the synthesis of peptides or small proteins that have 






2.1.2 Results of Asc reduction 
 We first set out to test the ability of ascorbate to reduce Sec(5-Npys) and Cys(5-
Npys) by visual inspection since ascorbolysis of the peptides should liberate 5-Npys, which 
has an absorbance maximum at 412 nm, similar to thio-nitrobenzoic acid, and a yellow 
color produced is visible to the naked eye at sufficiently high concentration. We found that 
the reaction between ascorbate and Sec(5-Npys) at 22 °C is fast upon addition of ascorbate 
to Sec(5-Npys) at a pH of 4.5 as a color change from clear to bright yellow was observed 
almost immediately (within minutes of addition), as displayed in Figure 2.3. In contrast, 
we observed that the reaction between ascorbate and Cys(5-Npys) is slow, as a color 
change could only be observed after hours of reaction and most prominently when heated 
to 37 °C.  
 Initially, we tried to add ascorbic acid directly to the solution of peptide dissolved 
in the cleavage cocktail containing DTNP and TFA (plus scavengers), after allowing for 
sufficient reaction time for Sec(Mob) to be converted to Sec(5-Npys). Such a procedure 
would be advantageous because such “one-pot” procedures are highly desirable in peptide 
chemistry96-98. However, the results of this reaction showed that ascorbate could not 
deprotect the Sec(5-Npys) in TFA (pH ~2) and thus, ascorbolysis was performed in 
aqueous solution.  
 Next, we explored various reaction conditions for both Sec(5-Npys) and Cys(5-
Npys) in order to maximize the extent of deprotection. We chose a pH of 4.5 as a lower 
bound because it is just slightly above the pKa of ascorbic acid, 4.2
99. At this pH ascorbic 
acid will be 67% ionized and in the active enolate form. Our chosen reaction pH of 4.5 fits 
well with the findings of Dutton and coworkers who showed that the use of DTNP to 
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catalyze heterodisulfide formation was fastest at pH values between 3.5 and 6.5100. Pyridyl 
disulfides are more reactive at acidic pH101 due to protonation of the pyridine nitrogen 
atom, which in the case of both Sec(5-Npys) and Cys(5-Npys) greatly polarizes the mixed 
disulfide bond. This polarization of the mixed disulfide bond activates the disulfide bond 
towards thiol/disulfide exchange as well as reduction by ascorbate101. Thus, our chosen 
reaction pH of 4.5 is a balance between conversion of ascorbic acid to the reactive ascorbate 
(enolate) form, and the maximum effective range of DTNP reactivity.  
In order to determine whether ascorbate could convert Sec(5-Npys) to Sec-SeH, we 
incubated a Sec-containing test peptide (crude product without HPLC purification) with 5-
fold excess ascorbate at either pH 4.5 or pH 7.0 under various reaction conditions as 
summarized in Table 2.1. Ascorbolysis was monitored by HPLC and ESI-MS. We found 
that near complete deprotection occurred at pH 4.5 and 25 ºC after 4 hrs of reaction time 
(reaction Se1, Table 2.1). Our results show that pH 4.5 was slightly better than pH 7.0 for 
achieving deprotection, but deprotection was very similar under all of the conditions listed 
in Table 2.1.  
The percentage of deprotection was estimated by measuring the area under the peak 
in the HPLC chromatogram compared to the control. In Figure 2.4A we show the HPLC 
chromatogram of the Sec-peptide without addition of ascorbate (control), while the effect 
of addition of 5-fold excess ascorbate to the Sec-peptide is shown in Figure 2.4B. The 
identity of each peak was determined by ESI-MS analysis before and after treatment with 
ascorbate. The MS data is shown in Figure 2.4C and Figure 2.4D. We note that some of 
the 5-Npys group was removed during work up of the peptide by an undetermined 
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mechanism before the addition of ascorbate. These results show that ascorbate successfully 
removes the 5-Npys group from Sec under relatively mild conditions.  
Our initial experiments with the Cys-containing peptide using a ratio of ascorbate 
to peptide that ranged from 2:1 to 20:1 for 4 hrs at pH 4.5 and 25 °C (conditions analogous 
to those used for complete conversion of Sec(5-Npys) to Sec-SeH) did not result in 
conversion of Cys(5-Npys) to Cys-SH as determined by HPLC analysis (data not shown). 
In order to see if we could deprotect Cys(5-Npys) with ascorbate, we increased the ratio of 
ascorbate to Cys-peptide to 100:1. At this ratio of ascorbate to peptide we found that ~50% 
deprotection was achieved at pH 4.5 and 25 °C with a reaction time of 24 hrs (reaction S2, 
Table 2.1). We next tried to push the reaction to completion by raising the pH from 4.5 to 
7 (potassium phosphate buffer, reaction S6, Table 2.1), but the result was nearly an 
identical level of deprotection as determined by HPLC analysis. We then explored the 
effect of elevated temperature on the reaction and found that increasing the temperature 
from 25 °C to 37 °C at pH 7 with a reaction time of 24 hrs improved deprotection (reaction 
S8, Table 1). One difference at pH 7 compared to pH 4.5 was the appearance of the 
disulfide form of the peptide in the HPLC chromatogram (Figure 2.5A). Using these 
reaction conditions conversion of Cys(5-Npys) to Cys-SH increased to 70-75%, but the 
reaction is still slow as is evidenced by the extended reaction time, high concentration of 
ascorbate, elevated temperature, and incomplete removal of the 5-Npys group. Both HPLC 
and mass analysis show incomplete removal of the 5-Npys group from Cys under these 
conditions (Figures 2.5A and B).  
 Our results do indeed show that ascorbate was very efficient in converting Sec(5-
Npys) to Sec-SeH at acidic pH (Table 2.1). Increasing the reaction pH to 7 slightly 
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decreases the extent of conversion for Sec as might be expected based on our discussion 
above. However, the opposite pH reaction profile is observed for the conversion of Cys(5-
Npys) to Cys-SH. At pH 4.5, only about 50% conversion can be achieved, even when the 
temperature is increased from 22 °C to 37 °C (compare S2 to S4 in Table 2.1).  Increasing 
the reaction pH to 7 did increase the extent of conversion of Cys(5-Npys) to Cys-SH, but 
only after extended reaction time (24 hrs) and elevated temperature (37 °C). Thus the ideal 
deprotection of Cys(5-Npys) occurs with 100 molar excess ascorbate at pH 7, 37 °C, and 
after 24 hours of incubation (reaction S8 in Table 2.1). These conditions are significantly 
different than that for Sec(5-Npys) and this difference might be exploited for orthogonal 
deprotection conditions in the future. 
 
 
Scheme 2.1: Strategy for creating an interstrand selenosulfide bond between two 
peptide chains. Directed disulfide bond formation could occur (1), followed by 
conversion of Sec(Mob) to Sec(5-Npys) (2). Treatment with Asc would liberate the 
selenol, which could then be coupled to a Cys residue on a second peptide strand. 
 
 While we do not report further on the utility of this deprotection reaction here, we 
envision multiple applications of this chemistry, which are discussed in Section 2.5. One 
such application we explore in Section 2.2 is the creation of interchain disulfide, 
diselenide, or selenosulfide bonds as depicted in Scheme 2.1. Such a strategy would be 
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identical to the biotin-switch assay where a mild reductant is needed so as to avoid 
reduction of the intact disulfide bond94, 95, 102. 
 In conclusion, we have developed a gentle and highly effective method for 
conversion of Sec(5-Npys) to Sec-SeH. This chemistry also works for deprotection of 
Cys(5-Npys), but higher concentrations of ascorbate and longer reaction times are required. 
However, we wanted to further explore the adaption of these deprotection method for Cys 




2.2. PySeSePy: A chemoselective tool for cysteine deprotection and disulfide 
formation 
As discussed in Chapter 1, disulfide bonds in peptides are very important for 
structure, function, and bioactivity. Synthesis of these bioactive peptides and therapeutics 
relies upon methods for oxidative refolding or regioselective disulfide bond formation.17,18 
Though many methods have been developed for regioselective disulfide bond formation, 
many of these methods suffer from a lack of orthogonality between pairs of protected 
cysteine (Cys) residues, efficiency, and high yields.19, 20 
As has been reviewed extensively by Moroder using the Fmoc/But strategy of solid-
phase peptide synthesis (SPPS), pairs of S-trityl (S-Trt), S-methoxytrityl (S-Mmt), S-tert-
butylmercapto (S-SBut), or S-2,4,6-trimethoxyphenylthio (S-Tmp) must be used to install 
the first disulfide bond in regioselective strategies involving orthogonal pairs of Cys-
protecting groups103-105. In the case of Cys(Trt) or Cys(Mmt) pairs, both protecting groups 
can be removed by trifluoroacetic acid (TFA) used in the cleavage step from the solid 
support68, 106-108. In the case of Cys(SBut) or Cys(Tmp) pairs, thiol or phosphine reducing 
agents can be used for deprotection107, 108. In both cases, air-oxidation can then be used to 
install the first disulfide bond.  
Common reducing agents lack chemoselectivity and must be avoided after 
formation of the first disulfide bond. For example, if a Cys(SBut) pair is used to install the 
first disulfide bond, then a Cys(Tmp) pair cannot be used later because reducing agents are 
required to remove the Tmp protecting group and these reducing agents would also disrupt 
the pre-existing disulfide bond. 
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We realized that this limitation might be overcome using chemistry described in 
Section 2.1. We previously showed that the 5-Npys protecting group could be removed 
chemoselectively from Sec, but not Cys using ascorbate (Asc) in aqueous buffer at pH 4.5 
as shown in Figure 2.6109. Thus, reduction of a mixed aryl-selenosulfide bond by Asc is 
very facile, while the same reduction of a mixed aryl-disulfide bond by Asc is slow. 
 
Figure 2.6: Removal of the 5-Npys group from Cys or Sec by ascorbolysis. We 
previously found that Asc can reduce the Se–S bond of Sec(5-Npys) very easily, while 
the same reduction of the S–S bond of Cys(5-Npys) is very slow.27 
 
 This finding gave rise to the idea of developing a new selenium-containing 
deprotection reagent. Since 2,2'-dithiobis(5-nitropyridine) (DTNP) was used by our group 
previously for simultaneous deprotection/disulfide bond formation with a wide variety of 
Cys-protecting groups89, 90, 110, we reasoned that we may be able to use 2,2´-dipyridyl 
diselenide (PySeSePy) or a substituted derivative, as a deprotection reagent. Use of 
PySeSePy to remove Cys-protecting groups would result in a mixed aryl-selenosulfide 
bond that could subsequently be removed by Asc as shown in Figure 2.7. 
Asc is a chemoselective reductant because it has been reported that it does not 
reduce peptide/protein disulfide bonds, or does so very slowly at neutral pH (and more 
slowly at acidic pH)93, 111. As such it has been widely used in the so-called “biotin switch 




Figure 2.7: Proposed reduction of the S–Se bond of Cys(PySe) by Asc. We found 
that reduction of Sec-Se–SPy with Asc was fast.27 In order to gain the same 
chemoselective advantage with Cys residues, we “switched” the position of sulfur and 
selenium through the use of PySeSePy and derivatives so as to create a Cys-S–SePy 
adduct. 
 
We are aware of only two other reports of chemoselective reduction of disulfides 
in the literature. Both reports involve borohydride derivatives that can chemoselectively 
reduce aromatic disulfides preferentially over alkyl disulfides and are only compatible with 
organic solvents112, 113. Asc is gentle, highly soluble in aqueous buffer, and can 
chemoselectively reduce mixed aryl-selenosulfide bonds over typical disulfide bonds as 
illustrated in Figure 2.8. This is especially true at acidic pH (pH 4 to 5) where Asc is very 
effective at only reducing the Cys(PySe) adduct and not peptide disulfide bonds. At acidic 
pH, the pyridyl ring is protonated, activating the selenosulfide for attack. In addition, when 
pH = pKa = 4.21, half of the ascorbic acid in solution is present as the active enolate
109. 
Thus, we sought out to develop a method to deprotect Cys residues using 
PySeSePy, with concomitant conversion to the Cys(PySe) adduct. We reasoned that the 
resulting S–Se bond of the Cys(PySe) adduct should be easy to reduce using Asc 
(especially at low pH), giving a chemoselective advantage to regioselective disulfide bond 









Figure 2.8: Advantage of chemoselective reduction of Cys(PySe) adducts by Asc 
compared to conventional reducing agents. A) Conventional reducing agents such as 
thiols will reduce each S–S or S–Se bond as shown. B) Asc chemoseletively reduces the 
S–Se bond of Cys(PySe) adducts. Note that R represents a covalent modification of Cys 
that can be removed by typical reducing agents. 
 
 
2.2.1. Results and Discussion of PySeSePy deprotection scheme 
Synthesis of PySeSePy: PySeSePy is not commercially available. Thus, we began with the 
synthesis of PySeSePy by first reducing elemental selenium with sodium borohydride, then 
introducing 2-bromopyridine for a nucleophilic displacement reaction, using reported 
methodologies114. The synthesis was completed giving 49% yield. Mass spectral (MS) 
analysis, 77Se-NMR, and 1H-NMR spectrograms of PySeSePy are given as Figure 2.9 and 
Figure 2.10. 
 
Use of PySeSePy and ascorbate as a cysteine deprotection strategy. With PySeSePy in 
hand, we went on to test its effectiveness as a deprotection reagent to convert Cys(Mob) to 
Cys(PySe). While we tested a variety of deprotection conditions, we found that quantitative 
deprotection of Cys(Mob) occurs using 5-fold excess PySeSePy after 4 h at 37 °C in 
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TFA/water (98:2) as judged by the HPLC and MS analyses shown in Figure 2.11. A 
deprotection cocktail of TFA/TIS/water (96:2:2) for 4 h at 37 °C gave very similar results 
(data not shown). We note that in order for full deprotection of the Cys(Mob) peptide to be 
achieved, a reaction temperature at 37 °C is required. If the reaction is done at rt, 30% of 
the peptide remained protected as Cys(Mob) (data not shown). 
We then reduced the formed Cys(PySe) adduct with Asc. We found that the adduct 
could be reduced using 5-fold excess Asc in 100 mM ammonium acetate buffer, pH 4.5, 
after 4 h incubation at rt. The reduction of the Cys(PySe) adduct with Asc resulted in 
quantitative conversion to Cys-SH as shown in Figure 2.11C and 2.11F. Ascorbolysis of 
the S–Se bond may be achieved in a shorter time, but we did not test a shorter reaction 
condition. 
We next turned our attention to the deprotection of Cys(Acm), which is 
significantly more difficult to deprotect than Cys(Mob). Deprotection of Cys(Acm) is 
commonly achieved by the use of iodine under acidic conditions with measures taken to 
suppress disulfide rearrangement69, 115, 116. Our group showed that deprotection of 
Cys(Acm) could be achieved by using the gentle, electrophilic disulfide DTNP. However, 
the drawback to this method is that at least 20-fold excess DTNP and 2% thioanisole in 
TFA is required and deprotection was only achieved in 68% yield90.  
We hypothesized that the deprotection of Cys(Acm) using PySeSePy could be 
achieved using similar conditions that were used above for the deprotection of Cys(Mob). 
We tested many conditions and found partial deprotection (~55%) using 5-fold excess 
PySeSePy in neat TFA at 37 °C for 12 h as judged by HPLC (Figure 2.12A). Interestingly 
we found that ~95% deprotection occurs under the same conditions, but with the addition 
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of 2% TIS (Figure 2.12B)117. The MS analysis corresponding to Figure 2.12 is given as 
Figure 2.13. Our observation that TIS is required for deprotection is discussed in further 
detail in Section 2.3. 
These findings agree very well with our prior results in which we showed that 
addition of TIS to deprotection cocktails greatly enhances the removal of Mob and Acm 
groups from Cys118. We found that TIS can directly reduce Cys(Acm) to Cys-SH in TFA 
at 37 °C  for 12 h,118 and this finding proved to be important in developing the deprotection 
of Cys(Acm) by PySeSePy. TIS likely facilitates the deprotection of Cys(Acm) by 
PySeSePy by two different pathways. First, Cys(Acm) is partially deprotected by TIS to 
the free thiol which can then act as a nucleophile attacking the diselenide. Second, the 
protected S-atom of Cys(Acm) attacks the soft diselenide of PySeSePy in similar way as 
S-protected derivatives attack the soft disulfide bond of DTNP, resulting in deprotection89.  
As before, we found that addition of Asc resulted in removal of the PySe-adduct 
(Figure 2.12D). The ability of the Cys(PySe) to be easily reduced by ascorbate, resulting 
in a free thiol, will undoubtedly find utility in numerous applications including 
regioselective disulfide bond formation. 
 Because PySeSePy required slight heat (37 °C versus rt) in order for deprotection 
of both Cys(Mob) and Cys(Acm) to be complete, we decided to revisit the use of DTNP 
for the deprotection of Cys(Acm), as full deprotection was not achieved at ambient 
temperatures90. We found that we were able to effect full deprotection of Cys(Acm) with a 
cocktail of 5 equivalents of DTNP dissolved in TFA/thioanisole (98:2) at 37 °C with a 12 
h incubation time as shown by the HPLC analysis in Figure 2.14A and 2.14B, and the MS 
analysis in Figure 2.15. While the addition of TIS to the deprotection cocktail containing 
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PySeSePy greatly enhanced the removal of Acm as shown by the results in Figure 2.12, 
addition of TIS to the cocktail containing DTNP resulted in breakdown of the Cys(5-Npys) 
adduct and the appearance of other unidentified products as shown by the HPLC 
chromatogram in Figure 2.14C. The breakdown of the Cys(5-Npys) adduct is most likely 
caused by reduction of this reactive disulfide bond by TIS. The identity of one of the side-
products could be a TIS-(5-Npys) adduct. We note that we attempted to deprotect Cys(But), 
another popular S-protecting group, with PySeSePy, but we found the reaction to be 
ineffective. In our hands, we could only achieve less than 30% deprotection under the same 
conditions used to deprotect Cys(Acm). 
 
Comparison of PySeSePy with DTNP as a deprotection reagent. Compared to DTNP, 
PySeSePy was not as effective as converting Cys(Mob) or Cys(Acm) to the corresponding 
pyridyl-adduct. For example, when our Cys(Mob)-containing peptide was treated with 5-
fold excess PySeSePy for 4 h at rt in (96:2:2) TFA:TIS:water, about 45% of Cys(Mob) 
remained (Figure 2.16). In contrast, nearly quantitative conversion of Cys(Mob) to Cys(5-
Npys) was achieved when using 5-fold excess DTNP under the same conditions (Figure 
2.17). Similarly, PySeSePy was less effective at deprotecting Cys(Acm), which can be 
realized by directly comparing Figure 2.14B and 2.16B. Using similar conditions, 5%-
10% of Cys(Acm) remained when using PySeSePy compared to when using DTNP in the 
deprotection cocktail. 
There are two reasons for PySeSePy being less effective as a deprotection reagent 
compared to DTNP. First, the disulfide bond of DTNP is more electrophilic (“softer”) due 
to the presence of the p-nitro group on the aromatic ring. The p-nitro group polarizes the 
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disulfide bond making it more reactive. Though we attempted synthesizing the p-nitro 
derivative of PySeSePy to increase its reactivity, attempts to obtain the compound in high 
yield and purity were unsuccessful. The second reason is that the redox potential of 
PySeSePy is much lower compared to DTNP, which means that diselenide bond formation 
is more favored compared to mixed disulfide bond formation119. However, the advantage 
that PySeSePy has is that the mixed Cys-S–SePy adduct that is formed as a result of the 
deprotection reaction can be reduced by ascorbate in a chemoselective fashion, whereas 
the mixed Cys-S–S(5-Npys) adduct cannot. 
 
Synthesis of guanylin using the PySeSePy/ascorbate strategy. Having showed that 
PySeSePy in combination with reduction by Asc was an effective method for removal of 
S-Mob and S-Acm protecting groups and resulting PySe-adduct, we next set out to 
demonstrate that this method could be used as part of an overall strategy for regioselective 
disulfide bond formation in a bioactive peptide containing multiple disulfide bonds. We 
chose the human intestinal peptide guanylin as our target. 
Guanylin is a human hormone that regulates electrolyte and water transport in 
intestinal and renal epithelia84, 85. Guanylin is a 15-AA polypeptide that has two disulfide 
bonds. One between Cys4 and Cys12, and the second disulfide is between Cys7 and Cys15. 
Previously reported syntheses of guanylin utilized the Trt-group to protect Cys4 and Cys12, 
and Acm to protect Cys7 and Cys1585, 120 The first step of the synthesis utilized TFA to 
remove S-Trt groups, followed by air oxidation to form the first disulfide bond. Next, 
iodine oxidation was used to remove S-Acm from the second set of Cys residues, forming 
the second disulfide85, 120. However, iodine oxidation is cumbersome; the peptide must be 
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dissolved in deoxygenated acetic acid/hydrochloric acid (4:1), resulting in a solution of pH 
2, then incubated with 10-20 equivalents of iodine85. Excess iodine is then reduced with 
sodium thiosulfate (or other quenching reagents such as activated charcoal or powdered 
zinc dust), and the peptide must be purified via HPLC85, 116. Such purification is necessary 
as iodine oxidation can result in disulfide bond scrambling116, 121, which leads to low yields 
of the desired peptide with correct disulfide pairing. Iodine oxidation can also modify 
oxidation-sensitive residues, such as methionine, tryptophan, and tyrosine75, 122-124. Rapid 
quenching of excess iodine after completion of the desired oxidation reaction can help to 
minimize the unwanted modification of Met, Trp, and Tyr116, 125. However, these 
quenching reactions can result in undesired side products such as the formation of a 
peptide-thiosulfate adduct when sodium thiosulfate is used as the quenching reagent126. 
Zhang and coworkers provide a detailed account of the cumbersome nature of working 
with iodine, and provide an alternative purification using ether precipitation116. 
To improve the synthesis of guanylin without using iodine, we also synthesized 
guanylin with Cys4 and Cys12 with S-Trt protecting groups, and Cys7 and Cys15 with S-
Acm protecting groups. During cleavage from the resin, both Trt protected Cys residues 
were converted to Cys-SH, and subsequent air oxidation provided the first disulfide bond 
(Figure 2.18A and 2.18B).  
Our next step replaces the use of iodine with PySeSePy. We envisioned that we 
would form the second disulfide bond by first forming the Cys-S–Se-Py adduct, followed 
by addition of Asc to catalyze formation of the second disulfide without reduction of the 
first formed disulfide. However, we found that ascorbate reduction of the Cys-S–Se-Py 





Figure 2.20: Possible mechanisms for 2,2´-dipyridyl diselenide-mediated disulfide 
formation. (A) Cys(PySe) adducts results after Acm removal with PySeSePy. Asc is a 
one-electron reducing agent53 that can reduce the Cys-S–SePy adduct, resulting in a Cys-
thiolate and a PySe• radical. The ejected PySe• radical can then combine with another 
PySe• radical, reforming PySeSePy. The Cys-thiolate then undergoes SN2 attack onto 
the remaining Cys-S–SePy adduct to install the second disulfide bond. (B) An alternate 
mechanism has the PySe• radical formed after the reaction with Asc undergoing a SRN2 
reaction54 with the remaining Cys-S–SePy adduct forming PySeSePy and a Cys-S• 
radical. The Cys-S• radical then can undergo a rapid radical recombination to form the 
second disulfide bond. (C) Experimentally, we found that disulfide bond formation was 
independent of the addition of Asc. In the partially folded intermediate, the two 
Cys(PySe) adducts are close together in 3D-space. We postulate that PySeSePy 
spontaneously forms as shown due to the low redox potential of the resulting 





Instead, we found that when incubating guanylin with 1 equivalent of PySeSePy in 
98:2 TFA:TIS for 8 h at 37 °C, the second disulfide bond formed spontaneously (Figure 
2.18C). The MS analysis confirms the correct mass for each step of the synthesis (Figure 
2.19). In this case, the propensity of PySeSePy to exist as the diselenide works in favor of 
disulfide bond formation. One can imagine that the two Cys-S–SePy adducts are close 
together in 3D-space in the partially folded peptide and that the two Se atoms 
spontaneously form a diselenide bridge with concomitant formation of the disulfide. This 
point is illustrated in Figure 2.20. 
We confirmed the correct disulfide connectivity by HPLC (Figure 2.18C and 
2.18D) by comparing our HPLC trace to that of commercially available guanylin. The 
peaks labelled in Figure 2.18 are confirmed by MS analysis (Figure 2.19). Notably, there 
is a one-minute change in retention time between guanylin with only one disulfide bond 
formed (Figure 2.18B), and native guanylin with two disulfide bonds (Figure 2.18C and 
2.18D). Thus, synthesis of guanylin was completed using orthogonal S-Trt and S-Acm 
groups, and PySeSePy to catalyze the formation of the second disulfide bond. 
 
Synthesis of Tachyplesin-1 using the PySeSePy/ascorbate strategy.  
Tachyplesin-1 is a 17-AA antimicrobial peptide (AMP) extracted from the 
hemocytes of the horseshoe crab, Tachypleus tridentatus127, 128. Tachyplesin-1 is a broad-
spectrum AMP as it has exhibited potent activity against Gram-positive and Gram-negative 
bacteria, as well as fungi129. It works as an AMP via a membranolytic mechanism of action 
that did not induce resistance in short-term studies. However, tachyplesin-1 did show signs 
of decreased susceptibility under long-term continuous selection conditions and has been 
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shown to compromise the integrity of both the outer and cytoplasmic cell membranes of E. 
coli130. Tachyplesin-1 was also found to be unsuitable for therapeutic development when 
it displayed high levels of toxicity toward mammalian cells. This, unfortunately, is a 
common detrimental characteristic of many AMPs128. 
For therapeutic development, there is a great desire to obtain tachyplesin-1, and 
other AMPs synthetically. A facile synthetic route to obtain AMPs would allow for studies 
where AA replacements could be used to analyze and optimize antimicrobial activity, 
cytotoxicity, membrane binding affinity, hemolytic activity, and other important AMP 
properties128. Currently, one major hurdle in synthesizing tachyplesin-1, and other AMPs, 
is the presence of multiple disulfide bonds79. We predicted that our PySeSePy deprotection 
scheme would allow for facile synthesis of tachyplesin-1, as it did for guanylin. 
First, tachyplesin-1 was synthesized using Fmoc-based SPPS63, 66 and orthogonal 
Cys protection103-105. Notably, the carboxyl-terminal end of Tachyplesin-1 contains an 
arginine α-amide127. To achieve this C-term amide functionality, Rink Amide AM resin 
(100-200 mesh, Novabiochem®) was used for SPPS. Tachyplesin also contains two 
disulfide bonds: one between Cys3 & Cys16, and one between Cys7 & Cys12127. To ensure 
correct disulfide connectivity, we utilized the same stepwise disulfide bond formation 
scheme that was used to successfully fold guanylin. 
Briefly, the first disulfide bond was formed between Cys7 & Cys12, which were S-
Trt protected during SPPS. Upon cleavage from the resin using (96:2:2) TFA:TIS:H2O, the 
Trt protecting groups were removed via acidolysis. The resulting Cys-thiols were air 
oxidized in ammonium bicarbonate buffer (pH 8.12), forming the first disulfide bond. The 
peptide was then frozen and lyophilized to remove water and volatile buffer salts. Next, 
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the second disulfide bond was formed between Cys3 & Cys16, which were S-Acm 
protected during SPPS. Lyophilized peptide powder was re-dissolved in (96:2:2) 
TFA:TIS:H2O containing 5-fold excess PySeSePy, and allowed to react for 8 h at 37 °C. 
After incubation with PySeSePy, the peptide was precipitated with cold ether and 
lyophilized to powder. Excess PySeSePy was subsequently removed via preparative high-
pressure liquid chromatography (HPLC) purification using a water/acetonitrile gradient. 
The correct mass was confirmed for each step of the synthesis using MS analysis, and the 
spectra are given as Figures 2.21-2.23.  
As expected, the use of PySeSePy to install a disulfide bond in the presence of an 
already formed disulfide bond was successful, even when using the larger peptide, 
tachyplesin-1. We predict that our new scheme will allow for facile synthesis of other 
AMPs in the future. 
 
Test of Asc as a chemoselective reductant of selenosulfide bonds. To show that Asc does 
not reduce disulfide bonds in the context of a folded peptide/protein under the acidic 
conditions used here to reduce a mixed Cys-S–SePy adduct, we tested whether 5-fold 
excess Asc would reduce guanylin at pH 4.5. Figure 2.24A-C shows the mass spectra of 
guanylin in buffer with or without 5-fold excess Asc at pH 4.5. Reduction should result in 
a gain of mass of either 2 or 4 daltons if Asc reduced one or both disulfide bonds of 
guanylin. The MS data in Figure 2.24 shows that 5-fold excess Asc does not reduce either 
disulfide bond at pH 4.5 after 4 h of incubation. Thus, Asc is a chemoselective reductant 
of Cys-S–SePy adducts. 
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While PySeSePy has some significant advantages for regioselective disulfide bond 
formation as discovered here such as the use of Asc to chemoselectively reduce a 
selenosulfide bond and spontaneous disulfide bond formation from pairs of Cys-S–SePy 
adducts thermodynamically driven by formation of PySeSePy, we must note two 
disadvantages. First, PySeSePy is not commercially available and this will undoubtedly 
preclude its use for some users. We hope that PySeSePy will soon become commercially 
available, so as not to be a limiting factor. Second, like DTNP, PySeSePy remains as a 




2.3. Reduction of cysteine-S-protecting groups by triisopropylsilane 
In Section 2.2, we showed that addition of TIS to deprotection cocktails greatly 
enhances the removal of Mob and Acm groups from Cys118. We found that TIS can directly 
reduce Cys(Acm) to Cys-SH in TFA at 37 °C  for 12 h,118 and this finding proved to be 
important in developing the deprotection of Cys(Acm) by PySeSePy. TIS likely facilitates 
the deprotection of Cys(Acm) by PySeSePy by two different pathways. First, Cys(Acm) is 
partially deprotected by TIS to the free thiol which can then act as a nucleophile attacking 
the diselenide. Second, the protected S-atom of Cys(Acm) attacks the soft diselenide of 
PySeSePy in similar way as S-protected derivatives attack the soft disulfide bond of DTNP, 
resulting in deprotection89.  
 
2.3.1 Background and Introduction 
Hindered hydrosilanes such as TIS are commonly used as cation scavengers in the 
deprotection of AA side-chains following SPPS65, 131. Protecting groups such as trityl (Trt) 
and tert-butyl (But) form stable cations upon acidolysis and are easily removed from N-, 
O-, and S-containing AA side-chains (for cysteine (Cys) But is not easily removed). In 
acid, TIS drives the equilibrium towards cleavage of the protecting group from the AA 
side-chain by donating a hydride to the resulting cation in an irreversible manner 131. In 
these cases the addition of TIS to the peptide cleavage cocktail is almost an afterthought 
because TIS need not directly participate in breaking of a carbon-heteroatom bond.  
Though TIS and other hindered hydrosilanes are exclusively thought of as 
protecting group scavengers in SPPS 65, 107, they are actually mild reducing agents and can 
reduce a carbon-heteroatom bond and can therefore directly participate in the removal of a 
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protecting group from an AA side-chain. This fact has largely been misunderstood in the 
peptide chemistry literature. Silicon is metallic in nature, and has low electronegativity 
relative to hydrogen resulting in polarization of the Si-H bond 132, 133. This polarization 
causes hydrogen to be hydridic, and results in a milder reducing agent than the usual 
aluminum-, boron-, and other metal-based hydrides 132, 133. Thus, hydrosilanes have long 
been commonly employed to provide the hydride in reductions of various carbenium ion 
precursors and it should not be surprising that TIS can function as a deprotection reagent, 
such as iodine or mercuric acetate, in SPPS as we now report.  
An earlier investigation into the use of various scavengers in the synthesis of a 
target Cys-containing peptide protected with the Acm group demonstrated that TIS 
afforded the highest yield of Cys(Acm)-protected peptide compared to other commonly 
used scavengers such as water, phenol, anisole, and ethanedithiol (EDT) 134. All of the 
tested scavengers including TIS also yielded a mixture of other products including the fully 
deprotected peptide and the peptide disulfide. The use of TIS in the deprotection cocktail 
yielded 4% fully deprotected peptide and 20% peptide disulfide 134. 
The results of Singh and coworkers were later misinterpreted in several reviews to 
mean that TIS helped to suppress removal of S-protecting groups 65, 107. In contrast, we 
have tested TIS and other commonly used scavengers used in Fmoc peptide cleavage 
cocktails, and provide evidence that TIS serves as a reducing agent to actively aid in the 
removal of S-protecting groups including Acm, 4-methoxybenzyl (Mob), and But in the 
presence of trifluoracetic acid (TFA) and mild heat. In addition, we find that TIS actually 




2.3.2 Results and Discussion of TIS deprotection scheme 
TIS is a hindered hydrosilane that is used in organic synthesis as a mild reducing 
reagent131-133. While working on methods to overcome the limitations of using DTNP to 
deprotect Cys(Acm) residues (described previously), we unexpectedly discovered that 
Acm was partially removed (70%) from a test peptide of sequence H-PTVTGGC(Acm)G-
OH in TFA:TIS (98:2), when incubated for 12 h at 37 ºC (Figure 2.25B). In contrast, the 
same test peptide incubated in 100% TFA showed almost no conversion of Cys-Acm to 
Cys-SH when incubated under the same conditions (Figure 2.25A). We found that the 
deprotected peptide existed as both the Cys-SH (35%) and disulfide forms (35%). The 
peptide disulfide was unambiguously identified by adding 5-fold excess TCEP to the 
peptide reaction mixture containing 2% TIS. Under these acidic conditions, reduction of 
the disulfide using TCEP is slow and the reaction was incomplete, but the amount of 
peptide disulfide dramatically decreased with a concomitant rise in the Cys-SH form as 
revealed by HPLC analysis (Figure 2.25C).  
Our identification of each of the peaks in Figure 2.25 is further supported by mass 
spectrometric (MS) analyses. Mass chromatograms of the reactions are shown in Figure 
2.26. The deprotection reactions in Figure 2.25 were carried out at 37 ºC and extended 
reaction time. However, use of elevated temperature allowed us to “discover” side 
reactions that may be absent under standard deprotection conditions. To test whether the 
inclusion of TIS would drive deprotection of our Cys(Acm)-containing peptide under 
typical deprotection conditions, we incubated the peptide in TFA/TIS (98/2) for 2 h at rt. 
HPLC analysis of this reaction shows that little or no deprotection occurred (Figure 2.27). 
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As demonstrated in Figures 2.25A and 2.27, the S-Acm protecting group is stable 
to incubation with neat TFA in agreement with earlier reports69, 107. However, others, both 
at elevated temperature and at rt, have questioned the stability of S-Acm. The reason for 
this disparity is most likely due to sequence specific effects. For example, Muttenthaler 
and coworkers report that S-Acm is stable to TFA at 25 ºC, but loss of ~10% of the Acm 
group occurs at 40 ºC of a bis-Acm protected oxytocin peptide135. We posit that one reason 
for the higher loss of the Acm group reported by Muttenthaler may be due to the peptide 
containing two Cys(Acm) residues whereas our peptide only contains one. Engebretsen 
and coworkers speculate that sequence specific effects may also play a role in the loss of 
the Acm group as they reported loss (11%) of both Acm groups of a fragment of human 
coagulation factor VII after incubation in TFA/H2O (95/5) at rt
124.  
We next tested water, anisole, phenol, thioanisole, and triethylsilane (TES) to see 
if these commonly used scavengers would also aid in the removal of the Acm group using 
our reaction conditions (2% scavenger, 37 ºC, and extended reaction time). The results of 
our HPLC analyses for these scavengers are shown in Figure 2.28. Peak assignments in 
Figure 2.28 are based upon retention times and MS analyses of the reactions (Figure 2.29). 
Of the scavengers tested, water was very ineffective at aiding in the removal of the Acm 
group, while anisole and phenol were comparable to TIS in ability to remove the Acm 
group. Thioanisole under these reaction conditions removed 80-90% of the Acm group and 
thus was significantly better than anisol or phenol in this respect, and like TIS promoted 
disulfide formation. This data is consistent with previous reports which showed that 
anisole136 and thioanisole137 act to enhance the lability of S-Acm. TES was slightly better 
than all other scavengers tested (including TIS) in promoting the removal of the Acm 
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group. This should not be surprising since TES is much less hindered than TIS and thus it 
is a better hydride donor131. However, one drawback of using TES is that it can reduce the 
indole ring of tryptophan, whereas this is much less of a problem with TIS131. One 
interesting thing to note is that like TIS, both thioanisole and TES promote disulfide bond 
formation whereas the other scavengers tested do not. 
We also wondered about the lability of other commonly used Cys-protecting groups 
in the presence of TIS. We synthesized peptides H-PTVTGGC(Mob)G-OH and H-
PTVTGGC(But)G-OH, isolated each peptide by ether precipitation and lyophilization, and 
then incubated each in TFA:TIS (98:2) at 37 ºC for 12 h as before. HPLC analyses of both 
of these reactions are shown in Figures 2.30 and 2.31.  
As is evident in Figure 2.30, S-Mob is mostly stable to TFA in the absence of TIS. 
In contrast, S-Mob is very labile in the presence of TIS at slightly elevated temperature and 
extended reaction time as shown by the complete conversion of Cys(Mob)-protected 
peptide to the Cys-SH and disulfide forms as shown by the HPLC trace in Figure 2.30C. 
We did not test shorter reaction times and it is likely that removal of Mob can be achieved 
using much shorter reaction times at 37 ºC.  
In the case of the Cys(But)-protected peptide, ~20% of the But-protecting group is 
removed when incubated in neat TFA in the absence of TIS (Figure 2.31), which indicates 
that Cys(But) is more acid labile than Cys(Mob). The addition of TIS to the reaction results 
in only slightly more deprotection of Cys(But), but also results in more disulfide formation 
(Figure 2.31C).  
Our HPLC analyses of the products of deprotection for Cys(Mob)- and Cys(But)-
containing peptides is further supported by the MS data shown in Figure 2.32. As shown 
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in Figure 2.32B, the amount of Cys(Mob) protected peptide is almost completely 
diminished, while the amount of disulfide and deprotected peptide are in abundance, in 
agreement with the HPLC trace shown in Figure 2.30C. The MS data shown in Figures 
2.32C and 2.32D show that the Cys(But)-containing peptide remains largely intact in the 
presence of 2% TIS, with a relatively small amount of peptide in the Cys-SH and disulfide 
forms, in agreement with the HPLC trace shown in Figure 2.31C. 
As is evident from the deprotection reactions with Cys(Mob) and Cys(But), one 
effect of using TIS in the deprotection cocktail is to help catalyze disulfide formation as 
originally observed by Singh and coworkers134. While we can only speculate on the 
mechanism by which TIS promotes disulfide formation, it most likely involves transient 
bonding of silicon to sulfur. A possible mechanism by which TIS helps to deprotect 
Cys(Acm) and other Cys-protecting groups is shown in Figure 2.33.  
The lability of the Cys protecting groups in TFA/TIS in this study are Cys(Mob) > 
Cys(Acm) > Cys(But). We suggest the reason for the higher lability of Cys(Mob) relative 
to Cys(Acm) is due to the higher stability of the resulting cation upon cleavage of the S–C 
bond of the protecting group. Cleavage of the S–C bond in the case of the Mob protecting 
group results in the formation of a 1º benzylic cation that can be stabilized by resonance 
from the electron donating methoxyphenyl substituent. Cleavage of the S–C bond in the 
case of the Acm protecting group also results in the formation of a 1º carbocation that can 
be stabilized by resonance from the adjacent lone pair of electrons on nitrogen, but the Acm 





Figure 2.33: Potential mechanism of reduction of Cys(Acm) containing test peptide 
to Cys-SH by TIS. See text for explanation.  
 
A potential reason for the unexpected lability of Cys(Acm) compared to other alkyl 
protecting groups is the formation of an iminium nitrogen in the transition state as shown 
in Figure 2.33. The iminium nitrogen would result from protonation of the sulfur atom in 
TFA, weakening the S–C bond. As a result, a partially empty p-orbital on carbon could be 
stabilized by donation of the lone pair of electrons on the neighboring nitrogen, resulting 
in an electrophilic iminium carbon that can more easily accept a hydride from TIS in 
comparison to the 3º carbon of S-But for example. 
If stability of the protecting group carbocation was the dominant factor in lability 
of the protecting group in a solution of TIS, it should be expected that But would be the 
most labile since it results in a 3º carbocation, but this is not observed. A likely explanation 
for the stability of S-But towards TIS is that steric hindrance prevents the tertiary carbon of 
But from accepting the hydride from TIS in agreement with our proposed mechanism in 
Figure 2.33. Thus, lability of the protecting group is a combination of factors including 
carbocation stability and lack of steric hindrance. These factors explain the lability of 
Cys(Mob) towards TIS. 
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The role of TIS as a reductant undoubtedly explains the results of Singh and 
coworkers who showed that a TFA:TIS (95:5) cleavage cocktail did in fact result in 
moderate conversion of a Cys(Acm)-containing peptide to the Cys-SH form (4%) and 20% 
to the disulfide form134. Therefore, the addition of TIS results in 24% removal of the Acm 
protecting group under their reported conditions. Our examination of their data shows that 
a cocktail of TFA:anisole (95:5) resulted in an even higher percentage of Acm removal 
(32%). On this basis in part, Singh and coworkers concluded that TIS gave the best yields 
of the fully protected peptide in comparison to phenol, EDT, and anisole134. However their 
study lacked an important control since they did not report the extent of removal of the 
Acm group when using only neat TFA. Based on our results, we believe they would have 
found minimal removal of the Acm group with neat TFA.  
The conclusion of Singh and coworkers is the source of subsequent incorrect 
statements about the role of TIS in deprotection of Cys(Acm) in TFA. For example, 
Houben-Weyl’s “Synthesis of Peptides and Peptidomimetics” cites the results reported by 
Singh, stating that:  
“The type of scavenger used, e.g. anisole or thioanisole as additive to HF, or thiols 
added to TFA, apparently plays an important role; for example, use of TIS as a scavenger 
prevents partial cleavage of S-(acetamidomethyl) by TFA.”107 
The key word in the quote above is “prevents” (bolded for our emphasis) as TIS 
does not prevent cleavage of the carbon-sulfur bond, but rather facilitates it. This 
mischaracterization was further propagated in the review of Isidro-Llobet and coworkers 
on AA protecting groups who also state that: 
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“Nevertheless, it (Acm) is partially removed with HF or even TFA depending on 
the scavengers used. In the latter case, absence of water and use of TIS minimizes the 
removal.”65  
We have again bolded a key phrase from the sentence above since our results 
contradict this statement. Our results are supported by the original work by Singh and 
coworkers who clearly showed that the presence of TIS in the deprotection cocktail resulted 
in the removal of Acm. Other examples of the misunderstanding regarding the abilities of 
TIS to act as reducing agents are present in the literature135, 138. 
Since its introduction as a scavenger for protecting group cations in 1989, the role 
of TIS as a reductant has been overlooked, even though the original report cites the known 
role of trialkylsilanes as mild reductants in TFA131. For example, it has been shown that 
TIS can reduce the indole ring of tryptophan residues to indoline131. Interestingly, indoles 
are commonly reduced via iodine oxidation, using similar techniques to those typically 
used to reduce the S-Acm bond139, 140. 
Our results present a cautionary tale for those attempting regioselective disulfide 
bond forming strategies using orthogonal pairs of Cys-protecting groups when using TIS 
as a scavenger. Using “standard” deprotection conditions, Cys(Mob) and Cys(Acm) will 
be more stable than reported here, but sequence specific effects as discussed above could 
result in a small percentage of deprotection that would result in low yields of the target 
disulfide as disulfide scrambling would inevitably occur.  
If peptide disulfide bonds are stable to TIS, then our results suggest that TIS itself 
could be used in orthogonal deprotection strategies of Cys-protecting groups. In a 
hypothetical peptide with two-disulfide bonds, the first disulfide bond could be installed 
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using a pair of Cys(Trt) residues. The Trt group could be removed in TFA with mild 
scavenger at rt, and then the peptide could be subjected to air oxidation. The second 
disulfide bond could then be installed using a pair of Cys(Mob) residues. The peptide could 
then be incubated in TFA/TIS or TFA/thioanisole at 37 ºC to remove the Mob groups, and 
help catalyze disulfide formation. If disulfide formation was incomplete, appropriate 
catalyst could be added to aid in formation of the second disulfide. 
In conclusion, we hope our results provide strong evidence that TIS can reduce S-
protecting group bonds under acidic conditions and draws attention to this observation to 




2.4 Materials and methods 
2.4.1 Materials. 
Solvents including DCM, dimethylformamide (DMF), and TFA for peptide synthesis were 
purchased from Fisher Scientific (Pittsburgh, PA). Tetrahydrofuran for PySeSePy 
synthesis was also purchased from Fisher Scientific (Pittsburgh, PA). Fmoc-Cys(But)-OH 
and Fmoc-Cys(Mob)-OH were purchased from NovaBiochem (Burlington, MA). Fmoc-
Cys(Acm)-OH, 2-Chlorotrityl chloride resin SS (100-200 mesh), and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) for solid-phase synthesis were purchased from Advanced 
ChemTech (Louisville, KY). All other Fmoc-amino acids were purchased from 
RSsynthesis (Louisville, KY). Peptide synthesis scavengers: triisopropylsilane (98%), 
triethylsilane (99%), thioanisole (99%), and anisole (99%) were purchased from Acros 
Organics (Pittsburgh, PA). L-Ascorbic acid sodium salt (99%) for deprotection 
experiments, as well as selenium powder (200 mesh), 2-bromopyridyine (99%), and 
sodium borohydride for the synthesis of PySeSePy, were purchased from Acros Organics 
(Pittsburgh, PA). Guanylin was purchased from CPC Scientific (Sunnyvale, CA). Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) was purchased from ThermoFischer 
Scientific. All other chemicals were purchased from either Sigma-Aldrich (Milwaukee, 
WI) or Fisher Scientific (Pittsburgh, PA). The HPLC system is from Shimadzu with a 
Symmetry® C18 -5 mm column from Waters Corp. (Milford, MA) (4.6 x 150 mm). Mass 
spectral analysis was performed on an Applied Biosystems QTrap 4000 hybrid triple-




2.4.2 Peptide Synthesis. 
For this chapter, test peptide sequence was chosen based on the C-terminal 
sequence of high Mr TrxR. Either Fmoc-Cys(Acm)-OH, Fmoc-Cys(Mob)-OH, or Fmoc-
Cys(But), were used to synthesize test peptides of sequence H-Pro-Thr-Val-Thr-Gly-Gly-
Cys-Gly-OH (H-PTVTGGCG-OH). Fmoc-Sec(Mob)-OH was synthesized as reported 
previously58 and used to construct test peptides of sequece H-Pro-Thr-Val-Thr-Gly-Gly-
Sec-Gly-OH (PTVTGGUG). All peptides were synthesized on a 0.05 or 0.1 mmol scale 
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. For each 
batch, 300 mg or 600 mg (for 0.05 or 0.1 mmol scale, respectively) of 2-chlorotrityl 
chloride resin SS (100-200 mesh), was swelled in dichloromethane (DCM) for 30 min. The 
first amino acid was directly coupled to the resin using 2% N-methylmorpholine (NMM) 
in DCM, shaking for 1 h. The resin was then capped using 8:1:1 DCM:methanol:NMM. 
Subsequent amino acids were coupled using 0.2 mmol of Fmoc-protected amino acid, 0.2 
mmol of HATU coupling agent, and 2% NMM in dimethylformamide (DMF), shaking for 
1 h. To couple Sec, and any AA residue after Sec, slightly different coupling conditions 
were used; 0.2 mmol HOAt and 1% DIC were used in place of HATU/NMM. Preactivation 
of any amino acid was not performed prior to coupling. These coupling conditions are 
essentially the same as those of Barany and co-workers, which were used to minimize 
racemization of cysteine141. Between amino acid couplings, the Fmoc protecting group was 
removed via two 10 min agitations with 20% piperdine in DMF. Success of Fmoc removal 
steps and amino acid couplings were monitored qualitatively using a ninhydrin test 142. 
Removal of the final Fmoc protecting group completed the peptide synthesis. Peptides were 
next cleaved from the resin as described below. 
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2.4.3 Cleavage of peptides from resin. 
Peptides were cleaved from the resin (via 1.5 h reaction at 22 °C) using a cleavage 
cocktail consisting of various scavengers in TFA. Our standard cleavage cocktail consists 
of TFA:TIS:H2O (96:2:2). Simultaneous cleavage of peptide from the resin and 
deprotection of Cys or Sec protecting groups, was achieved via a 2 hr reaction using a 
cleavage cocktail consisting of 2-excess 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved 
in TFA:TIS:H2O:thioanisole (94:2:2:2). This reaction mixture removes the Mob, Acm, and 
But protecting group from Cys, replacing it with 5-Npys90, 110. Note: this reaction does not 
go to completion for all protecting group/peptide sequence combinations. This is a topic of 
study in this chapter. The same DTNP reaction can be used for the concomitant cleavage 
and deprotection of the Sec-containing peptide, but without the addition of thioanisole89, 90, 
110. Following cleavage and side chain deprotection, the resin was washed with minimal 
amounts of TFA and DCM and the volume of the cleavage solution was reduced by 
evaporation with nitrogen gas. The peptide solution was then transferred by pipette into 
cold, anhydrous diethyl ether, where the peptides were observed to precipitate. 
Centrifugation at 3000 rpm on a clinical centrifuge (International Equipment Co., Boston, 
MA) for 10 min pelleted the peptide. Peptides were dried, then dissolved in a minimal 
amount of water with 20% acetonitrile, lyophilized, and used without further purification. 
 
2.4.4 Deprotection of Cys(5-Npys) and Sec(5-Npys) by ascorbate. 
Lyophilized Cys(5-Npys) and Sec(5-Npys) peptides were then dissolved in 
distilled/deionized water and divided into eight aliquots of 0.5 mL before treatment with 
ascorbate. Two ascorbate-containing buffers were prepared either at pH 4.5 and pH 7.0. 
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Buffer A consisted of 40 mM ascorbate dissolved in 500 mM potassium phosphate buffer, 
pH = 7.0 ± 0.1, and buffer B consisted of 40 mM ascorbate dissolved in 500 mM 
ammonium acetate buffer pH = 4.5 ± 0.1. Deprotection of the Cys-containing peptide was 
initiated by adding 0.5 mL of either buffer A or buffer B to the sample so that the total 
reaction volume was 1.0 mL, and the final concentration of ascorbate was 20 mM. At this 
concentration of ascorbate, the ratio of ascorbate to peptide was 100:1. Deprotection of the 
Sec-containing peptide was initiated by adding 0.1 mL of either buffer A or buffer B to 0.5 
mL of the sample and then the reaction volume was adjusted to 1.0 mL by addition of either 
0.4 mL of 500 mM potassium phosphate buffer (pH 7.0), or 500 mM ammonium acetate 
buffer (pH 4.5). At this concentration of ascorbate, the ratio of ascorbate to peptide was 
5:1. The reactions were then allowed to proceed at either rt or 37 °C for either 4 hours or 
24 hours according to Table 2.1.  
 
2.4.5. Synthesis of 2,2´-dipyridyl diselenide. 
PySeSePy was synthesized following previously reported methods.39 Water (20 
mL), in a round bottom flask containing 0.596 g (15.75 mmol) of sodium borohydride, was 
cooled on ice to 0 °C. To this, 92 mg (7.5 mmol) of elemental selenium was added with 
vigorous stirring. The reaction was warmed to rt and stirred for ~10 min. Another 92 mg 
(7.5 mmol) of elemental selenium was then added, the reaction warmed to 40 °C, and 
stirred until all selenium had dissolved (~35 min). A brown/red solution of disodium 
diselenide resulted, which was sealed with a rubber septum and purged under nitrogen gas. 
To the aqueous solution of disodium diselenide, 1.43 mL (15 mmol) of 2-bromopyridine 
in 40 mL of anhydrous THF was added under a flow of nitrogen gas, and refluxed for ~36 
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h. After reflux, a clear, dark yellow/green solution resulted. This solution was diluted with 
~400 mL brine, extracted 8X with ethyl acetate, dried with magnesium sulfate, then 
concentrated via rotary evaporation to a thick orange oil. The resulting oil was column 
purified using 35 g silica and 80:20 hexane:ethyl acetate as the solvent. Yellow product 
was collected, concentrated, then dried, resulting in 952 mg of an orange solid (~49% 
yield). The correct product was verified via 1H- and 77Se- NMR and mass spectrometry. 
 
2.4.6 Deprotection of Cys(Acm) and Cys(Mob) by PySeSePy. 
Lyophilized test peptide H-PTVTGGCG-OH, with either S-Acm or S-Mob 
protection on the Cys residue, was dissolved in cleavage cocktail consisting of either neat 
TFA, or TFA with addition of 2% TIS and/or 2% water, and the solution was divided into 
two aliquots. To one aliquot, 5-fold excess PySeSePy was added. Both aliquots were 
incubated either at rt, or in a 37 ºC water bath for either 4 or 12 h. For all reactions, the 
final reaction volume was 1.0 – 1.5 mL and contained 1.7 – 2.5 mM peptide. After 
incubation, peptides were precipitated with cold diethyl either, pelleted via centrifugation 
(as described above), and dried using nitrogen gas. For purification; dried pellets were re-
dissolved in minimal amounts of neat TFA, precipitated with cold ether, pelleted via 
centrifugation, and dried using nitrogen gas. Dried peptide pellets were then dissolved in 







2.4.7 Reduction of Cys(PySe) by ascorbate. 
Lyophilized H-PTVTGGC(PySe)G-OH peptide (3 mg, 0.0035 mmol) was 
dissolved in 100 mM ammonium acetate buffer pH = 4.5, and divided into two aliquots. 
To one aliquot, 5-fold excess (0.0177 mmol) L–ascorbic acid sodium salt was added, while 
buffer missing ascorbate was added to the control aliquot. Both aliquots were covered in 
foil, incubated for 4 h at 22 °C, then flash frozen and lyophilized. For purification; dried 
pellets were re-dissolved in minimal amounts of neat TFA, precipitated with cold ether, 
pelleted via centrifugation, and dried (all as described previously). Dried peptide pellets 
were then dissolved in water:acetonitrile (80:20), lyophilized, and analyzed without further 
purification. 
 
2.4.8 Synthesis of guanylin. 
Guanylin peptide of sequence H-Pro-Gly-Thr-Cys(Trt)-Glu-Ile-Cys(Acm)-Ala-
Tyr-Ala-Ala-Cys(Trt)-Thr-Gly-Cys(Acm)-OH was synthesized on a 0.1mmol scale using 
standard solid phase peptide synthesis, as described above. The peptide was cleaved from 
the resin via a 1.5 h reaction with a cleavage cocktail consisting of 96:2:2 TFA:TIS:water. 
Following cleavage, the resin was washed with TFA and DCM and the volume of the 
cleavage solution was reduced by evaporation with nitrogen gas. The peptide solution was 
then transferred by pipette into cold, anhydrous diethyl ether, where the peptides were 
observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge for 10 min 
pelleted the peptide. Guanylin peptide was dried, then dissolved in a minimal amount of 
water:acetonitrile (80:20), lyophilized, and used without further purification. The first 
disulfide bond between Cys4 & Cys12 was formed by dissolving 24 mg (0.015 mmol) of 
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lyophilized peptide in 50 mL of 0.1 M ammonium bicarbonate buffer pH = 8.2, and stirred 
vigorously in a large round bottom flask for 40 h. Complete formation of the first disulfide 
bond was monitored qualitatively using Ellman’s regent. The reaction was frozen and 
lyophilized to remove water. The second disulfide bond (between Cys7 & Cys15) was 
formed by dissolving 5.6 mg (0.0035 mmol) lyophilized peptide in neat TFA, then divided 
into two aliquots. To one aliquot, 2.75 mg (0.00873 mmol) of PySeSePy, 20 L of TIS, 
and 20 L of water was added, then the reaction was filled to 1 mL with TFA. The second 
aliquot (control) was filled to 1 mL with neat TFA, then both aliquots were incubated for 
4 h at 37 °C. After incubation, excess TFA was blown off using nitrogen gas, and peptides 
were precipitated with cold diethyl ether, pelleted via centrifugation, and dried (all as 
described previously). Dried peptide pellets were then dissolved in water:acetonitrile 
(80:20), lyophilized, and analyzed without further purification. 
 
2.4.9 Solid phase peptide synthesis of tachyplesin-1 
Either Fmoc-Cys(Acm)-OH or Fmoc-Cys(Trt)-OH were used to synthesize 
tachyplesin-1 of sequence: H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-Tyr-
Arg-Arg-Cys-Arg-CONH2 (H-KWCFRVCYRGICYRRCR-CONH2), on a 0.2 mmol scale 
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. To begin, 
0.136 g of Rink Amide AM resin (200-400 mesh, Novabiochem®), was swelled in 1:1 
dimethylformamide (DMF):dichloromethane (DCM) for 1 h. Fmoc was removed from the 
resin via two, 10 min agitations using 20% piperidine in DMF (10 mL total). Success of 
Fmoc removal steps (from resin and amino acids) and subsequent amino acid couplings 
were monitored qualitatively using a ninhydrin test142. The first amino acid was directly 
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coupled to the resin using 0.8 mmol Fmoc-Arg(Pbf)-OH, 0.8 mmol HATU, and 1.6 mmol 
N,N-diisopropylethylamine (DIPEA) in ~5mL DMF, shaking for 2 h at 22 °C. Subsequent 
amino acids were coupled using 0.8 mmol of Fmoc-protected amino acid, 0.8 mmol of 
HATU coupling agent, and 1.6 mmol, shaking for 2 h. Between amino acid couplings, the 
Fmoc protecting group was removed via two, 10 min agitations with 20% piperdine in 
DMF. Removal of the final Fmoc protecting group completed the peptide synthesis. 
Tachyplesin was cleaved from the resin via 2 h reaction with a cleavage cocktail consisting 
of 96:2:2 TFA:TIS:water at 22 °C. Following cleavage, the resin was washed with TFA 
and DCM and the volume of the cleavage solution was reduced by evaporation with 
nitrogen gas. The peptide solution was then transferred by pipette into cold, anhydrous 
diethyl ether, where the peptide was observed to precipitate. Centrifugation at 3000 rpm 
on a clinical centrifuge (International Equipment Co., Boston, MA) for 10 min pelleted the 
peptide. The pellet was dried, then dissolved in a minimal amount of 80:20 water: 
acetonitrile (ACN), frozen and lyophilized to powder form. 
2.4.10 Tachyplesin stepwise disulfide bond formation 
The first disulfide bond between Cys7 & Cys12 was formed by dissolving 62 mg 
(0.026 mmol) of lyophilized peptide in 150 mL of 0.1 M ammonium bicarbonate buffer 
pH = 8.12, and stirred vigorously in a large round bottom flask for 50 h. Complete 
formation of the first disulfide bond was monitored qualitatively using Ellman’s regent. 
The reaction was frozen and lyophilized to remove water and volatile buffer salts. The 
second disulfide bond (between Cys3 & Cys16) was formed by dissolving 48 mg (0.020 
mmol) lyophilized peptide in neat TFA. To this, 32 mg (0.10 mmol) of PySeSePy was 
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added. The reaction was incubated for 8 h at 37 °C. After incubation, excess TFA was 
blown off using nitrogen gas, and peptides were precipitated with cold diethyl ether, 
pelleted via centrifugation, and dried. Dried peptide pellets were then dissolved in 
water:acetonitrile (80:20), lyophilized, then purified via preparative, reverse-phase high 
pressure liquid chromatography (HPLC). HPLC purification was completed using a 
Shimadzu instrument with a Symmetry® C18 5 µm column. Aqueous and organic phases 
were 0.1% TFA in distilled, deionized water (buffer A) and 0.1% TFA in HPLC‐grade 
acetonitrile (buffer B), respectively. Beginning with 100% buffer A, buffer B was increased 
by 1% up to 50% over 50 min by gradient elution. Buffer B was then increased by 10% up 
to 100% over 5 min. Peptide elution was monitored via absorbance at both 214 and 254 nm, 
and fractions were collected of major peaks. 
2.4.11 Testing ability of ascorbate to reduce peptide disulfide bonds. 
Guanylin, synthesized as described previously, (lyophilized powder, (1.6 mol) 
was dissolved in 2 mL of 100 mM ammonium acetate buffer, pH 4.5. The sample was split 
into two aliquots, and five-fold excess ascorbate was added to one of the samples. To the 
other (control), no ascorbate was added. In addition, the guanylin standard (0.5 mol, from 
CPC scientific) was dissolved in 1 mL of 100 mM ammonium acetate buffer, pH 4.5, and 
five-fold excess ascorbate was added. All samples were incubated at rt for 4 h, then flash 






2.4.12 Reduction of Cys(Acm), Cys(Mob), and Cys(But) by triisopropylsilane. 
 Lyophilized test peptide H-PTVTGGCG-OH with either S-Acm, S-But, or S-Mob 
protection on the Cys residue were dissolved in neat TFA and the solution was divided into 
two aliquots. To one aliquot, 2% TIS was added. Both aliquots were incubated in a 37 ºC 
water bath for 12 h. To test TIS reduction under standard cleavage conditions, S-Acm 
protected peptide was dissolved in neat TFA, divided into two aliquots, 2% TIS was added 
to one aliquot, and both aliquots were incubated at rt for 2 h. For all reactions, the final 
reaction volume was 1.0 – 1.5 mL and contained 1.7 – 2.5 mM peptide. After incubation, 
peptides were precipitated with cold diethyl either, pelleted via centrifugation (as described 
above), and dried using nitrogen gas. For purification; dried pellets were re-dissolved in 
minimal amounts of neat TFA, precipitated with cold ether, pelleted via centrifugation, and 
dried (all as described previously). Dried peptide pellets were then dissolved in water, 
lyophilized, and analyzed without further purification. 
 
2.4.13 Reduction of Cys(Acm) with water, phenol, anisole, thioanisole, and 
triethylsilane. 
Test peptide H-PTVTGGC(Acm)G-OH was dissolved in neat TFA and the solution 
divided into two aliquots. To one aliquot, 2% scavenger (either water, phenol, anisole, 
thioanisole or triethylsilane) was added. Both aliquots were incubated in a 37 °C water bath 
for 12 h. For all reactions, the final reaction volume was 1.0 mL with 2.0 mM peptide. 
After incubation, peptides were precipitated with cold diethyl ether, pelleted via 
centrifugation (as described above), and dried using nitrogen gas. For purification, dried 
pellets were re-dissolved in minimal amounts of neat TFA, precipitated with cold ether, 
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pelleted via centrifugation, and dried (as described previously). Peptide pellets were then 
dissolved in a minimal amount of water, lyophilized, and analyzed without further 
purification. 
 
2.4.14 Reduction of peptide disulfide by TCEP. 
Cys(Acm) protected test peptide (3.45 mol) that was previously incubated with 
TFA:TIS (98:2) for 12 h at 37 °C was precipitated and lyophilized as described above. The 
peptide was next re-dissolved in 4:1 water: acetonitrile. To this solution, 4.95 mg (17.3 
mol) of TCEP was added and allowed to react for 12 h at rt. HPLC analysis was then 
performed without further purification. 
 
2.4.15 High Pressure Liquid Chromatography. 
HPLC analysis of all samples was completed using a Shimadzu with a Symmetry® 
C18 5 µm column from Waters (4.6 × 150 mm). Aqueous and organic phases were 0.1% 
TFA in distilled, deionized water (buffer A) and 0.1% TFA in HPLC‐grade acetonitrile 
(buffer B), respectively. Beginning with 100% buffer A, buffer B was increased by 1% up 
to 50% over 50 min with a 1.4 mL/min gradient elution. Buffer B was then increased by 
10% up to 100% over 5 min. This method was used for analysis of each sample. Peptide 
elution was monitored via absorbance at both 214 and 254 nm. 
 
2.4.16 Mass spectrometry 
Peptides were using an Applied Biosystems QTrap 4000 hybrid triple-
quadrupole/linear ion trap liquid chromatograph-mass spectrometer operating in positive 
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ESI mode. Aliquots of peptide were injected into the sample loop with a guard column at 
10 μL/min into a 100 μL/min mobile phase flow consisting of 50/50 water/acetonitrile with 





2.5 Conclusions and future work 
Herein, we have developed a gentle and highly effective method for conversion of 
Sec(5-Npys) to Sec-she using Asc, and this deprotection has multiple applications as 
described above. This chemistry also works for deprotection of Cys(5-Npys), but higher 
concentrations of ascorbate and longer reaction times are required. Based on this, we 
concluded that the reduction of a S-Se is chemoselective; that is, ascorbate will not reduce 
a S-S bond. These concepts are illustrated in Figure 2.34. 
 
 
Figure 2.34: Summary of ascorbolysis S-X bond reduction at pH 4.5 and 22 °C. 
Notably, the reduction of an S-S bond is slow, while the reduction of an S-Se bond is 
fast by ascorbate, regardless of the position of the S or Se atom in the bond to be reduced. 
 
To better adapt ascorbolysis of a S-Se bond for Cys deprotection, we developed the 
use of PySeSePy as a new deprotection reagent for Cys(Acm) and  Cys(Mob) residues after 
SPPS. We found that incubation of these protected Cys residues with PySeSePy in TFA 
with scavengers for various lengths of time at 37 °C resulted in a stable Cys(PySe) adduct. 
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This Cys(PySe) adduct was noticeably stable in TFA with TIS, while the Cys(5-Npys) that 
results from using DTNP is not. In addition, the Cys(PySe) adduct can be chemoselectively 
reduced by Asc in buffer, as Asc is very slow to reduce unactivated disulfide bonds at pH 
4.5. In addition, we show the utility of this new deprotection reagent for the regioselective 
formation of disulfide bonds in the synthesis of the human intestinal hormone guanylin, 
and anti-microbial peptide tachyplesin-1.  
During the course of this investigation, we also found that in the case of Cys(Acm), 
TIS scavenger is essential for deprotection using PySeSePy. This is due to the ability of 
TIS to reduce the S–C bond between Cys and the Acm protecting group. This reduction by 
TIS had previously been mischaracterized in the literature. 
 Our new deprotection chemistry, especially the chemoselective reduction of S-Se 
by Asc, has numerous potential applications that should be explored in the future. First, 
our ascorbate chemistry is still limited to aqueous conditions, so ascorbate ester derivatives 
should be explored for utilization of this chemistry in organic/lipid environments. An 
example includes commercially available, 6-O-palmitoyl-L-ascorbic acid, which is a lipid 
soluble ester of ascorbic acid. The use of lipid or organic soluble ascorbate would allow 
for generation of a free-selenol in situ, which can be used for nucleophilic alkylation 
reactions in organic synthesis. This could be highly effective for installing selenium into 
molecules, a task that is otherwise challenging143. 
Another application of this chemistry may be in the use of N-terminal Cys(PySe) 
or Sec(5-Npys) residues in peptide fragments that also contain a C-terminal thioester where 
three or more peptides segments are to be ligated together in native chemical ligation 
(NCL) reactions144, 145. NCL is a method of joining together two or more peptides via 
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reaction between an N-terminal Cys residue of one peptide and a C-terminal thioester of 
another peptide to yield a product with a native amide bond at the ligation site146, 147. The 
use of PySe protected Cys for this application is depicted in Figure 2.35. Protection of the 
N-terminal Cys is needed in such cases to avoid cyclization and polymerization of the 
peptide containing both a N-terminal Cys residue and a C-terminal thioester148, 149. Cys 
protecting groups currently used for this application are methylsulfonylethyloxy-carbonyl 
amine (Msc), acetamidomethyl (Acm), and the thiazolidine protecting group (Thz)148, 150, 
151. Both Acm and Msc require harsh conditions for their removal146, 150, 152, 153. While the 
Thz group has found wide use for this application151, 154, removal of the Thz group requires 
a large excess of methoxylamine, which can result in hydrolysis/solvolysis of the 
thioester147, 155, 156. The use of ascorbate to deprotect Sec(5-Npys) or Cys(PySe) would be 
extremely mild and should not require further purification due to the absence of exogenous 
thiol to affect deprotection.  
 
Figure 2.35: NCL of three peptide segments utilizing a C-terminal thioester and a 
N-terminal Cys(PySe) protected residue. Ascorbate can be used to gently liberate the 
nucleophilic N-terminal Cys to facilitate amide bond formation.  
 
 Another application could be the generation of C-terminal thioesters from C-
terminal Cys or Sec residues. In NCL, the most difficult step is typically the generation of 
a C-terminal thioester. Because resin-bound thioesters are unstable to repeated piperidine 
77 
 
exposure, these derivatives are largely incompatible with standard (Fmoc)-based SPPS 
approaches157, 158. Many strategies have been used to address these problems such as 
development of a thioester-compatible Fmoc cleavage cocktails, and use of “safety-catch” 
linker resins158, 159. Another widely used method of thioester generation that avoids the 
need for “safety-catch” linker resins is via an N → S acyl shift157, 160-162. In an N → S acyl 
shift, the nucleophilic sulfur atom attacks the peptide backbone initiating an acyl shift that 
results in a thioester. However, while nature has evolved ways to catalyze this step, in a 
regular peptide sequence such migration is not favorable163. Macmillan and coworkers 
proposed using Sec instead of Cys to facilitate this acyl shift due to higher acidity, lower 
redox potential and consequentially increased nucleophilicity of selenium to sulfur157. 
However, when Macmillan and coworkers attempted such an approach, they 
reported that generation of the free selenol was difficult157. A cyclic peptide was 
synthesized from a linear precursor by generating a C-terminal thioester that originated 
from a C-terminal Sec(5-Npys) residue. The reported reaction conditions used for the 
synthesis of this cyclic peptide were 10% w/v MESNA, in 0.1 M sodium phosphate buffer 
pH 5.8, with 5% w/v sodium ascorbate and 0.5% w/v TCEP157. Macmillan reported that 
the use of ascorbate helped to prevent deselenization of the peptide, which has also been 
reported by others164, 165. We hypothesize that TCEP could be eliminated from this reaction 
because ascorbate will directly reduce the Sec(5-Npys) group to the desired selenol, thus 
initiating the formation of the desired selenoester. Though we have not tested this 
hypothesis experimentally, it seems to be an attractive route for generating stable thioesters 
for use in NCL reactions.   
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2.6 Figures and tables 
 










Se1 4.5 22 4 5:1 > 95 
Se2 4.5 22 24 5:1 > 95 
Se3 4.5 37 4 5:1 > 95 
Se4 4.5 37 24 5:1 > 95 
Se5 7 22 4 5:1 90-95 
Se6 7 22 24 5:1 90-95 
Se7 7 37 4 5:1 90-95 
Se8 7 37 24 5:1 90-95 
S1 4.5 22 4 100:1 50-55 
S2 4.5 22 24 100:1 50-55 
S3 4.5 37 4 100:1 50-55 
S4 4.5 37 24 100:1 55-60 
S5 7 22 4 100:1 35-40 
S6 7 22 24 100:1 45-50 
S7 7 37 4 100:1 50-55 







Figure 2.3: Observed color change when a Sec(5-Npys) containing peptide is treated 
with ascorbate in pH 4.5 buffer at 22 °C. The clear solution on the left is the no ascorbate 
control, and the right is the ascorbate treated peptide. A yellow color appears almost 












Figure 2.4: HPLC chromatograms and mass spectrometry of the Sec-containing 
test peptide treated with ascorbate under various conditions for 24 hrs with a 5:1 
ascorbate: peptide ratio. (A) HPLC chromatogram of the Sec-containing peptide 
without ascorbate treatment (control). (B) HPLC chromatogram of the Sec-containing 
peptide treated with ascorbate at 22 °C and pH = 4.5. (C) Mass spectrum of the Sec-
containing peptide without ascorbate treatment (control). (D) Mass spectrum of the Sec-









Figure 2.5: HPLC and mass spectroscopic analysis of the Cys-containing test 
peptide treated with 100-fold excess ascorbate. (A) HPLC chromatogram of the 
Cys(5-Npys)-containing peptide treated with ascorbate at 37 °C, pH = 7 for 24 hrs. (B) 
Mass spectrum of the Cys-containing peptide treated with ascorbate at 37 °C and pH = 






Figure 2.9: Mass spectrum of PySeSePy. The double-Se isotope pattern is present 
using this high-resolution analysis. The arrow points to the observed m/z whereas the 










Figure 2.10: NMR spectra of PySeSePy. (A) 77Se-NMR of pyridyl diselenide 
compound. The diselenide gives a single peak at 450 ppm in deuterated chloroform. (B) 
1H-NMR of pyridyl diselenide compound in deuterated chloroform. Both spectra were 










Figure 2.11 (A, B, C): Deprotection of the 
Cys(Mob)-containing peptide using 
PySeSePy and Asc determined by HPLC 
and MS analyses. A) HPLC chromatogram 
of the Cys(Mob)-containing peptide 
incubated in neat TFA for 4 h at 37 °C 
(control).  B) HPLC chromatogram of the 
Cys(Mob)-containing peptide incubated in 
TFA:water (98:2) with 5-fold excess 
PySeSePy for 4 h at 37 °C. Quantitative 
conversion to the PySe-adduct is apparent. 
C) HPLC chromatogram of the peptide 
containing the Cys(PySe) adduct treated 
with 5-fold excess ascorbate in 100 mM 











Figure 2.11 (D, E, F): Deprotection of the 
Cys(Mob)-containing peptide using 
PySeSePy and Asc determined by HPLC 
and MS analyses. Panels D, E, and F are the 
mass spectra that correspond with panels A, 
B, and C, respectively. The arrow points to 
the observed m/z whereas the number inside 















Figure 2.12: Deprotection of the Cys(Acm)-containing peptide using PySeSePy and 
Asc determined by HPLC analysis. A) HPLC chromatogram of the Cys(Acm)-
containing peptide incubated in neat TFA with 5-fold excess PySeSePy for 12 h at 37 
°C. B) HPLC chromatogram of the Cys(Acm)-containing peptide incubated in TFA:TIS 
(98:2) with 5-fold excess PySeSePy for 12 h at 37 °C. C) HPLC chromatogram of the 
Cys(Acm)-containing peptide incubated in neat TFA for 12 h at 37 °C (control). D) 
HPLC chromatogram of the peptide containing the Cys(PySe) adduct treated with 5-fold 
excess ascorbate in 100 mM ammonium acetate pH 4.5, for 4 h at rt. The MS analysis 













Figure 2.13. Deprotection of the Cys(Acm)-containing peptide using PySeSePy and 
Asc determined by mass spectrometry. A) Mass spectrum of the Cys(Acm)-containing 
peptide incubated in neat TFA with 5-fold excess PySeSePy for 12 h at 37 °C. B) Mass 
spectrum of the Cys(Acm)-containing peptide incubated in TFA:TIS (98:2) with 5-fold 
excess PySeSePy for 12 h at 37 °C. C) Mass spectrum of the Cys(Acm)-containing 
peptide incubated in neat TFA for 12 h at 37 °C (control). D) Mass spectrum of the 
peptide containing the Cys(PySe) adduct treated with 5-fold excess ascorbate in 100 mM 










Figure 2.14: Deprotection of the 
Cys(Acm)-containing peptide using 
DTNP in the presence or absence of TIS 
determined by HPLC analysis.  A) HPLC 
chromatogram of the Cys(Acm)-
containing peptide incubated in neat TFA 
for 12 h at 37 °C (control). B) HPLC 
chromatogram of the Cys(Acm)-
containing peptide incubated in 
TFA:thioanisole (98:2) with 5-fold excess 
DTNP for 12 h at 37 °C. C) HPLC 
chromatogram of the Cys(Acm)-
containing peptide incubated in 
TFA:thioanisole:TIS (96:2:2) with 5-fold 
excess DTNP for 12 h at 37 °C. The MS 
analysis that corresponds to panels 2.14A 












Figure 2.15. Deprotection of the Cys(Acm)-containing peptide using DTNP in the 
absence of TIS determined by mass spectrometry.  A) Mass spectrum of the 
Cys(Acm)-containing peptide incubated in neat TFA for 12 h at 37 °C. B) Mass spectrum 
of the Cys(Acm)- peptide incubated in TFA:thioanisole (98:2) with 5-fold excess DTNP 






Figure 2.16: Deprotection of the Cys(Mob)-containing peptide using PySeSePy 
determined by HPLC analysis. HPLC chromatogram of the Cys(Mob)-containing 








Figure 2.17: Deprotection of the Cys(Mob)-containing peptide using DTNP 
determined by HPLC and MS analysis.  A) HPLC chromatogram of the Cys(Mob)-
containing peptide incubated in TFA:TIS:H2O (96:2:2) with 5-fold excess DTNP for 4 














Figure 2.18: HPLC chromatograms of guanylin peptide at various stages of 
synthesis. A) Crude guanylin peptide after cleavage from the resin with concomitant 
removal of S-Trt protecting groups. Cys4 and Cys12 are in the free thiol form, while 
Cys7 and Cys15 remain S-Acm protected. B) HPLC trace of the guanylin intermediate 
after the formation of the first disulfide bond between Cys4 and Cys12 using air 
oxidation. C) HPLC trace of the mature guanylin peptide after the formation of the 
second disulfide bond between Cys7 and Cys15 using 1 eq. of PySeSePy, incubated for 
8 h at 37 °C. D) HPLC trace of the guanylin standard purchased from CPC Scientific. 












Figure 2.19: Mass spectra of guanylin 
peptide at various stages of synthesis. A) 
Crude guanylin peptide after cleavage from 
the resin with concomitant removal of S-
Trt protecting groups. Cys4 and Cys12 are 
in the free thiol form, while Cys7 and 
Cys15 remain S-Acm protected. B) The 
guanylin intermediate after the formation 
of the first disulfide bond between Cys4 
and Cys12 using air oxidation. C) The 
mature guanylin peptide after the 
formation of the second disulfide bond 
between Cys7 and Cys15 using 1 eq. of 






Figure 2.21: Mass spectrum of tachyplesin-1 after cleavage from the resin. Cys7 & 
Cys12 are in Cys-thiol form, while Cys3 & Cys16 are S-Acm protected. Due to the high 
Arg and Lys content of this peptide, which pick up positive charges readily, the peptide 
is detected as a mixture of multiply charged species. Species “A” is the m/z+6 product 
(theoretical m/z+6 = 402.76); species “B” is the m/z+5 product (theoretical m/z+5 = 
482.63); species “C” is the m/z+4 product (theoretical m/z+4 = 603.04); species “C +Na” 
is the sodium adduct of the m/z+4 product (theoretical m/z+4 + Na+ = 626.60); and species 
“D” is the m/z+3 product (theoretical m/z+3 = 803.92). The major peaks are labeled in the 







Figure 2.22: Mass spectrum of tachyplesin-1 with first disulfide bond formed. 
Tachyplesin after formation of first disulfide bond between Cys7 & Cys12 by air 
oxidation. Cys3 & Cys16 remain S-Acm protected. Species “C” is the m/z+4 product 
(theoretical m/z+4 = 602.54); and species “D” is the m/z+3 product (theoretical m/z+3 = 







Figure 2.23: Mass spectrum of tachyplesin-1 with both disulfide bonds formed. 
Tachyplesin after formation of second disulfide bond between Cys3 & Cys16 using 
PySeSePy, and after HPLC purification using a gradient of water/acetonitrile (ACN). 
Species “C” is the m/z+4 product (theoretical m/z+4 = 566.50); species “C +Na+” is the 
sodium adduct of the m/z+4 product (theoretical m/z+4 + Na+ = 588.5); species “C +H2O” 
is the monohydrate of the m/z+4 product (theoretical m/z+4 + H2O = 584.50); species “C 
+K+” is the potassium adduct of the m/z+4 product (theoretical m/z+4 + K+ = 505.60); 
species “C +ACN” is the acetonitrile/NH3
+ adduct of the m/z+4 product (theoretical m/z+4 
+ ACN/NH3
+  = 622.6); species “D” is the m/z+3 product (theoretical m/z+3 = 755.00); 
species “D +Na+” is the sodium adduct of the m/z+3 product (theoretical m/z+3 + Na+ = 
778.00); and species “D +ACN” is the acetonitrile/NH3
+ adduct of the m/z+3 product 
(theoretical m/z+3 + ACN/NH3
+  = 811.10). Note: the ACN adduct is prevalent in our 
final product due to the HPLC purification step where ACN is the solvent. The major 










Figure 2.24. Mass spectra of guanylin 
with and without Asc treatment at pH 
4.5 for 4 h at rt. A) Mass spectrum of the 
synthesized guanylin peptide incubated in 
100 mM ammonium acetate at pH 4.5 
without Asc (control). B) Mass spectrum of 
the synthesized guanylin peptide incubated 
in 100 mM ammonium acetate at pH 4.5 
with 5-fold excess Asc. C) Mass spectrum 
of the commercially available guanylin 
peptide incubated in 100 mM ammonium 
acetate at pH 4.5 with 5-fold excess Asc. 
As is evident, there is no change in mass 
upon reduction with Asc under these 
conditions. For all samples, the arrow 
points to the observed m/z whereas the 
number inside the parentheses denotes the 











Figure 2.25 (A, B, C): Extent of 
deprotection of Cys(Acm) by TIS at 37 
ºC as measured by HPLC. (A) No 
reduction of the S-Acm bond in the 
Cys(Acm) test peptide was observed by 
HPLC after incubation in neat TFA for 12 
h at 37 ºC.  (B) In contrast, incubation of 
the test peptide with TFA:TIS (98:2) for 12 
h at 37 ºC resulted in conversion of S-Acm 
to S-H (35%) and peptide disulfide (35%) 
as evidenced by the HPLC trace. (C) 
Addition of 5-fold excess TCEP to the 
reaction in (B) for 12 h resulted in nearly 













Figure 2.25 (D, E, F): Extent of 
deprotection of Cys(Acm) by TIS at 37 
ºC as measured by HPLC. Traces D, E, 
and F are zoomed in views of traces A, B, 












Figure 2.26: Mass chromatograms of the Cys(Acm) protected peptide under 
various conditions. The arrow points to the observed m/z whereas the number inside 
the parentheses denotes the theoretical m/z value. (A) Mass chromatogram of the Acm-
test peptide after 12 h incubation in neat TFA at 37 ºC. The MS data show that nearly all 
of the peptide exists in the Cys(Acm) form, in agreement with HPLC analysis. (B) Mass 
chromatogram of the Acm-test peptide after 12 h incubation in TFA:TIS (98:2) at 37 ºC. 
The MS data show that inclusion of 2% TIS in the reaction mixture drives deprotection 
to the Cys-SH (m/z = 691.4) and disulfide (m/z = 690.46) forms in support of our HPLC 
analysis. Please note that the value m/z = 690.46 for the peptide disulfide correspond to 














Figure 2.27: Extent of deprotection of 
Cys(Acm) by TIS under standard 
deprotection conditions as measured by 
HPLC. (A) HPLC chromatogram of the 
Acm-test peptide after cleavage from the 
solid support using a cleavage cocktail 
containing TFA:TIS:H2O (96:2:2) for 2 h 
at rt. (B) HPLC chromatogram of the Acm- 
test peptide after further incubation of the 
isolated peptide in neat TFA for 2 h at rt. 
(C) HPLC chromatogram of the Acm-test 
peptide after further incubation of the 
isolated peptide in TFA:TIS (98:2) for 2 h 
at rt.  Little or no deprotection is observed 





















Figure 2.28: Extent of deprotection of 
Cys(Acm) by commonly used SPPS 
scavengers at 37 ºC in TFA as measured 
by HPLC. (A) 2% H2O. (B) 2% anisole. 













Figure 2.29: Mass chromatograms of the Cys(Acm) protected test peptide using 
various scavengers in TFA at 37 ºC. The arrow points to the observed m/z whereas the 
number inside the parentheses denotes the theoretical m/z value. (A) 2% H2O. (B) 2% 











Figure 2.30: Extent of deprotection of 
Cys(Mob) by TIS at 37 ºC as measured 
by HPLC. (A) HPLC chromatogram of the 
Cys(Mob) test peptide after cleavage from 
the solid support using a cleavage cocktail 
containing TFA:TIS:H2O (96:2:2) for 2 h 
at rt. (B) HPLC chromatogram of the 
Cys(Mob) test peptide after incubation in 
neat TFA for 12 h at 37 ºC. (C) HPLC 
chromatogram of the Cys(Mob) test 
peptide after incubation in TFA:TIS (98:2) 












Figure 2.31: Extent of deprotection of 
Cys(But) by TIS at 37 ºC as measured by 
HPLC. (A) HPLC chromatogram of the 
Cys(But) test peptide after cleavage from 
the solid support using a cleavage cocktail 
containing TFA:TIS:H2O (96:2:2) for 2 h 
at rt. (B) HPLC chromatogram of the 
Cys(But) test peptide incubation in neat 
TFA for 12 h at 37 ºC. (C) HPLC 
chromatogram of the Cys(But) test peptide 
after incubation in TFA:TIS (98:2) for 12 h 













Figure 2.32: Mass chromatograms of the Cys(Mob)- and Cys(But) protected test 
peptides under various conditions. The arrow points to the observed m/z whereas the 
number inside the parentheses denotes the theoretical m/z value. (A) Mass spectrum of 
the Cys(Mob) test peptide incubated in TFA for 12 h at 37 ºC. The peak at m/z = 827 
corresponds to the oxidized Cys(Mob) peptide and the peak at m/z 793 corresponds to a 
dehydrated form of the Cys(Mob) peptide, (B) Mass spectrum of the Cys(Mob) test 
peptide after incubation in TFA:TIS (98:2) for 12 h at 37 ºC. The inset shows a close up 
of the region between m/z 685 and m/z 695. The m/z values in the inset show the 
presence of the deprotected peptide and the peptide disulfide. (C) Mass spectrum of the 
Cys(But) test peptide incubated in TFA for 12 h at 37 ºC. (D) Mass spectrum of the 





CHAPTER 3: SYNTHESIS OF ALPHA-METHYL SELENOCYSTEINE AND ITS 
UTILIZATION AS A GLUTATHIONE PEROXIDASE MIMIC. 
 
3.0 ABSTRACT 
Selenocysteine (Sec) is the 21st AA in the genetic code where this AA is primarily 
involved in redox reactions in enzymes due to its high reactivity towards oxygen and 
related reactive oxygen species. Sec has found wide utility in synthetic peptides, especially 
as a replacement for cysteine. One limitation of using Sec in synthetic peptides is that it 
can undergo β-syn elimination reactions after oxidation, rendering the peptide inactive due 
to loss of selenium. This limitation can be overcome by substituting Cα-H with a methyl 
group. The resulting Sec-derivative is α-methylselenocysteine ((αMe)Sec). In 
collaboration with Dr. Masterson and coworkers from University of Southern Mississippi, 
we previously reported a novel strategy for the synthesis of (αMe)Sec166. We then 
synthesized two peptides, one containing Sec, and the other containing (αMe)Sec, based 
on the sequence of glutathione peroxidase (GPX). We made these two peptides with the 
goal of designing a GPX mimic therapeutic that could be administered in times of high 





 As described in Section 1.3.1, Sec-containing glutathione peroxidases are enzymes 
whose canonical function is to reduce lipid hydroperoxides to their corresponding alcohols 
and H2O2 to water. When concentrations of H2O2 are elevated, such as during 
reoxygenation after a period of ischemia, GPX can become overwhelmed and does not 
reduce H2O2 fast enough to prevent reperfusion injury.
33 Thus, it is desirable to design a 
small molecule GPX mimic therapeutic to assist GPX in times of high oxidative stress. 
One example of a small molecule GPX mimic is ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one). Ebselen, first reported in 1924,167 became a widely studied 
GPX mimic after its antioxidant properties were recognized in 1984 
by Müller and coworkers.168 Like GPX, ebselen relies on the redox 
properties of selenium to reduce harmful oxidants and proceeds 
through a similar catalytic mechanism. Ebselen previously made it to clinical trials as a 
neuro- and cardioprotective agent,169 and is currently in clinical trials for treatment of 
hearing loss that is related to oxidative stress.170, 171 However, ebselen is not water soluble, 
making rapid intravenous administration impossible and has shown cellular toxicity in 
some studies.172-174 Other selenium containing GPX mimics have been synthesized and 
some have potent GPX-like activity including cyclic seleninate and selenenate esters,175-
180 spirodioxyselenuranes,181-183 pincer selenuranes,181 and spirodiazaselenuranes.184, 185 
However, many of these compounds are expected to be toxic, are not water soluble, are 
unstable, or quickly lose catalytic activity in the presence of thiols.34 
Peptide therapeutics are growing in popularity due to their high efficacy, high 
selectivity for their desired targets, and relatively low toxicity79, 186. Peptides would also be 
109 
 
water soluble, which would overcome many of the issues presented with other small 
molecule GPX mimics.  
One possible reason that the GPX enzyme itself cannot respond optimally to very 
high concentrations of H2O2, as occurs during reperfusion injury, is that GPX can be 
inactivated by conversion of the Sec residue to dehydroalanine (DHA).187 DHA results 
when the Sec residue becomes overoxidized to the seleninic acid (Sec-SeO2
–) state 
followed by rapid β-syn elimination.  
Ebselen is not as efficient of a catalyst as GPX, but it can be overoxidized without 
undergoing β-syn elimination because it contains an aromatic selenol. Sec-containing 
peptides however can undergo β-syn elimination,188 so the design of any successful peptide 
based GPX mimic needs to avoid this problem. One useful derivative of Sec is (αMe)Sec 
in which the α-hydrogen has been replaced with a methyl group, removing the possibility 
of β-syn elimination (Figure 3.1).  
 
 
Figure 3.1: Avoidance of -syn elimination in (Me)Sec. Sec and Sec-containing 
peptides can undergo deselenization due to oxidation of the selenol followed by rapid -




Thus, (αMe)Sec can resist inactivation by overoxidation while Sec cannot. These 
unique properties are suitable for many potential applications. In the work described in this 
chapter, we used a peptide containing (αMe)Sec to function as a GPX mimic; our (αMe)Sec 
-peptide can rapidly convert H2O2 to water without undergoing self-inactivation, even with 




3.2 Materials and methods 
3.2.1 Materials. 
Solvents for peptide synthesis were purchased from Fisher Scientific (Waltham, 
MA).  Solvents for synthesis including N,N-dimethylformamide (DMF) and 
dichloromethane (DCM) were purchased from Fisher Scientific (Fair lawn, NJ) or Acros 
Organics (Morris Plains, New Jersey). N-Fmoc amino acids were purchased from 
RSsynthesis (Louisville, KY). 2-Chlorotrityl chloride resin SS (100-200 mesh) and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) for solid-phase synthesis were purchased from Advanced 
ChemTech (Louisville, KY). Triisopropylsilane (98%) was purchased from ACROS 
Organics (Pittsburgh, PA). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and 
hydrogen peroxide for enzyme assays were purchased from ThermoFischer Scientific 
(Waltham, MA). NADPH was purchased from AppliChem (Darmstadt, Germany). 
Diphenylphosphoryl azide (DPPA) was purchased from TCI America (Portland, OR). 9-
fluorenemethanol was purchased from Chempep Inc. (Miami, Fl). Titanium (IV) tert-
butoxide was purchased from EMD Millipore. Silica gel (230-400 mesh) for purifications 
was purchased from Silicycle (Quebec City, QC, Canada). Deuterated solvents were 
purchased from Cambridge Isotope Laboratories (Andover, MA). All other chemicals were 
purchased from Sigma-Aldrich (Milwaukee, WI), Fisher Scientific (Waltham, MA), or 
ACROS Organics (Pittsburgh, PA). Mass spectral analysis for synthetic peptides was 
performed on an Applied Biosystems QTrap 4000 hybrid triple-quadrupole/linear ion trap 
liquid chromatograph-mass spectrometer (SciEx, Framingham, MA). Enzyme kinetic 




3.2.2 Peptide Synthesis. 
Either Fmoc-(Me)Sec(But)-OH, or Fmoc-Sec(Mob)-OH were used to synthesize 
peptides of sequence H-(Me)Sec-Gly-Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH (H-
(Me)UGTTVRDYTQ-OH), or H- Sec-Gly-Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH (H-
UGTTVRDYTQ-OH).  We note that we followed the recommendations of Jones for all of 
the abbreviations of amino acids and reagents for peptide synthesis in this thesis.189 All 
peptides were synthesized on a 0.1 mmol scale using a glass vessel that was shaken with a 
model 75 Burrell wrist action shaker. For each batch, 300 mg of 2-chlorotrityl chloride 
resin SS (100-200 mesh), was swelled in DCM for 30 min. The first amino acid was directly 
coupled to the resin using 2% N-methylmorpholine (NMM) in DCM, shaking for 1 h. The 
resin was then capped using 10 mL of 8:1:1 DCM:methanol:NMM. Subsequent amino 
acids were coupled using 0.2 mmol of Fmoc-protected amino acid, 0.2 mmol HATU, and 
2% NMM in dimethylformamide (DMF), shaking for 1 h, rt. Fmoc-Sec(Mob)-OH or 
Fmoc-(Me)Sec(But)-OH were coupled using a solution of 0.2 mmol amino acid, 1% N,N′-
Diisopropylcarbodiimide (DIC), and 0.2 mmol 1-hydroxy-7-azabenzotriazole (HOAt) in 
DMF, shaking for 2 h, rt. Preactivation of any amino acid was not performed prior to 
coupling. Between amino acid couplings, the Fmoc protecting group was removed via two 
10 min agitations with 10 mL of 20% piperidine in DMF. Success of Fmoc removal steps 
and amino acid couplings were monitored qualitatively using a ninhydrin test 142. Removal 
of the final Fmoc protecting group completed the peptide synthesis. Peptides were cleaved 
from the resin via a 4 h reaction with a cleavage cocktail consisting of 0.4 mmol of 2,2′-
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dithiobis(5-nitropyridine) (DTNP), in 10 mL of 96:2:2 TFA/TIS/H2O. Following cleavage 
and side chain deprotection, the resin was washed with TFA and DCM and the volume of 
the cleavage solution was reduced by evaporation with nitrogen gas. The peptide solution 
was then transferred by pipette into cold, anhydrous diethyl ether, where the peptides were 
observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge (International 
Equipment Co., Boston, MA) for 10 min pelleted the peptide. To wash the peptides, peptide 
pellets were dried, dissolved in minimal 96:2:2 TFA/TIS/H2O, then precipitated and 
pelleted as described previously. This wash process was repeated 5 times for each peptide. 
After washing, the final peptide pellet was dried, dissolved in a minimal amount of water, 
lyophilized, and used without further purification.  
 
3.2.3 Measurement of peroxidase activity via glutathione reductase coupled assay. 
  A coupled glutathione reductase (GR) assay was used to test the abilities of the 
peptides to function as GPX mimics. A 0.5 mL solution containing 100 mM potassium 
phosphate (KP) buffer, pH 8.0, 1 mM EDTA, 100 M glutathione, 200 M NADPH, 2 
units of GR, and 10 M of ebselen, H-UGTTVRDYTQ-OH, or H-(Me)UGTTVRDYTQ-
OH, were added to a quartz cuvette and mixed thoroughly. This was used to blank the 
spectrophotometer at 340 nm. Assays were initiated by addition of 200 M H2O2. Activity 
was followed by the decrease of absorption at 340 nm using an extinction coefficient of 
6220 M-1 cm-1, at 25 °C, and each initial rate was measured at least three 
times.  Background NADPH consumption was corrected for by subtracting control 
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experiment activities in which no peptide was present as well as an additional control in 
which no H2O2 was present. 
 
3.2.4 Stability test of Sec-containing peptides. 
To test the stability of peptides in the presence of oxygenated buffer, H-
UGTTVRDYTQ-OH or H-(Me)UGTTVRDYTQ-OH were incubated in 100 mM KP 
buffer, pH 8.0, at 25 °C. Aliquots were taken and centrifuged to pellet precipitated selenium 
after 24, 48, and 96 h. GPX-like activity of the aliquots was monitored as described above. 
To obtain mass spectra, aliquots were infused with a guard column at 10 L/min into a 100 
L/min mobile phase flow consisting of 50/50 water/acetonitrile with 0.1% formic acid. 
The mobile phase flow was introduced into an Applied Biosystems QTrap 4000 hybrid 
triple-quadrupole/linear ion trap liquid chromatograph-mass spectrometer operating in 






3.3.1 Synthesis of GPX-peptide mimics 
Owing to the quaternary α-carbon, (αMe)Sec has proven challenging to synthesize. 
Previously, a racemic pathway by Reich 190 and a chiral pathway by Iwaoka 191, 192 have 
been executed for the synthesis of (αMe)Sec, however each have their limitations. Our 
previously reported synthetic method allows for quick synthesis, with moderate yields 
while also obtaining high enantiomeric excess166. Briefly, this synthesis starts by alkylation 
of an achiral methyl malonate through the use of a selenium-containing alkylating agent 
synthesized in the presence of dichloromethane. The seleno-malonate was then subjected 
to an enzymatic hydrolysis utilizing pig liver esterase followed by a Curtius rearrangement 
producing a protected derivative of (αMe)Sec that could be used in solid phase peptide 
synthesis166. By utilizing this methodology, access to both enantiomers, as well as other 
relevant analogues, such as α-AAs, are possible. 
With  (αMe)Sec in hand, we synthesized the peptide of sequence: H-(αMe)Sec-Gly-
Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH, and the control peptide of sequence: H-Sec-Gly-
Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH using standard solid phase Fmoc-based protocols. 
109 Both peptides correspond to AAs 49-58 of the human GPX active site. For the control 
peptide, Fmoc-Sec(Mob)-OH was synthesized as reported previously. 58 Sec and (αMe)Sec 
residues were coupled using HATU and DIC in DMF. 193 During cleavage of both peptides 
from the 2-cholortrityl resin, DTNP was included in the cleavage cocktail (TFA/TIS/H2O) 
to remove the Mob protecting groups, 89 and this deprotection afforded a mixture of three 
different forms of the peptide: (i) peptide diselenide, (ii) peptide selenol, and (iii) Sec(5-
Npys) or (αMe)Sec(5-Npys) protected peptide. This crude peptide mixture containing these 
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three redox states of the peptide were used without further purification for the enzyme 
assay. The HPLC chromatograms of each unpurified peptide is shown in Figure 3.2. 
 
3.3.2 GPX like peroxidase activity of peptide mimics 
A coupled glutathione reductase (GR) assay was used to test the abilities of the 
peptides to function as GPX mimics. 194 Both peptides were able to reduce H2O2 
significantly higher than the background rate. The rate for the (αMe)Sec-containing peptide 
with 200 µM H2O2 was 23.50 ± 1.88 µM/min, while the rate for the Sec-containing peptide 
was 17.96 ± 0.37 µM/min based on the slopes of the plot of A340 vs. time shown in Figure 
3.3A. These values compare favorably to that of ebselen in our hands (38.84 ± 1.80 
µM/min, data not shown). While the (αMe)Sec-containing peptide had only a slight kinetic 
advantage, a much larger difference in stabilities of the two peptides was observed as 
shown in Figure 3.3B, which shows the activity remaining after incubation in oxygenated 
KP buffer, pH 8.0, as a function of time. 
 
3.3.3 Mechanisms of loss in activity of GPX-peptide mimics 
The loss in activity of the Sec-containing peptide in oxygenated buffer quantified 
in Figure 3.3B is most likely due to oxidation of the Sec residue followed by 
deselenization, which can occur by various mechanisms including β-syn elimination. 
Deselenization results in the appearance of a red precipitate due to the insolubility of 
elemental red selenium. Visual evidence for this phenomenon can be seen in Figure 3.4, 
which shows a comparison of deselenization of peptides. As can be seen, a red precipitate 
clearly forms after 96 hours in the tube with the Sec-containing peptide, but not in the 
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(αMe)Sec-containing peptide. As is evident in Figure 3.4, no color change was observed 
in the reaction containing our (αMe)Sec-peptide even after 96 hours of incubation. Fitting 
with these observations, the (αMe)Sec-containing peptide maintained greater than 65% 
activity (Figure 3.3B).  
The (αMe)Sec-containing peptide cannot lose selenium through an oxidation/β-syn 
elimination pathway and thus this cannot be the reason for the modest loss in activity after 
96 h in oxygenated buffer. Some possible explanations for the observed decrease in activity 
of the Sec-peptide are photo-degradation of the peptide due to the presence of selenium or 
oxidation of other AAs. 
To further investigate deselenization of both peptides, we submitted them for MS 
analyses at the initial time point and after 96 hours of incubation in oxygenated buffer. The 
results of these analyses are shown in Figure 3.5. Initially both peptides exist as a mixture 
of three species: selenol (species A), diselenide (species B), and Sec(5-Npys) adduct 
(species C). The MS analysis of the Sec-peptide provides clear evidence that β-syn 
elimination occurred upon 96 h of incubation in oxygenated buffer due to the presence of 
the dehydroalanine-containing peptide present in Figure 3.5D (species D). In contrast, the 
dehydroalanine species is absent from our (αMe)Sec-peptide after incubation for the same 
time period (Figure 3.5B). In addition, the MS data in Figure 3.5D show that 
deselenization occurred by other mechanisms as evidenced by the presence of a truncated 
peptide (species E) and a peptide in which the Sec residue was converted into alanine via 
a radical mechanism (species F).195 Species D-F are absent in the mass spectrogram of the 
(αMe)Sec-peptide after incubation for the same time period as is evidenced by a much less 
complex mass spectrogram (compare Figures 3.5B and 3.5D).  
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While the mechanism of β-syn elimination of a seleninate and selenoxides are well 
understood,13, 188, 196 we are unaware of any report where oxidation of a Sec-containing 
peptide results in cleavage of the peptide backbone. The cleavage product in which the Sec 
residue eliminated from Sec-peptide completely (species E) is the most intense peak in the 
mass spectrogram visible in Figure 3.5D. This truncation is possible through a mechanism 
in which the seleninate oxygen attacks the carbonyl carbon of the peptide backbone, 
resulting in a 5-membered, cyclic seleninate ester. Deselenization of Sec to alanine (species 
F) has previously been reported and experimental evidence supported a radical 
deselenization mechanism.195 Proposed mechanisms to explain the formation of species D-
F from the (αMe)Sec-peptide are shown in Figure 3.6. 
As far as we are aware, the cleavage of the peptide backbone by a seleninate has 
not been reported in the literature and potentially represents a mechanism by which Sec-
containing enzymes can be inactivated. The cleavage reaction is undoubtedly accelerated 
at basic pH as done here, and highlights the fact that Sec-containing enzymes may be better 
suited to work at acidic pH.62 We do note however, that Adams and Macmillan report a 
related phenomenon whereby a side chain selenolate attacks the backbone carbonyl to form 
a selenoester, which can then be used for native chemical ligation.157 
 
3.3.4 Enhanced stability of alpha-methyl Sec containing peptide. 
We believe a likely explanation for the absence of truncated product in the 
(αMe)Sec-peptide is due to steric hindrance caused by the methyl group on the α-carbon. . 
It is well known that the  and  angles of -methyl AAs are restricted in comparison to 
AAs lacking the methyl group at C.197 The resulting rigidity introduced by the methyl 
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group on Cα most likely prevents nucleophilic attack, explaining the absence of species E 
upon prolonged incubation in oxygenated buffer. 
An additional mechanism in which the Sec-containing peptide can be oxidized in 
buffer at basic pH is shown in Scheme 3.1.198 Initially a significant fraction of both peptides 
are oxidized to the diselenide form. At basic pH, the diselenide can be oxidized to a 
selenoseleninate. The selenoseleninate can then undergo hydrolysis to yield the seleninate 
and a selenol. The selenol can reoxidize back to the diselenide to start the cycle over, or be 
converted to an alanine-containing peptide via a radical mechanism (species F).195 The 
seleninate can breakdown via β-syn elimination or truncation to yield species D and E.  
 
 
Scheme 3.1: Oxidation of the diselenide forms of Sec- and (aMe)Sec-peptides. See 





In principle, the diselenide of the (αMe)Sec-containing peptide can undergo the 
same cycle of oxidation shown in Scheme 3.1 to yield the seleninate. However, the MS 
data in Figure 3.5B does not show evidence of the seleninate form being present. Either 
our analysis has not detected this intermediate form, or the diselenide of the (αMe)Sec-
containing peptide is resistant to oxidation. Of course the seleninate form of the (αMe)Sec-
containing peptide cannot undergo β-syn elimination or truncation due to the presence of 
the methyl group on Cα as discussed earlier. The selenol form of the (αMe)Sec-containing 
peptide could also be converted into α-methyl-alanine-containing peptide by a radical 




3.4 Summary and Future work 
In conclusion, we have synthesized an (αMe)Sec-containing peptide that functions 
as a GPX mimic to convert H2O2 into water. This peptide demonstrated peroxidase activity 
that was 60% of that of ebselen, a known small molecule GPX mimic. We also found that 
replacement of Sec with (αMe)Sec confers superior stability to the peptide as the oxidized 
form of (αMe)Sec cannot undergo β-syn elimination or cleavage of the backbone. This AA 
will undoubtedly find many chemical and biotechnological applications. 
An obvious next step in this project is to test other substrates beyond H2O2. Since 
GPX mostly reduces lipid hydroperoxides to their corresponding alcohols, work is needed 
to test the ability of our (αMe)Sec-peptide to reduce lipid hydroperoxides. It is possible 
that for larger substrates, the steric constrains imposed by (αMe)Sec may make this large 
peptide mimic unsuitable for efficient catalysis.  
Importantly, there is much work needed to increase the rates of peroxide reduction. 
As stated, our peptide mimic was only 60% as active as ebselen. One way to improve rates 
of our current GPX-mimic peptide is to change the AA sequence. The AA sequence of the 
peptide might allow it to take on conformations that would speed up the rates of peroxide 
reduction. For example, Yin and coworkers develevoped a GPX mimic peptide of 
sequence: H-Arg-Gly-Sec-Arg-Asp-COOH (5P), and concluded: “In comparison with 
other enzyme models, 5P provided a suitable substrate with proper catalytic site positions, 
resulting in enhanced catalytic activity. In our mouse model, 5P showed excellent 
inhibition of tumor growth and improved immunity.” We postulate that replacing Sec with 
(αMe)Sec in their 5-mer sequence will provide enhanced stability to this already optimized 
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peptide. Thus, the combination of peptide conformation with enhanced stability owning to 
(αMe)Sec, should make a superior GPX-peptide mimic199.  
 
3.4.1 Biotechnological applications of alpha-methyl Sec 
Beyond it’s role as a GPX mimic, we envision there will be many other applications 
for (αMe)Sec due to its unique stability. As described in Section 2.1.3, thioester formation 
is a major limitation in commonly used native chemical ligation (NCL) reactions. One way 
to overcome N→S acyl shift limitations for thioester formation is to modify the Cys residue 
by targeting the amide bond to be alkylated to disrupt conjugation and increase the 
electrophilicity of the carbonyl amide163, 200-202. Offer and coworkers used such an approach 
to develop an Fmoc compatible method to generate thioesters that would permit direct use 
in NCL203. Offer and coworkers found that trityl side-chain protected (αMe)Cys was stable 
throughout peptide synthesis, and after deprotection, N→S acyl transfer and ligation could 
occur efficiently resulting in a peptide thioester203. As discussed previously, Macmillian 
and cowokers report that Se is a superior acyl transfer reagent over sulfur157. Thus, a 
combination of the work done by Offer and Macmillian to generate C-terminal thioesters 
via utilization of (αMe)Sec and an N→Se acyl shift should be highly effective; (αMe)Sec 
should be a superior acyl-transfer reagent due to the increased nucleophilicity of Se to S 
for carbonyl attack and its unique steric properties that will increase electrophilicity of the 
carbonyl amide.  
Additionally, (αMe)Sec can act as a reversible redox switch as it can readily cycle 
between the -2 and +2 redox states (and others) due to its resistance to β elimination. One 
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application of (αMe)Sec is that it could be used as a switchable surfactant. (αMe)Sec could 
be esterified and N-acylated with a fatty acid and oxidized as depicted in Figure 3.7.  
 
 
Figure 3.7: Switchable surfactant utilizing (αMe)Sec and its redox properties. (Left) 
This molecule would be hydrophobic in the diselenide form. (Right) when oxidized to 
the seleninic acid form, the molecule would have a charged, hydrophilic head group and 
act as a detergent. Ascorbate reduction and oxidation back to the hydrophobic disulfide 
form would be possible. 
 
There are commercially available products available that function similarly, 
including PPS Silent Surfactant™ from Expedeon and ProteaseMax™ from Promega204, 
205. PPS Silent Surfactant™, which is commonly used as a Mass Spec detergent, can only 
be cleaved using treatment with strong acids for 30 minutes, and is not reversible206. Using 
(αMe)Sec as a redox-active switchable surfactant is advantageous in that it is recyclable 
with little waste accumulation, would be time efficient, and uses ascorbate as an 
inexpensive reductant.  
These are only a few of the biotechnological applications we envision for 
(αMe)Sec, and there is still much work to be done in exploring the chemical abilities of 
this unique AA. We hope it will someday become commercially available as it is a powerful 
tool in peptide and protein chemistry.  
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Figure 3.2: HPLC chromatograms of unpurified (αMe)Sec- and Sec-containing 











Figure 3.3: GPX-like activity and stability of Sec- and (αMe)Sec-containing 
peptides. (A) GPX-like activity of (αMe)Sec-peptide (blue) and Sec-peptide (red) 
assayed with H2O2. GSSG is formed as a by-product of the peptide catalytic cycle. GR 
reduces GSSG back to GSH using NADPH, and the consumption of NADPH can be 
measured via absorbance at 340 nm. (B) Percent activity remaining after incubation of 













Figure 3.4. β-syn elimination in a Sec-containing peptide exposed to oxygenated 
buffer, pH 8.0:  Peptides (1 mM) were incubated in KP buffer, pH 8.0, for the indicated 
times above. After 96 hours β-syn elimination is clearly visible in the Sec-peptide (tube 













Figure 3.5: Mass spectra of GPX-mimic peptides after 96 h of incubation in 
oxygenated buffer. The arrow points to the observed m/z, given in the plot. The 
(αMe)Sec-containing-peptide at time zero (A) and after 96 h incubation in KP buffer, 
pH 8.0 (B). For (αMe)Sec-peptides; species A is the peptide in selenol form (theoretical 
m/z = 1204.46), species A-NH3 is the ammonium adduct of A (theoretical m/z = 
1220.46), species B is the peptide diselenide (theoretical m/z = 2406.91), and species C 
is the 5-Npys adduct (theoretical m/z = 1359.45). The Sec-containing-peptide at time 
zero (C) and after 96 h incubation in KP buffer, pH 8.0 (D). For Sec-peptides; species A 
is the peptide in selenol form (theoretical m/z = 1190.45), species A-NH3 is the 
ammonium adduct of A (theoretical m/z = 1207.45), species B is the peptide diselenide 
(theoretical m/z = 2377.88), species C is the 5-Npys adduct (theoretical m/z = 1344.43), 
species D is dehydroalanine in place of Sec (theoretical m/z = 1108.51), species D-NH3 
(theoretical m/z = 1125.52), species E is truncated peptide where Sec is missing 
(theoretical m/z = 1040.49), species E-potassium adduct (theoretical m/z = 1080.49), and 






Figure 3.6: Potential chemical mechanisms of deselenization of Sec-peptide. The 
selenol in the sample can undergo oxidation to form the seleninate, which then undergoes 
rapid β-syn elimination to produce the dehydroalanine-containing peptide (species D). 
The truncated peptide (species E) is potentially explained by attack of the nucleophilic 
seleninate oxygen onto the carbonyl of the amide backbone, resulting in a cyclic 
seleninate ester and elimination of the Sec residue (lower pathway). Species F can be 
produced through a radical mechanism. Initiation of the radical could be photo-induced 
or alternatively, the selenolate can react with molecular oxygen to produce the selanyl 
radical and superoxide. The selanyl radical could recombine with molecular oxygen 






CHAPTER 4: INCORPORATION OF ALPHA-METHYL SELENOCYSTEINE 
INTO THIOREDOXIN REDUCTASE CONFERS RESISTANCE TO (I) 
OXIDATIVE INACTIVATION AND (II) INACTIVATION BY REACTIVE 
BIOLOGICAL ELECTROPHILES. 
 
4.0 ABSTRACT  
Selenocysteine (Sec) is the 21st proteogenic AA and it exists in the proteome of 
mammals and other higher-level eukaryotes. The incorporation of Sec into proteins 
involves the recoding of stop codon UGA into a sense codon and is energetically costly. 
For this reason and others, the question of “why did nature chose selenium?” often arises 
when selenoproteins are studied. It is now widely accepted that Sec-proteins evolved to 
resist oxidative stress since Sec can be oxidized and rapidly reduced by biological reducing 
agents. Herein, we provide biochemical evidence to expand this hypothesis: selenoproteins 
can resist permanent inactivation by biological reactive electrophilic species (RES) such 
as acrolein, 4-hydroxynonenal, and curcumin better than orthologous sulfur-containing 
(cysteine (Cys)) enzymes. To test this hypothesis, we constructed a mutant thioredoxin 
reductase (TrxR) where the penultimate Sec residue is replaced with alpha-methyl Sec 
((αMe)Sec). Since this unique AA does not have a proton at its α-carbon, it can resist β-
syn elimination when oxidized and is therefore forced to undergo a selenoxide elimination 
with a formed Michael adduct. We show that our (αMe)Sec-TrxR is able to resist oxidative 
inactivation even better than the WT Sec-TrxR when incubated with increasing amount of 
H2O2 (0-100 mM). We then went on to inactivate TrxR enzymes with acrolein and showed 
that we could restore up to ~30% Trx reductase activity for the (αMe)Sec-mutant using 
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H2O2 and imidazole at 37 °C. We could also restore ~25% Trx reductase activity in acrolein 




Thioredoxin reductase (TrxR) is a NADPH dependent pyridine nucleotide-
disulphide oxidoreductase whose canonical function is to reduce the small protein, 
thioredoxin (Trx)29. TrxR and thioredoxin comprise the thioredoxin system which is a vital 
antioxidant system responsible for maintaining redox homeostasis in the cell by providing 
essential reducing equivalents to a number of important cellular targets35. Mammalian 
thioredoxin reductase (mTrxR) has a selenocysteine (Sec) residue at the penultimate 
position of its C-terminus that is involved in the catalytic function of the enzyme5. 
However, cysteine (Cys) containing orthologs of TrxR exist in prokaryotes and lower level 
eukaryotes that can catalyze the same reactions as their Sec-containing TrxR counterparts. 
Due to the complicated and bioenergetically costly process of incorporating Sec into 
mTrxR (which involves the recoding of stop codon UGA into a sense codon)48, 49, 58, the 
question of “why did nature chose selenium?” frequently arises when mTrxR, and other 
selenoproteins, are studied5.   
It was previously thought that Sec replaced Cys in selenoenzymes as a chemical 
necessity; that is, the reaction catalyzed by these enzymes would be much faster with 
selenium at the C-terminus active site than sulfur11. However, this was found to be untrue 
when Kanzok and coworkers found that the rate of E. coli Trx reduction by human (Sec-
containing) TrxR was only about ~4 fold higher than the rate of E. coli Trx reduction by 
Drosophila melanogaster (Cys-containing) TrxR12 (DmTrxR-CCS). The authors 
determined that “these data speak against the proposition that selenocysteine in the COOH-
terminal Cys-X sequence of high Mr TrxRs is a chemical necessity.”
12 Thus, it can be 
concluded that the presence of Sec in mTrxR is not confined to a purely catalytic role. 
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One hypothesis, first proposed by Chaudiere in 199213 and strongly revived by the 
Hondal lab, is that Sec replaces Cys to resist oxidative stress14, 15. This hypothesis is 
described in Section 1.2.1. 
A new hypothesis that we explore in this work expands upon the idea that Sec has 
evolved in enzymes to resist oxidative stress. We hypothesize that Sec evolved in enzymes 
to not only resist oxidative stress, but electrophilic stress in general, better than Cys. 
Ground-state oxygen atoms, which are diradicals, behave as distinctly electrophilic 
reagents18. However, oxygen is not the only biological electrophile that Sec-enzymes 
encounter in vivo. Indeed, there are many biological reactive electrophilic species (RES) 
that have been shown to interact with selenoproteins, including Sec-TrxRs. Many RES 
contain an α,β-unsaturated carbonyl moiety that makes them Michael acceptors for Michael 
addition type reactions. Given its low pKa, Sec is an excellent biological nucleophile at 
neutral pH making it a strong target for adduction by RES as demonstrated in Figure 4.1.  
 
Figure 4.1: Sec RES 
adduction. Due to the low 
pKa of Sec, it acts as a 
nucleophile at neutral pH 
and can undergo Michael 
addition reactions with RES 
containing α,β-unsaturated 
carbonyl functional groups. 
 
Interactions between Sec-TrxRs and RES, and the biological consequences of such 
reactions, have been well documented19-21, 207. Sec-TrxRs adducted by RES are sometimes 
referred to as “SecTRAPs” (selenium compromised thioredoxin reductase-derived 
apoptotic proteins). SecTRAPs are known to be devoid of thioredoxin reductase activity, 
however, the N-terminus redox center of TrxRs (which contain two Cys residues) can 
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donate one electron to molecular oxygen which then dismutates, producing H2O2
208. Thus, 
while Sec-TrxRs are typically considered antioxidant proteins, when adducted by RES, 
SecTRAPs are pro-oxidants, increasing cellular oxidant levels (Figure 4.2). 
 
Figure 4.2: Formation of a “SecTRAP” by electrophile alkylation of the C-terminal 
Sec residue. (Left): First, NADPH donates two electrons to FAD, which in turn donates 
two e- to the N-terminal redox center. This reduces the N-terminal S-S bond, and one of 
the Cys-thiols goes on to reduce the C-terminal Se-S bond (shown at the bottom). Once 
reduced, the Sec-selenol can reduce substrates, such as Trx. When Sec is adducted (as 
displayed at the top), TrxR cannot reduce Trx and the N-terminal redox center is 
accessible. (Right): One electron can be donated to molecular oxygen from the flavin 
cofactor (pink, FAD), which then dismutates to H2O2. 
 
We hypothesize that the accumulation of oxidant surrounding SecTRAPs may act 
as a “molecular timer” and oxidize the Sec-selenide to a selenoxide, which will 
subsequently undergo a selenoxide elimination reaction. The elimination of the RES-







Figure 4.3: Selenoxide elimination mechanism for RES reversibility. (A) Once Sec 
is alkylated by acrolein, mTrxR-CUG will produce oxidant, and Sec will be converted 
to a selenoxide which can undergo β-syn elimination with a proton from acrolein 
(pathway 1), or with the α-H from the enzyme backbone (pathway 2). Pathway 1 would 
effectively remove the acrolein adduct, resulting in Sec-SeOH, which can be reduced by 
the neighboring Cys residue back to the active form of the enzyme. Pathway 2 results in 
Se leaving along with the acrolein adduct, and formation of DHA. Without Sec in the 
active site, enzyme activity cannot be restored. (B) Our mutant mTrxR-C(αMe)UG 
enzyme forces the removal of acrolein to take place through pathway 1. Thus, the mutant 





One potential problem with testing this hypothesis is that β-syn elimination by 
pathway 2 results in elimination of Se from the enzyme with concomitant dehydroalanine 
(DHA) formation and inactivation of the enzyme. To circumvent this ambiguity, we 
constructed a mutant mTrxR enzyme using protein semisynthesis that contains alpha-
methyl selenocysteine ((αMe)Sec) in place of the penultimate Sec residue in the C-terminus 
of mTrxR. We previously reported the synthesis of this unique AA and demonstrated its 
ability to resist β-syn elimination from overoxidation in a peptide that mimics the active 
site of glutathione peroxidase (GPX)166. The benefit of using our mutant protein is 
emphasized in Figure 4.3B. 
First, we explored the ability of the (αMe)Sec-containing mTrxR mutant 
((αMe)SecTrxR) to resist oxidative stress compared to the mTrxR-CUG wild type (WT). 
We tested the abilities of WT mTrxR, (αMe)SecTrxR, and DmTrxR to resist inactivation 
by H2O2 (0-100 mM) for several substrates including Trx, H2O2, and DTNB. In all cases, 
but especially for peroxidase and DTNB reductase activity, our (αMe)SecTrxR showed a 
superior ability to resist oxidative inactivation compared to the mTrxR WT and DmTrxR. 
We next utilized the unique stability of (αMe)SecTrxR to explore a non-enzymatic 
mechanism by which selenoproteins can reverse RES adduction. Acrolein is a potent 
biological electrophile that is produced both endogenously and exogenously209. We found 
that incubating (αMe)SecTrxR with ~1:1 acrolein for 10 min at 22 °C depleted ~76% Trx 
reductase activity compared to an acrolein untreated control. We were able to subsequently  
restore activity to 55% of the control, a gain of ~30% activity, when we treated the acrolein-
adducted αMeSecTrxR with 2 mM H2O2 and 5 mM imidazole at pH 7.15 and 37 °C for 15 
min. Notably, WT mTrxR-CUG also can be reversed from acrolein inhibition using H2O2 
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and imidazole (albeit, to a lesser extent than our mutant), but inhibition of DmTrxR (which 
lacks Sec) cannot be reversed under the same conditions.  
The results of our in vitro acrolein reversibility experiments provide strong 
evidence to support previous in vivo work by Randall and coworkers, who demonstrated 
that acrolein rapidly inactivates Sec-TrxR in human bronchiolar epithelial cells, which 
recovers over 4–8 h by a mechanism depending on the presence of cellular glutathione and 
Trx.  Their reported loss then subsequent recovery of Sec-TrxR activity corresponds with 
reversal of the formed protein–acrolein adduct. Based on their results, the authors 
concluded: “These findings indicate that acrolein-induced protein alkylation is not 
necessarily a feature of irreversible protein damage, but may reflect a reversible signaling 
mechanism that is regulated by GSH and Trx.”27 
For the first time, we are providing mechanistic evidence that Sec-TrxRs can resist 
electrophilic stress by breaking the selenium-carbon bond that forms when selenoproteins 
are adducted by RES. Our findings have enormous implications in many areas of redox 
biochemistry as they strongly suggest that protein alkylation by RES may be an important 
reversible event. Sec-RES reversibility likely plays a role in adaptive responses to RES, or 
may functions as an electrophile-specific signaling mechanism analogous to protein S-
modifications27, 210. A more complete understanding of these reversal mechanisms provides 
insight into the biological functions of electrophiles and will undoubtably contribute to 
improved strategies for therapeutic intervention of RES affected proteins27.  
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4.2 Materials and Methods 
4.2.1 Materials. 
Solvents such as dichloromethane, acetonitrile, dimethylformamide, methanol, 
anhydrous diethyl ether, trifluoroacetic acid, and ethyl acetate were purchased from Fisher 
Scientific (Waltham, MA).  N-Fmoc amino acids and Boc-Cys(Mob)-OH were purchased 
from RSsynthesis (Louisville, KY). 2-Chlorotrityl chloride resin SS (100-200 mesh), 1-
hydroxy-7-azabenzotriazole (HOAt) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) for SPPS were purchased 
from Advanced ChemTech (Louisville, KY). Chitin resin for TrxR semisynthesis was 
purchased from New England Biolabs (Ipswich, MA). Immobilized catalase beads was 
obtained from BioVision Incorporated (San Francisco, CA). Corning™ Costar™ Spin-X™ 
Centrifuge Tube Filters utilized to remove catalase agarose were purchased through Fisher 
Scientific (Waltham, MA). Hydrogen peroxide (30%, certified ACS), acrolein solution 
(100μg/mL or 5000μg/mL in methanol, Ultra Scientific), were also purchased from Fischer 
Scientific (Waltham, MA). NADPH for enzyme assays was purchased from AppliChem 
(Darmstadt, Germany). Amicon® Ultra Centrifugal Filter Units were purchased from 
Millipore Sigma (Darmstadt, Germany). RapiGest™ SF surfactant for MS analysis of TrxR 
enzymes was purchased from Waters Corp. (Milford, MA). Sequencing grade modified 
trypsin for digestion of TrxR enzymes was purchased from Promega (Madison, WI). 
Imidazole (reagent grade), bovine serum albumin (lyophilized powder, BioReagent), 
iodoacetamide, 2,2′-dithiobis(5-nitropyridine) (DTNP), 5,5′-dithiobis(2-nitrobenzoic acid) 
(DTNB, 99%), selenocysteamine dichloride, pentafluorophenol (>99%), iodoacetaminde 
(BioUltra), 4-hydroxynonenal (Calbiochem), curcumin (from Curcuma longa, powder), 
138 
 
and silica gel for column chromatography were purchased from Millipore Sigma 
(Milwaukee, WI). Sodium borohydride (98+%, powder), triisopropylsilane (98%), 
piperidine, ninhydrin, formic acid (98+%), N-methylmorpholine (99%), and N,N'-
dicyclohexylcarbodiimide (99%), were purchased from ACROS Organics (Pittsburgh, 
PA). All other chemicals were purchased from Sigma-Aldrich (Milwaukee, WI), Fisher 
Scientific (Waltham, MA), or ACROS Organics (Pittsburgh, PA). Mass spectral analysis 
was performed via positive ESI on a Thermo Q Exactive mass spectrometer where full MS 
scans were performed at a resolution of 70,000 in positive ion mode. Collected data files 
were analyzed using Xcalibur Qual Browser V3 (ThermoScientific, Waltham, MA). 
Enzyme kinetic assays were performed on a Cary50 UV-Vis spectrophotometer (Walnut 
Creek, CA).    
 
4.2.2 Synthesis of Boc-Cys(Mob)-OPfp. 
Boc-Cys(Mob)-OH (6.0 mmol, 2.05g) was dissolved in 10 mL of dry DCM and 
cooled to 0 °C via ice bath, under nitrogen gas. To this, DCC (3.0 mmol, 619.0 mg) 
dissolved in 10 mL of dry DCM was added. Reaction was allowed to proceed ~15 min with 
constant stirring. A white precipitate was observed to form after ~5 min. Pentafluorophenol 
(6.0 mmol, 1.1g) dissolved in 20 mL dry ethyl acetate was added under nitrogen gas, and 
the reaction was immediately removed from ice and allowed to warm to rt (~22 °C), and 
stirred an additional 1.5 hr. The white urea precipitate was removed from solution via 
filtration, and the filtrate was placed on ice for 15 min to prompt formation of more 
precipitate and filtered again. The final filtrate was reduced to a yellow oil via roto-
evaporation, and column purified using ~25 g silica gel and ~300 mL of 80:20 hexanes: 
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ethyl acetate as a solvent. 20 mL fractions were collected and the desired Boc-Cys(Mob)-
OPfp eluted with an Rf = 0.44. Impurities stick to the silica. The final eluant containing 
Boc-Cys(Mob)-OPfp was dried using roto-evaporation and hi-vac producing a white, 
crystalline solid in 89% yield (4.3 g). 
 
4.2.3 Solid phase peptide synthesis of H-CUG-OH. 
Fmoc-Sec(Mob)-OH, synthesized as described previously, was used make the 
peptide of sequence H-Cys-Sec-Gly- OH (H-CUG-OH).  We note that we followed the 
recommendations of Jones189 for all of the abbreviations of amino acids and reagents for 
peptide synthesis in this dissertation. The peptide was synthesized on a 0.1 mmol scale 
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. First, 300 
mg of 2-chlorotrityl chloride resin SS (100-200 mesh), was swelled in DCM for 30 min. 
Fmoc-Gly-OH was then coupled directly to the resin using 8 mL of 2% N-
methylmorpholine (NMM) in DCM, shaking for 1 h at 22°C. The resin was then capped 
using 10 mL of 10% methanol, 10% NMM in DCM. Next, Fmoc-Sec(Mob)-OH was 
coupled to Gly using a solution of 0.2 mmol amino acid, 1% N,N′-Diisopropylcarbodiimide 
(DIC), and 0.2 mmol 1-hydroxy-7-azabenzotriazole (HOAt) in DMF, shaking for 2 h, rt. 
The last amino acid, Fmoc-Cys(Trt)-OH, was coupled using a solution of 0.2 mmol amino 
acid, 1% DIC, and 0.2 mmol HOAt in DMF, shaking for 1 h, rt. Preactivation of any amino 
acid was not performed prior to coupling. Between amino acid couplings, the Fmoc 
protecting group was removed via two 10 min agitations with 10 mL of 20% piperidine in 
DMF. Success of Fmoc removal steps and amino acid couplings were monitored 
140 
 
qualitatively using a ninhydrin test142. Removal of the final Fmoc protecting group 
completed the peptide synthesis.  
 
4.2.4 Solid phase peptide synthesis of H-C(αMe)UG-OH. 
The preparation of 2-chlorotrityl chloride resin, coupling and subsequent 
deprotection of Fmoc-Gly-OH was completed a described above on a 0.1 mmol scale. 
Next, Fmoc-(αMe)Sec(But)-OH, synthesized as described previously166, was coupled to N-
deprotected Gly using a solution of 0.2 mmol amino acid, 1% DIC, and 0.2 mmol HOAt 
in DMF, shaking for 2 h, rt. The Fmoc group was then removed from (αMe)Sec via six, 45 
min agitations with 10 mL of 20% piperidine in DMF. Note: ninhydrin test was not used 
to monitor complete Fmoc removal as we found the (αMe)Sec-amine to be too hindered to 
react with the ninhydrin dye. To couple Cys to (αMe)Sec, resin was washed extensively 
with DCM to remove any DMF, then swelled in a minimal volume of DCM and shaken 
with 2% NMM for 15 min. A solution of 0.22 mmol Boc-Cys(Mob)-Opfp (synthesized as 
described above) in 5 mL DCM was then added to the resin, and the resin shaken for 1.5 
hours at 22 °C. After 1.5 h shaking, 0.15 mmol HATU in 5mL of DMF was added and for 
an additional 1 h. The resin was washed 4x with DMF, then 4x with DCM and the Boc-
Cys(Mob)-OPfp coupling step was repeated 12-15 times. Note: we were able to scale this 
tripeptide synthesis up to a 0.3 mmol scale, but for best results typically made the tripeptide 






4.2.5 Cleavage of peptides from resin. 
Peptides H-CUG-OH and H-C(αMe)UG-OH were cleaved from the resin via a 1.5 
h reaction with a cleavage cocktail consisting of 4 fold excess of 2,2′-dithiobis(5-
nitropyridine) (DTNP), in 10 mL of cleavage cocktail (2% H2O, 2% TIS in TFA). 
Following cleavage and side chain deprotection, the resin was washed with TFA and the 
volume of the cleavage solution was reduced by evaporation with nitrogen gas. The peptide 
solution was then transferred by pipette into cold, anhydrous diethyl ether, where peptide 
was observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge 
(International Equipment Co., Boston, MA) for 10 min pelleted the peptide. To wash the 
peptide, pellets were dried, dissolved in minimal volume of cleavage cocktail, then 
precipitated and pelleted as described previously. This wash process was repeated 5 times 
for each peptide to remove any unreacted DTNP. After washing, the final peptide pellet 
was dried, dissolved in a minimal amount of water, lyophilized, and used without further 
purification.  
 
4.2.6 Semisynthesis of TrxR enzymes. 
The production and purification of the recombinant DmTrxR-CCS and the semi-
synthetic mTrxR-CUG enzymes used in this study have been previously reported57, 61. In 
order to replace the active site Sec of mTrxR (Sec489) with (αMe)Sec, we used a mTrxR-
intein fusion protein in which the final three amino acids (Cys-Sec-Gly) are missing. A 
tripeptide of sequence H-Cys-(αMe)Sec-Gly-OH (synthesized as described above) was 
then ligated to the enzyme using the technique of protein semisynthesis58. Procedures for 
construction of this fusion protein and the conditions needed to carry out peptide ligation 
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in order to create mutants of mTrxR by semisynthesis have previously been reported57, and 
we used analogous procedures in this work to obtain mTrxR-C(αMe)UG. The 
concentrations of the final, purified mTrxR-CUG, mTrxR-C(αMe)UG, and DmTrxR-CCG 
enzymes were determined based on the extinction coefficient of flavin at 460 nm (ε460 = 
22.6 mM−1 cm−1 for the dimer)11. 
 
4.2.7 Characterization of TrxR, general 
After purification, TrxR enzymes were assayed for activity using Trx, DTNB, 
selenocysteamine, and hydrogen peroxide substrates, as described previously211. All 
activity assays were performed on a Cary 50 UV/VIS spectrophotometer from Varian 
(Walnut Creek, CA) at 22 °C, in 100 mM KP, 1 mM EDTA, pH 7.0. Activity was 
monitored over 2 min and Vo was determined from the linear slope. Plots of Vo/ET vs. 
substrate concentration were fit by the Michaelis-Menten equation using KaleidaGraph 
4.02 from Synergy Software (Reading, PA) and activities reported as moles of NADPH 
consumed per min per mole of TrxR.  
 
4.2.8 Activity Assays with Trx, H2O2, and selenocysteamine substrates 
Activity assays for Trx, H2O2, and selenocysteamine substrates were performed by 
monitoring NADPH consumption via decrease in absorbance at 340 nm (A340) using an 
extinction coefficient of 6220 M−1cm−1. Stock solutions of H2O2 were freshly prepared in 
ddI H2O before each experiment and the concentration of the solution was determined 
spectrophotometrically using an extinction coefficient of 43.6 M−1cm−1 at 240 nm. Stock 
solutions of selenocysteamine were freshly prepared in ddI H2O before each experiment. 
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A stock solution of 20 mM NADPH in ddI H2O was prepared prior to experiments and 
frozen in aliquots. Trx activity was measured via a 0.5 mL reaction containing 200 μM 
NADPH and varying concentrations of E. coli Trx that ranged from 0-180 µM. All assays 
were initiated by addition of the following concentrations of enzyme: 260 nM mTrxR-
C(αMe)UG, 2 nM mTrxR-CUG, and 200 nM DmTrxR-CCS. H2O2-peroxidase activity was 
measured via a 0.5 mL reaction containing 200 μM NADPH and varying concentrations of 
H2O2 that ranged from 0-400 mM. All assays were initiated by addition of the following 
concentrations of enzyme: 260 nM mTrxR-C(αMe)UG and 6 nM mTrxR-CUG. 
Selenocysteamine reductase activity was measured via a 0.5 mL reaction containing 200 
μM NADPH and varying concentrations of selenocysteamine that ranged from 0-500 µM. 
All assays were initiated by addition of the following concentrations of enzyme: 104 nM 
mTrxR-C(αMe)UG and 2 nM mTrxR-CUG. Background NADPH consumption was 
corrected for by subtracting the activity of control assays in which either TrxR enzymes or 
substrates were omitted from the reaction. All assays were repeated in triplicate for each 
enzyme. 
 
4.2.9 Activity Assays with DTNB substrate. 
DTNB activity assays were performed by monitoring formation of TNB ion via 
increase in absorbance at 412 nm (A412) using an extinction coefficient of 13600 M−1cm−1. 
Stock solutions of DTNB were freshly prepared in ethanol before each experiment. A stock 
solution of 20 mM NADPH in ddI H2O was prepared prior to experiments and frozen in 
aliquots. DTNB reductase activity was measured via a 0.5 mL reaction containing 200 μM 
NADPH and varying concentrations of DTNB that ranged from 0-5 mM. All assays were 
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initiated by addition of the following concentrations of enzyme: 6 nM mTrxRΔ3, 12 nM 
mTrxR-C(αMe)UG, and 4 nM mTrxR-CUG. Background TNB- formation was corrected 
for by subtracting the activity of control assays in which enzyme was omitted from the 
reaction. All assays were repeated in triplicate for each enzyme. 
 
4.2.10 Inactivation of TrxR enzyme activity by H2O2. 
Resistance to oxidative stress of TrxR enzymes was completed by a two-part assay 
in which TrxR enzymes were first exposed to increasing concentrations of H2O2 (0-100 
mM), and second, enzyme activity remaining was assessed relative to a control reaction 
where H2O2 was omitted. For all oxidative resistance reactions, 150 µL assays were 
completed in 100 mM KP, 1 mM EDTA, pH 7 buffer at 22 °C. To monitor the Trx-
reductase activity remaining, mTrxR-CUG (25 nM), mTrxR-C(αMe)UG (1 µM), and 
DmTrxR-CCS (225 nM) were pre-reduced by 5 min incubation with 200 µM NADPH. 
Next, TrxR enzymes were incubated with increasing amounts of H2O2 for 25 min followed 
by addition of 50 µL catalase agarose. Catalase agarose was then removed from the reaction 
via centrifugation (3200 RPM, 2 min) in Corning™ Costar™ Spin-X™ Centrifuge Tube 
Filters. Flow through was then combined with an additional 200 µM NADPH, and activity 
assays were initiated by addition of 110 µM Trx. Trx-reductase activity was measured by 
monitoring the consumption of NADPH as a decrease in A340 for three minutes. Treatment 
of mTrxR enzymes with H2O2 and subsequent peroxidase activity was monitored exactly 
as described for Trx reductase activity, except activity assays were initiated by addition of 
250 mM H2O2. As before, peroxidase activity was measured by monitoring the 
consumption of NADPH as a decrease in A340 for three minutes. To monitor the DTNB-
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reductase activity remaining, mTrxR-CUG (8 nM), mTrxR-C(αMe)UG (13 nM), and 
DmTrxR-CCS (75 nM) were pre-reduced by 5 min incubation with 200 µM NADPH. Next, 
TrxR enzymes were incubated with increasing amounts of H2O2 for 25 min followed by 
centrifugation in Amicon filters (30 kDa MWCO) at 13,000 RPM for 2 min. To ensure 
complete removal of H2O2, a washing step was performed where 300 µL of 100 mM KP, 
1 mM EDTA, pH 7 buffer was added, and reaction spun again (30 kDa MWCO amicon, 
13,000 RPM). The washing step was repeated for a total of two washes. After spins, 45 µL 
of retained enzyme solution was combined with 200 µM NADPH and buffer (final volume 
150 µL assay), and DTNB-reductase activity was measured by monitoring the formation 
of TNB- as an increase in A412 for three minutes. The assays were repeated in triplicate 
for each enzyme and for each assay, a “no substrate” background was performed. In each 
of these control experiments, no activity was detected ensuring complete removal of H2O2 
by catalase agarose. For all substrates, the change in absorbance was converted to 
percentage of activity remaining relative to the oxidant-untreated control.  
 
4.2.10 The half maximal inhibitory concentration (IC50) of RES 
 Inhibition of TrxR enzymes by RES was completed by a two-part assay in which 
TrxR enzymes were first exposed to increasing concentrations of either curcumin (0-100 
µM), acrolein (0-18 nM), or 4-hydroxynonenal (0-800 µM), and second, enzyme activity 
remaining was assessed relative to a control reaction where RES was omitted. Prior to 
experimentation, fresh stock solutions of acrolein, 4-hydroxynonenal, or curcumin were 
prepared in ethanol. For all RES inhibition reactions, assays were completed in 100 mM 
KP, 1 mM EDTA, pH 7 buffer at 22 °C. To determine the IC50 of curcumin, mTrxR-CUG 
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(12 nM) or mTrxR-C(αMe)UG (650 nM) were pre-reduced by 5 min incubation with 200 
µM NADPH in a 0.5 mL assay. Next, TrxR enzymes were incubated with increasing 
amounts of curcumin for 20 min followed by addition of 200 µM NADPH. To determine 
the IC50 of 4-hydroxynonenal, mTrxR-CUG (12 nM) or mTrxR-C(αMe)UG (650 nM) were 
pre-reduced by 5 min incubation with 200 µM NADPH in a 150 µL assay. Next, TrxR 
enzymes were incubated with increasing amounts of 4-hydroxynonenal for 1 hr followed 
by addition of 200 µM NADPH. To determine the IC50 of acrolein, mTrxR-CUG (10 nM), 
mTrxR-C(αMe)UG (780 nM), or DmTrxR-CCS (150 nM) were pre-reduced by 5 min 
incubation with 200 µM NADPH in a 150 µL assay. Next, TrxR enzymes were incubated 
with increasing amounts of acrolein for 10 min followed by addition of 200 µM NADPH. 
For all RES experiments, activity assays were initiated by addition of 150 µM Trx. Trx-
reductase activity was measured by monitoring the consumption of NADPH as a decrease 
in A340 for three minutes. For each assay, a “no substrate” background was performed. In 
each of these control experiments, no activity was detected. For all substrates, the change 
in absorbance was converted to percentage of activity remaining relative to the RES-
untreated (ethanol only) control. 
 
4.2.11 Reversal of acrolein inhibition using imidazole and hydrogen peroxide. 
Inhibition and subsequent reversal of TrxR enzymes by acrolein was completed by 
a three-part assay in which TrxR enzymes were first inhibited by acrolein, then acrolein 
inhibition was reversed via imidazole/H2O2 combinations, and third, enzyme activity 
remaining was assessed relative to a control reaction where acrolein was omitted. Prior to 
experimentation, fresh stock solutions of acrolein were prepared in ethanol and stock 
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solutions of H2O2 were prepared in ddI H2O and the concentration was determined 
spectrophotometrically using an extinction coefficient of 43.6 M−1cm−1 at 240 nm. 
Reversal assays utilized a combination of three buffers to facilitate pH changes. For all 
enzymes, “Buffer A” was composed of 10 mM KP, 10 mM sodium acetate (NaOAc), 5 
mM KCl, pH 7.0; “Buffer C + imidazole” was composed of 200 mM KP, 1 mM EDTA, 
210 uM BSA, 21 mM imidazole, pH 7.25; and “Buffer C - imidazole” was composed of 
200 mM KP, 1 mM EDTA, 210 uM BSA, pH 7.25. For reactions with mTrxR-CUG, 
“Buffer B” was composed of 50 mM NaOAc, pH 4.5. For reactions with mTrxR-
C(αMe)UG, “Buffer B” was composed of 50 mM NaOAc, pH 5.3. For reactions with 
DmTrxR-CCS, “Buffer B” was composed of 100 mM KP, pH 7.  
To begin, either mTrxR-CUG (30 nM), mTrxR-C(αMe)UG (780 nM), or DmTrxR-
CCS (240 nM) were incubated with 400 µM NADPH in 55 µL of Buffer A for 5 min at 22 
°C. To this, 35 µL of Buffer B was added (adjusting the reaction pH to 4.6 for mTrxR-
CUG; to pH 5.5 for mTrxR-C(αMe)UG; and to pH 7 for DmTrxR-CCS, followed 
immediately by addition of either acrolein, or ethanol for control experiments. To achieve 
75-85% inhibition: for mTrxR-CUG, 2.5 µM acrolein was used; for mTrxR-C(αMe)UG, 
800 nM acrolein was used; and for DmTrxR-CCS, 7 µM acrolein was used. Enzymes could 
react with acrolein or ethanol for 10 min at 22 °C.  
Next, to reverse acrolein adduction, 40 µL of Buffer C (+/-) imidazole was added 
to the reaction (i.e. for reversal conditions with imidazole, Buffer C + imidazole was used 
and for reversal conditions with no imidazole, Buffer C – imidazole was used). For reversal 
conditions involving H2O2, 2 mM H2O2 was added immediately after addition of Buffer C 
(+/-) imidazole. Addition of Buffer C (+/-) imidazole adjusted reaction pH to ~7.1 for all 
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enzymes. Reversal reactions were incubated for 10 min in a 37 °C water bath. After 
incubation, to all reactions, 50 µL catalase agarose was added and incubated for 15 min at 
22 °C. To remove catalase agarose, reactions were transferred to a Corning™ Costar™ 
Spin-X™ Centrifuge Tube Filter and centrifuged for 2 min at 3000 RPM. Flow through 
was collected and an additional 200 µM NADPH was added, then enzymes were assayed 
with Trx (150 µM Trx for assays with mTrxR-CUG and DmTrxR-CCS; and 220 µM Trx 
for assays with mTrxR-C(αMe)UG). For all enzymes, final assays were 150 µL and Trx 
reductase activity was measured by monitoring the consumption of NADPH as a decrease 
in A340 for three minutes. For each assay, a “no substrate” background was performed. In 
each of these control experiments, no activity was detected. For all substrates, the change 
in absorbance was converted to percentage of activity remaining relative to the acrolein-
untreated (ethanol only) control. 
 
4.2.12 Mass Spec analysis of acrolein adducted mTrxR. 
Reagents for acrolein adduction and reversal were prepared exactly as described 
previously, with the exception that BSA was excluded from Buffer C (+/-) imidazole. 
Briefly, to detect acrolein adduct via MS analysis, mTrxR-CUG (15 ug per sample, 30 nM 
in solution) was incubated with 400 µM NADPH in Buffer A for 5 min at 22 °C, as 
described previously. To this, Buffer B was added, adjusting the reaction pH to 4.6, 
followed immediately by addition of 2.5 µM acrolein, and allowed to react for 10 min at 
22 °C. Next, for reversal samples, Buffer C + imidazole followed by 2 mM H2O2 was 
added, adjusting pH to ~7.1. For acrolein adducted samples, Buffer C – imidazole was 
added, adjusting pH to ~7.1. All samples were incubated for 10 min in a 37 °C water bath. 
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After incubation, 100 µL catalase agarose was added and incubated for 15 min then 
removed via centrifugation, as described previously. Samples were then reduced with 
sodium borohydride (NaBH4) to make the acrolein adduct more stable for MS experiments, 
as described by Cassidy et al25. Briefly, to a solution of 15 µg mTrxR-CUG in Buffer C 
(+/-) imidazole, 10 µL of 85 mM NaBH4 in 0.1 M sodium hydroxide was added and the 
mixture was allowed to react overnight at 4 °C. After overnight reduction, excess NaBH4 
was removed via centrifugation (2 min, 13,000 RPM) in 3kDa MWCO Amicon filters. 100 
mM ammonium bicarbonate was added to the samples, and the reaction spun again in a 
wash step. This wash step was repeated twice. After washing, mTrxR-CUG samples were 
dried via speed vac prepared and analyzed via LCMS as described below. 
 
4.2.13 Digestion of TrxR enzymes for liquid chromatography mass spectrometry  
This work was completed in collaboration with Daniel Haupt. Samples of 15 µg 
TrxR enzymes were isolated and dried down using a speed-vac. 75 µL of 0.1% RapiGest™ 
surfactant in 50 mM ammonium bicarbonate pH 7.8 was then added to each sample and 
incubated at 37 ℃ for 1 h. Samples where then reduced with 5 µL of 100 mM DTT and 
heated at 37 ℃ for 10 min. Next, samples were alkylated with 10.4 µL of 10 mM 
iodoacetamide and incubated in the dark at rt for 30 min. To each sample, 25 µL of 0.1 
µg/µL sequence-grade trypsin was added and then incubated at 37 ℃ overnight. The 
following day, samples were dried down via speed-vac. Next, 100 µL of 7% formic acid 
(FA) in 50 mM ammonium bicarbonate pH 7.8 was added to each sample prior to a 1 h 
incubation at 37 ℃. Samples were dried down again prior to an addition of 100 µL of 0.1% 
trifluoroacetic acid and incubated for 1 h at 37 ℃. Samples were dried down a third time 
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using a speed-vac and then resuspended in 100 µL of 0.1% TFA. Each sample was then 
centrifuged at 14,000 rpm at 4 ℃ for 5 min and the top 95 µL was collected for LCMS. 
 
4.2.14 LCMS general method 
Sample (20 µL of each) was injected onto a Waters X-select HSST3 (3.5 µm, 1.0 x 
150 mm) liquid chromatography column at a flow rate of 0.1 mL/min. A 78-minute LC 
method was used with mobile phase A containing 0.1% FA in H2O and mobile phase B 
containing 0.1% FA in Acetonitrile (ACN). From 0.0 to 4.0 min, B was held at 3%. From 
4.0 to 44.0 min, B was raised to 40%. From 44.0 to 48.0 min, B was raised to 60%. From 
48.0 to 52.0 min, B was held at 60%. From 52.0 to 58.0 min B was dropped to 3%. Finally, 
from 58.0 to 78.0 min, B was held at 3%. Samples were then ionized by ESI on a Thermo 
Q Exactive mass spectrometer where full MS scans were performed at a resolution of 
70,000 in positive ion mode. Collected data files were analyzed using Xcalibur Qual 
Browser V3 (ThermoScientific, Waltham, MA).  
 
4.2.15 MS analysis of full-length TrxR enzymes 
This work was completed by Daniel Haupt. It is included herein for clarity. 
Theoretical trypsin digests of wild type mitochondrial fruit fly thioredoxin reductase 1 
(UniProtKB-P91938) and wild type mitochondrial mouse thioredoxin reductase 2 
(UniProtKB- Q9JLT4) were performed manually based on available FASTA files taken 
from the UniProt website and confirmed using the online ExPASy Peptide Mass feature. 
A theoretical digest of mutated mouse thioredoxin reductase containing (αMe)Sec was also 
performed by assuming an identical amino acid sequence as the mouse wild type with the 
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exception of a single substitution of Sec489 to (αMe)Sec489. To determine the presence 
of full-length enzyme, single charged [M+H]+ monoisotopic masses corresponding to the 
elemental composition of each complete C-terminal peptide were calculated using NIST 
mass values. However, for selenocysteine-containing peptides, the more abundant 80Se 
isotope mass was used rather than the monoisotopic 72Se isotope mass. Total peptide 
elemental composition also factored in the treatment of each cysteine and selenocysteine 
residue with iodoacetamide to form carbamidomethyl-cysteine (CAM-Cys), 
carbamidomethyl-selenocysteine (CAM-Sec), and carbamidomethyl-
(αMethyl)selenocysteine (CAM-(αMe)Sec). The resulting mass/charge values for singly-
charged c-terminal peptides SGLDPTPACCS (C48H79N14O21S2, 1251.50 m/z), 
SGLEPTVTGCUG (C46H78N13O19SSe, 1285.46 m/z) and SGLEPTVTGC(αMe)UG 
(C47H80N13O19SSe, 1299.48 m/z) were determined for wild type fruit fly, wild type mouse 
and mutant mouse thioredoxin reductase enzymes, respectively. Next, data files were 
opened with Thermo Xcalibur Qual Browser V3 to extract ion current peaks corresponding 
to the mass/charge value designated for the sample-specific c-terminal peptide. Spectra 
were visually evaluated and those containing singly charged isotopic envelopes differing 
by no more than 0.05 m/z from the theoretical monoisotopic mass/charge values were used 




4.3 Results and Discussion 
4.3.1 Synthesis of peptide containing (αMe)Sec 
To the best of our knowledge, this is the first time that the incorporation of 
(αMe)Sec into a peptide has been reported other than our earlier report where we 
demonstrated that an (αMe)Sec-containing peptide was able to function as a GPX mimic166. 
Importantly, in our previous study, (αMe)Sec was the N-terminal AA in the peptide 
sequence (which was chosen to correspond to the active site of GPX), and we did not 
attempt to couple another AA onto the amine of (αMe)Sec during solid phase peptide 
synthesis (SPPS). For this study, we sought out to make the peptide of sequence H-Cys-
(αMe)Sec-Gly-OH for the semisynthesis of mutant mTrxR, and therefore had to couple 
Fmoc-Cys-OH onto the amine of (αMe)Sec during SPPS, which proved to be a difficult 
task.  
Previous reports have highlighted the synthetic challenges of making peptides that 
contain sterically hindered and bulky (αMe)AAs212-216. Specifically, it has been noted that 
forming an amide bond between an (αMe)AA and the carboxylic acid of the next AA in 
the peptide sequence is difficult due to the steric hinderance of the amine group, which is 
adjacent to the disubstituted α-carbon, of an (αMe)AA212, 215. It has also been reported that 
the incorporation of (αMe)AAs into peptides is exceptionally challenging since the 
reactivities of both (i) the amino groups and (ii) the carboxyl groups of sterically hindered 
α,α-disubstituted AAs are significantly lower than those of typical AAs213. 
Traditional activation methods employed for amide bond formation, such as 
carbodiimide protocol, are usually inefficient for (αMe)AA coupling, suffering from low 
yields, slow reaction rates, and a necessity for large excess of reagents212-215. Other 
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coupling reagents, such as HATU or HOAt, have also proven to be ineffective in the 
synthesis of peptides containing (αMe)AAs. Albericio and coworkers previously reported 
synthesis of peptides that consist of difficult sequences with 7-
azobenzotriazolyoxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)217. 
PyAOP has been successfully applied for the preparation of a range of peptides containing 
hindered AAs, such as Aib213, 218. PyAOP and the related PyBrOP were also used for the 
synthesis of peptides containing the disubstituted Cα,α-dipropylglycine and Cα,α-
diisobutylglycine215, and α-methyl cysteine219. However, in our hands, the best yield 
achieved when attempting to couple Fmoc-Cys(Trt)-OH onto the deprotected 
(αMe)Cys(Trt)-Gly on 2-chlorotrityl chloride resin using PyBOP was less than 30% 
despite 5 or more coupling reactions (Trial 2, Table 4.1). We were not able to scale this 
synthesis up to a 0.1 mmol scale (Trial 2, Table 4.1), and found the 0.05 mmol scale to 
not always be reproducible. To speed up the coupling reaction, we applied heat via water 
bath at 37 °C. However, heat resulted in undesired side products and very little peptide 
produced (Trial 6 and 7, Table 4.1). It is possible that the peptide was cleaved from the 
resin when heated and washed away after the coupling step. It is also possible that the Trt 
protecting group was prematurely removed from either one of the Cys residues, and side 
reactions with the reactive sulfur atom occurred.  All trials using PyBrOP as a coupling 
reagent are summarized in Table 4.1. 
The symmetric anhydride method has been previously employed to facilitate the 
acylation of Aib and other bulky α-disubstituted AA’s216. This method involves the 
formation of the symmetric anhydride of the incoming amino, then coupling this directly 
to the resin in the absence of other coupling reagents in polar solvents such as DCM216, 220. 
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Again, when we employed this method for the acylation of N-deprotected (αMe)Sec(But)-
OH on 2-chlorotrityl chloride resin, we achieved low yields of our desired tripeptide (data 
not shown).  
Another method we explored was use of a proton sponge to increase the overall 
basicity of the reaction. Carpino and coworkers previously showed that including a proton 
sponge greatly improved the yield of an acylation reaction between resin-bound AIB and 
an incoming 5-mer peptide without causing racemization221. After studying numerous 
reaction conditions and bases to increase the nucleophilicity of the AIB-amine, they 
conclude that a mixture of 2,6-di-tert-butyl-4-(dimethylamino)pyridine (DB(DMAP)) and 
proton sponge is more effective than either one alone and much more effective than N,N-
diisopropylethylamine (DIEA) or 2,4,6-trimethylpyridine (TMP) bases221. While the use 
of a strong base is important in boosting the coupling process toward completion, these 
bases must be sterically hindered to avoid racemization221. Based on this, we included a 
proton sponge in a number of attempted coupling reactions, using it in combination with 
DB(DMAP) and other coupling reagents such as PyBrOP or HOAt. Unfortunately, 
inclusion of a proton sponge did not improve the yield of our acylation reaction in any trial 
(data not shown). Based on this, we abandoned the use of a proton sponge. 
We also explored moving away from SPPS and attempting the synthesis in solution 
since it is possible that the resin itself could contribute to steric hinderance. Additionally, 
we reason it might be possible for a bound peptide to be constrained and less flexible than 
a peptide in solution, which may prevent the peptide from adopting the necessary 
conformation for successful acylation. Therefore, we attempted two synthetic pathways 
exploring the use of various N-protecting groups including the base labile Fmoc protecting 
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group, and the acid-labile p-methoxybenzyl carbonyl (Moz) protecting group. The 
synthetic routes attempted for are displayed in Schemes 4.1 and 4.2. 
 
Scheme 4.1: Synthetic pathway to obtain Cys-(αMe)Cys-Gly-OH in solution using 
Fmoc-protection. N-Fmoc protected (αMe)Cys-OH is coupled to glycine ethyl ester 
using PyBrOp coupling agent and diisopropylethylamine (DIPEA) base in 
dichloromethane (DCM) solvent. The dipeptide is then column purified. Fmoc is then 
removed using 1:3 diethylamine: acetonitrile (DEA: ACN), with subsequent DEA 
extraction. Next, Fmoc-Cys(Trt)-OH is coupled to the deprotected dipeptide using 
PyBrOp coupling agent. The final step of the synthesis, which was not completed, is the 
removal of N-Fmoc and Gly COOH-ethyl ester using a LiOH saponification. MS for the 




For the Fmoc synthesis (Scheme 4.1), while we were able to obtain the Fmoc-
(αMe)Cys-Gly-ethyl ester dipeptide in 83% yield after silica purification, the subsequent 
step resulted in very little desired tripeptide. After Fmoc-removal, almost none of the 
incoming Cys(Trt) was coupled to the amine of (αMe)Cys. Instead, we observed self-
coupling of the (αMe)Cys-Gly dipeptide which resulted in H-(αMe)Cys-Gly-(αMe)Cys-
Gly-COOH dimer. This is shown by MS analysis in Figure 4.4. This is mostly likely due 
to the premature removal of the ethyl ester from Gly during the Fmoc-deprotection step 
using base. Thus, we wanted to move away from an Fmoc-protection strategy. 
 
Scheme 4.2: Synthetic pathway to obtain Cys-(αMe)Cys-Gly-OH in solution using 
Moz-protection. N-Moz protected (αMe)Cys(But)-OH is coupled to glycine ethyl ester 
using PyBrOp coupling agent and diisopropylethylamine (DIPEA) base in 
dichloromethane (DCM) solvent. The dipeptide is then column purified. Moz is then 
removed using TFA with TIS scavenger, and subsequent TFA removal. Next, Fmoc-
Cys(Trt)-OH is coupled to the deprotected dipeptide using PyBrOp coupling agent. The 
final step of the synthesis is the removal of N-Fmoc and Gly COOH-ethyl ester using a 




 We next attempted the Moz-synthesis depicted in Scheme 4.2. This proved to be 
more successful than the Fmoc-synthesis since we were able to obtain desired tripeptide. 
However, the final product was found as a mixture of dipeptide and tripeptide where the 
Cys-S-protecting groups were partially removed. Purifying these products is undesirable 
since HPLC purification would be needed which typically results in a huge loss in yield 
for small hydrophobic peptides. This problem is compounded by the fact that the final 
crude product was only obtained in very small quantities. The MS analysis for the final 
Moz- strategy product after saponification is given as Figure 4.5. 
 Though we were able to detect our desired tripeptide using the Moz-solution phase 
synthesis strategy, we found solution phase synthesis to be challenging since the final 
products were not entirely Cys-protected and were only obtained in very small yield. 
Furthermore, preparative HPLC would be necessary, and this would cause a loss of yield 
which is a problem considering the large amount of peptide needed for protein semi-
synthesis. Thus, we turned our attention back to SPPS, which typically results in pure 
peptide and higher yields than solution synthesis. 
Finally, we explored the use of activated esters to facilitate the synthesis of our 
desired tripeptide as they have been well studied for the coupling of Cys residues during 
SPPS222, 223. Like symmetric anhydrides, AA pentaflurophenol (PfP) esters are known to 
be highly reactive and free from undesired side reactions220. Additionally, they are 
advantageous over anhydrides because manual preparation of anhydrides must be 
performed immediately before each coupling reaction, whereas PfP esters can be prepared 
beforehand and stored as crystalline solids220, 224.  
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We next turned our efforts to the synthesis of Fmoc-Cys(Mob)-OPfP to facilitate 
the acylation between (αMe)Sec and Cys. Fmoc-Cys(Mob)-OPfP was synthesized 
following literature procedures, stored as a solid, and used for SPPS of the tripeptide. 
However, upon numerous couplings using Fmoc-Cys(Mob)-OPfP, we observed premature 
removal of the Fmoc-protecting group on the incoming Cys(Mob)-OPfP, which resulted in 
a mixture of double, triple, and even quadruple incorporated Cys residues, as observed via 
MS analysis (Figure 4.6).  
There are two possibilities when considering this undesired side reaction. First, it 
is possible that the amino group of (αMe)Sec is basic enough to remove Fmoc. The ability 
of the basic amino group to abstract a proton from the β-carbon of a negatively substituted 
ethyl ester is not negligible, and it has previously been shown by Bodanszky and coworkers 
that this can occur during SPPS225. Second, while Fmoc is stable to NMM for standard 1-
2 hr acylation reactions, Fmoc may not be stable in the presence of NMM (or even weaker 
bases) over prolonged coupling times. Indeed, it has previously been reported that up to 
18% Fmoc-deprotection can occur using 10% morpholine in DCM after only 4 hours226. 
To overcome multiple couplings, we utilized the base stable N-Boc protecting group on the 
incoming Cys residue. 
We began with the synthesis of Boc-Cys(Mob)-OPfP by first forming the 
symmetric anhydride of Boc-Cys(Mob)-OH via a DCC coupling at 0 °C in dry DCM, then 
opening up the anhydride by adding pentafluorophenol in dry EtOAc. After silica 
purification, white, crystalline Boc-Cys(Mob)-OPfP was obtained in 84% yield (Figure 
4.7 and 4.8). Next, Boc-Cys(Mob)-OPfP was utilized to facilitate the acylation reaction 
between itself and the bound N-deprotected (αMe)Sec(But) in DCM, with no additional 
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coupling reagent required. To ensure complete formation of the tripeptide, this coupling 
step was repeated at least 10 times, as depicted in Scheme 4.3.  
 
 
Scheme 4.3: Synthetic route to obtain Cys-(αMe)Sec-Gly tripeptide. (Top:) Starting 
with Boc-Cys(Mob)-OH, N,N'-dicyclohexylcarbodiimide (DCC) is used to make a 
symmetric anhydride intermediate in dichloromethane (DCM), which is then opened up 
using pentafluorophenol in ethyl acetate (EtOAc). The resulting Boc-Cys(Mob)-OPfP is 
added directly to the resin (grey sphere) with H-(αMe)Sec(But)-Gly-OH dipeptide 
attached. SPPS procedures are used to perform ≥10 Boc-Cys(Mob)-OPfP couplings with 
N-methylmorpholine and no coupling reagents. 
 
The tripeptide was then cleaved from the resin in the presence of DTNP to remove 
the Mob and But protecting groups from Cys and Sec respectively. This effectively 
replaced each side chain protecting group with a 2-thio(5-nitropyridyl) (5-Npys) adduct, or 
with the subsequent S-Se bond that forms spontaneously when adjacent Cys/Sec AAs are 
treated with DTNP89, 90, 110. The deprotected tripeptide was washed via ether precipitations 
to remove any remaining small organic compounds, including excess DTNP, which are 
soluble in ether. The peptide was not purified before use in the semi-synthesis of TrxR 





4.3.2 Semisynthesis of mTrxR enzymes. 
With tripeptides in hand, we went on to obtain mTrxR enzymes: mTrxR-CUG 
(mouse WT), mTrxR-C(αMe)UG (mouse mutant), and mTrxRΔ3 (truncated mouse). To 
circumvent the challenges of heterologous production of selenoproteins in E. coli48, 49, we 
utilized intein-mediated peptide ligation to join residues 1-487 of mTrxRΔ3 with the 
tripeptides H-Cys-Sec-Gly-OH or H-Cys-(αMe)Sec-Gly-OH, to produce full length 
enzyme57, 58.   
MS analysis of mTrxR enzymes confirmed the presence of the full-length WT and 
mutant proteins, as shown in Tables 4.4 and 4.5. Mass spectra of the N- and C-terminal 
redox centers are given as Figures 4.11-4.13. We classified our semi-synthetic enzymes 
using kinetics for several known mTrxR substrates including Trx, H2O2, selenocysteamine, 
and DTNB. The kcat and Km parameters for the WT, truncated, and mutant mTrxR enzymes 
are summarized in Table 4.6, and the kinetics curves are given as Figures 4.14-4.17. 
For each substrate, our (αMe)Sec mutant is ~100 fold less active than the WT 
mTrxR. This is likely due to a combination of two factors: (i) the ligation of the tripeptide 
to the C-terminus of the recombinantly expressed TrxR was not completed in 100% yield 
(low Sec incorporation) and (ii) the added methyl group to Sec constrains the enzyme 
backbone such that the C-terminus tail is not as flexible in the mutant than the WT, or 
perhaps not in the correct conformation for catalysis. This is especially true for the larger 
substrates tested, such as Trx which had the largest difference in catalytic efficacy between 
the WT and (αMe)Sec-mutant mTrxRs. The mutant enzyme was more active (when 
compared to the mTrxR WT) towards smaller substrates, H2O2 and DTNB, where steric 
hinderance of the C-term was not a crucial factor. 
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It is well known that (αMe)AA can induce secondary structures into enzymes they 
are incorporated in. α-Aminoisobutyric acid (Aib) is the most commonly studied 
(αMe)AA, and it  has been well documented that Aib has dramatic influences on peptide 
backbone conformation and often induces α-helical structures.197, 215, 227, 228  Additionally, 
for Aib and other (αMe)AAs, the rotation about the N-Cα and Cα-C’ bond is restricted, 
adding high rigidity to the peptides197, 229. Therefore, it is not unreasonable to conclude that 
the lower enzyme activity observed for our mutant mTrxR compared to the WT could be 
due to an unfavorable conformation induced into the C-terminus of the enzyme by the 
incorporation of the (αMe)Sec residue. 
 
4.3.3 Oxidative resistance of TrxR enzymes. 
 We previously showed that (αMe)Sec conferred resistance to oxidative inactivation 
to a GPX-mimic peptide166. We hypothesized that (αMe)Sec would also confer resistance 
to mTrxR if incorporated into the C-terminus redox center of the protein. A study by Snider 
and coworkers showed that Sec-containing mTrxR was able to resist inactivation by 50 
mM H2O2, maintaining ~70% Trx reductase activity
14. However, we theorized that 
replacing Sec with (αMe)Sec would give mTrxR enhanced protection against H2O2 at 50 
mM or higher concentrations. One way in which the mTrxR wild type (WT) enzyme can 
lose activity in the presence of H2O2 is through β-syn elimination which results in the 
conversion of Sec to DHA, as described in Chapter 3. Without the catalytic Sec residue, 
enzymes containing DHA would not be active. We have previously shown that (αMe)Sec 
is not able to β-syn eliminate and chemically, cannot lose Sec166. Though (αMe)Sec can be 
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oxidized to the selenenic acid or seleninic acid, these oxidation states can be reduced back 
to the active selenol via the neighboring resolving Cys residue15, depicted in Scheme 4.4.  
 
 
Scheme 4.4: Oxidation states of Cys and Sec-TrxR enzymes. When DmTrxR-CCS is 
oxidized, it can only return to the original, active state from the Cys-SOH oxidation state, 
as Cys-SO2
– and Cys-SO3
– forms are strongly resistant to reduction by glutathione, or 
other biological reductants. In contrast, oxidation of mTrxR-CUG to either Sec-SeOH or 
Sec-SeO2
– does not result in permanent inactivation as these redox forms can be rapidly 
reduced by non-enzymatic reduction by thiols or ascorbate back to the parent state. 
However, when oxidized past the Sec-SeO2
– form, mTrxR can undergo β-syn 
elimination to DHA, or be oxidized to the irreversible Sec-SeO2
– form, which would 
result in loss of enzyme activity.   
 
To test this, we exposed pre-reduced mTrxR-CUG, mTrxR-C(αMe)UG, and 
DmTrxR-CCS enzymes to various concentrations of H2O2 for 25 min in 100 mM KP, 1 
mM EDTA, pH 7 buffer at 22 °C. After incubation with H2O2, catalase agarose was added 
to the reaction to quench any excess H2O2. Catalase agarose was then filtered away from 
the reaction using Corning™ Costar™ Spin-X™ Centrifuge Tube Filters. Next, the 
enzymes were assayed for peroxidase activity (H2O2 substrate), Trx reductase activity (Trx 
substrate), and DTNB reductase activity (DTNB substrate). In all cases, the mTrxR-
C(αMe)UG mutant was able to resist oxidative inactivation better than both the WT mTrxR 
and WT DmTrxR enzymes (Figure 4.18 A-C).  
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The difference in oxidative resistance of Sec-TrxR enzymes was especially 
apparent for the peroxide substrate (Figure 4.18 B). It is possible that for Trx and DTNB 
substrates, both WT and mutant mTrxR enzymes are oxidized to higher oxidation states 
such as the Sec-SeOH and Sec-SeO2
- forms but can be reduced readily once excess H2O2 
is removed, retaining activity (Figure 4.18A and C). However, when H2O2 is both the 
oxidant and the substrate, the reduction of the selenenic and selenininc acid forms back to 
the active selenol would be competing with the oxidation of Sec to the Sec-SeO3
- form, 
which cannot be reduced back to the active form of the enzyme (Scheme 4.4). It is also 
possible in all cases, that the WT mTrxR is undergoing β-syn elimination with the 
backbone, forming DHA.  
In theory, our mutant mTrxR should retain nearly 100% enzyme activity since the 
Sec residue should never be overoxidized to DHA. However, we do see some loss in 
activity when the mTrxR-C(αMe)UG mutant is incubated with higher concentrations of 
H2O2. It is possible that this loss of activity is due to oxidation of the C-terminus Cys 
residue (adjacent to the (αMe)Sec), or either of the N-terminus redox active Cys residues. 
The over oxidation of catalytic Cys residues would be especially detrimental to Trx 
reductase activity. It is also possible that the (αMe)Sec residue itself is over oxidized to the 
SeO3
- form, which is not readily reversible. This would account for the loss of activity seen 
for all substrates, but especially for loss of peroxidase activity which is dependent on the 






4.3.4 Inactivation of TrxR by reactive biological electrophiles. 
The adduction of TrxR enzymes by RES has been well documented19-21, 207. Many 
RES that are found to inhibit TrxR are Micheal acceptors; that is, they contain an α,β-
unsaturated carbonyl functional group, as displayed in Figure 4.19.  
 
 
Figure 4.19: Biological 
RES. The α,β-
unsaturated carbonyl 
functional groups (in 




Acrolein is the simplest and most reactive of the α,β-unsaturated aldehydes, and it 
rapidly binds to and depletes cellular nucleophiles such as glutathione209. It can also adduct 
protein nucleophiles such as Cys, Lys, and His residues of proteins, and nucleophilic sites 
in DNA. The high reactivity of acrolein is the basis for the cytotoxicity, genotoxicity, and 
mutagenic activity observed in cells exposed to high concentrations of acrolein209. Acrolein 
is universally present in the environment, cooked foods, and cigarette smoke. In foods, 
acrolein is formed from the heating of carbohydrates, vegetable oils, animal fats, and AAs. 
In the atmosphere, acrolein is produced by combustion of petroleum fuels and biodiesel230. 
Acrolein can also be released in vivo via biochemical reactions such as heat-induced 
dehydration of glycerol, retro-aldol cleavage of dehydrated carbohydrates, and lipid 
peroxidation of polyunsaturated fatty acids. However, the main source of endogenous 
acrolein is through the degradation of spermine and spermidine in situations of oxidative 
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stress and inflammation230. Smoking of tobacco products equals or exceeds the total human 
exposure to acrolein from all other sources231, 232.  
Like acrolein, 4-hydroxynonenal (4-HNE) is an endogenous byproduct of lipid 
peroxidation. Recent studies suggest that protein modification by 4-HNE can result in the 
pathogenesis of several diseases, including liver disease and inflammation233. Curcumin is 
a biologically active, polyphenolic natural product found in turmeric, which is derived from 
the plant Curcuma longa19. It is a lipid-soluble, bright yellow compound that is used as a 
spice to flavor curry and to dye textiles. Curcumin has been shown to exhibit antioxidant, 
anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer activities and thus has 
a potential against various malignant diseases, diabetes, Alzheimer’s disease, and other 
chronic illnesses.234 The interaction of curcumin with TrxR accounts for most of 
curcumin’s biological functions19, and both curcumin and 4-hydroxynoneal have been 
demonstrated as potent inhibitors of mTrxRs25, 235.  
We began by studying the effect of various RES on TrxRs. Pre-reduced TrxR 
enzymes were incubated with various concentrations of RES including acrolein (Figure 
4.20A and B), 4-hydroxynonenal (Figure 4.21A), and curcumin (Figure 4.21B), in 100 
mM KP, 1 mM EDTA, pH 7 buffer, at 22 °C for various times depending on the RES.  
The percent enzyme activity remaining was measured spectrophotometrically and 
used to determine the IC50 value for each RES/enzyme combination. This data is 
summarized in Table 4.5. Acrolein is the most potent RES for all TrxR enzymes tested, as 
only nM concentrations of acrolein are needed to totally inhibit the enzymes.  
Curcumin is the least potent RES and interestingly, there is a large difference 
between the IC50 values of curcumin when comparing mTrxR-CUG and mTrxR-
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C(αMe)UG. In fact, an IC50 value was never reached for the mutant mTrxR as curcumin is 
only soluble in aqueous solutions up to 100 uM. At 100 uM, ~65% Trx reductase activity 
remains for the mutant while an IC50 value of 34 uM curcumin was determined for the WT 
mTrxR. This large difference can be attributed to the bulky methyl group at the Sec residue 
of the mutant; curcumin is a relatively large RES and steric hindrance must prevent it from 
binding to the hindered (αMe)Sec-residue at the active site of the mutant mTrxR. 
 
4.3.5 Reversibility of Sec-acrolein adduct using imidazole and hydrogen peroxide. 
 The role of selenium in proteins has long been debated, but it is now generally 
accepted that the ability of Sec to reverse oxidative modifications, which confers resistance 
to oxidative stress to selenoproteins, is one reason that higher level eukaryotes undergo the 
costly process of Sec incorporation15. A more recent hypothesis to explain the role of 
selenium in proteins is that Sec-enzymes can reverse other electrophilic modifications, 
such as Sec-adduction by RES like acrolein27 and 4-hydroxynonenal25 through non-
enzymatic mechanisms. Notably, such reversibility would be very slow for orthologous 
Cys-TrxR enzymes as sulfur carbon bonds are much less labile than selenium carbon 
bonds.  
 The idea that Sec-adduction by a Michael acceptor could be reversible is not new 
in the field of organic chemistry. It is well known that selenium-carbon bonds can be 
broken through selenoxide eliminations. The selenoxide elimination is a common synthetic 
tool used to install alkenes and convert ketones to enones236, 237. One form of selenoxide 
elimination is β-syn elimination: where the selenoxide abstracts a proton that is attached to 
a carbon beta to the selenoxide. We predict that a β-syn elimination mechanism could 
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facilitate the removal of acrolein (or other RES) adduct, as shown in Figures 4.2 and 
Scheme 4.5.  
One limitation in testing the reversibility of RES adducts using mTrxR-CUG is that 
there are two possible ways in which the selenoxide can β-eliminate (Figure 4.3A, 
pathway 1 and 2). It can eliminate through the desired pathway 1 to remove the RES 
adduct, but it could also abstract the α-proton of the enzyme backbone resulting in the 
formation of DHA in place of the catalytic Sec residue, as shown in Figure 4.3A pathway 
2. Without Sec, the enzyme would be inactive. Therefore, if we were unable to restore Trx 
reductase activity during RES reversibility experiments, we would not be able to 
distinguish if formation of DHA or the inability to reverse acrolein adduction was the 
reason for our observed negative result. Our mutant mTrxR-C(αMe)UG enzyme negates 
this ambiguity since it lacks the α-proton necessary for β-syn elimination with the protein 
backbone. The formation of DHA is not possible, and therefore, it forces reversibility to 
occur through the mechanism depicted in Scheme 4.5.  
To test this, we inhibited pre-reduced mTrxR-CUG and mTrxR-C(αMe)UG with 
acrolein at low pH of (pH 4.6 for WT and pH 5.5 for mutant) for 10 min at 22 °C. The 
greater acidity of Sec (pKa ~ 5.3) versus Cys (pKa ~ 8.3) or His (pKa ~ 9.2) causes it to be 
deprotonated at lower pH, and this property allowed us to selectively adduct Sec instead of 
other AA residues. We attempted to adduct the (αMe)Sec-mutant at pH 4.6 (as we did the 
WT), however the enzyme precipitated so we chose pH 5.5, which we found to be the 
lowest pH the mutant enzyme could tolerate for the 10 min acrolein incubation step. The 
precipitation of mTrxR-C(αMe)UG at pH 4.6 could be due to conformational changes of 
the C-term induced by the addition of the methyl group. As a negative control (i.e. we are 
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confident reversal would not be obtained), we also adducted DmTrxR-CCS with acrolein 
under similar conditions. To ensure the Cys residues were primarily in the reactive thiol 
form, we conducted the adduction reaction at pH 7 instead of pH 4.5 or 5.5. Our full 
reversibility pathway is displayed in Scheme 4.5. 
 
Scheme 4.5: Alkylation of mTrxR-CUG with acrolein and subsequent reversibility 
of the acrolein adduct through a selenoxide elimination pathway. Here, H2O2 
converts the acrolein adducted Sec-enzyme to a selenoxide, which can undergo β-
elimination with a proton from the acrolein adduct. Imidazole is included to scavenge 
acrolein once eliminated from the enzyme. 
 
For all acrolein adduction experiments, we chose an acrolein concentration that 
provided 70-80% inhibition of Trx reductase activity (see Figure 4.22, condition 1). At 
this level of reduced activity, we are confident that only enough acrolein was used to adduct 
the most reactive residue, which should be the penultimate Sec at low pH. Using a larger 
excess of acrolein would undoubtably inhibit all enzyme activity, but we aimed to use 
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minimal concentrations of acrolein to avoid the unwanted adduction of other AAs. Further 
chemoselectivity comes from the fact that RES are considered “soft” electrophiles and have 
been shown to preferentially target “soft” nucleophiles, such as Cys27. Since Sec is even 
larger, and hence, “softer” than Cys, acrolein should react preferably with the Sec residue 
over other nucleophilic AAs. 
We next explored conditions by which we could restore Trx reductase activity in 
the acrolein adducted enzymes. One important feature of SecTRAPs is that they produce 
their own biological oxidants by providing one electron from the N-terminus redox center 
to O2
208. Additionally, when TrxR is alkylated with an electrophile, the antioxidant function 
of TrxR is turned off, increasing the amount of cellular oxidative stress. We predict that 
this accumulation of surrounding oxidant acts as a “molecular timer” to oxidize the selenide 
to a selenoxide (Figure 4.3). We also anticipate needing a scavenger to bind to acrolein 
and prevent acrolein from reattaching to the Sec (or other nucleophilic AAs) once removed. 
Initially, we envisioned that GSH would be a good candidate for a scavenger as it 
is omnipresent in the cell and was previously shown by Randall and coworkers to be an 
essential part of acrolein reversal in vivo27. Thus, we began by incubating acrolein-inhibited 
mTrxR-CUG with GSH in buffer pH 6.5 and monitored Tr-reductase activity. We tested 
many conditions; we varied pH, GSH incubation time and temperature, concentration of 
GSH, etc., but we did not observe any significant increases in activity for any condition 
tested. A sample of this data is given in Figure 4.23. One potential problem is that GSH 
might not be in the thiol form at neutral pH since the pKa of Cys is ~8.3. We hope to find 
conditions where GSH can be used for acrolein reversibility in the future. 
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Imidazole is another good candidate for an acrolein scavenger as it should react 
readily with acrolein yet have no side reactions with TrxR or Trx in the subsequent enzyme 
assay. Like hydralazine, which has previously been used as a protective reagent for 
acrolein, imidazole contains amidine functionality that reacts strongly with acrolein238. The 
imidazole functionality is found in His residues which would undoubtably be present to 
scavenge acrolein in biological systems. 
Using the above rational, we incubated acrolein adducted enzymes with 2 mM H2O2 
and 5 mM imidazole in 200 mM KP buffer, pH 7.15, at 37 °C for 10 min (Figure 4.22, 
condition 4) and were able to restore Trx-reductase activity to 55% of the control (a gain 
of 30%) for the mTrxR-C(αMe)UG mutant, and 45% of the control for the mTrxR-CUG 
WT (a gain of 25%). The ability for our mutant mTrxR to restore more activity than the 
WT is likely due to the inability for (αMe)Sec-TrxR to undergo β-elimination with the 
peptide backbone. In other words, it is possible that when acrolein-adducted mTrxR-CUG 
was oxidized, it underwent β-syn elimination with both the α-H of the protein backbone 
(forming inactive DHA), and the α-H of the acrolein adduct, restoring partial Trx reductase 
activity.  
Despite efforts to optimize the reversal reactions (data not shown), we were not 
able to achieve 100% reversal of Trx-reductase activity for any TrxR tested. This is likely 
due to unwanted acrolein adduction of Cys or His residues (which would not be reversible), 
despite our rigorous efforts to avoid such occurrence. 
To further explore the mechanism of the reversal reaction, we attempted to reverse 
acrolein inhibition using either imidazole alone (Figure 4.22, condition 2) or H2O2 alone 
(Figure 4.22, condition 3). Notably, some Trx reductase activity is restored for both the 
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mTrxR WT and mutant with H2O2 alone, indicating the importance of oxidants in the repair 
mechanism. A small percentage of Trx reductase activity is recovered using imidazole 
alone for the mTrxR-C(αMe)UG mutant, but the Trx reductase activity for the WT is within 
error of the acrolein inhibited enzyme (i.e. the WT did not appear to recover activity with 
imidazole alone). The ability of mTrxR-C(αMe)UG to restore Trx reductase activity with 
imidazole alone could be the result of two mechanisms. First, it is possible that TrxR 
produces enough H2O2 on its own that the selenoxide elimination can still occur as depicted 
in Figures 4.2 and Scheme 4.5. It is also possible for reversal to occur through a base-
mediated mechanism, as depicted in Scheme 4.6. 
 
 
Scheme 4.6: Removal of acrolein from Sec 
through a base mediated mechanism. 
Once adducted, the ketone/enol forms of 
acrolein are in equilibrium. When in the enol 
form, imidazole acts as a base to abstract the 
proton from the acrolein alcohol, which 
causes removal of the acrolein adduct. 
 
We were not able to restore any activity under the above discussed conditions for 
our DmTrxR-CCS negative control, and conditions for which H2O2 was included, 
DmTrxR-CCS lost more Trx reductase activity than the non-reversed condition. This is 
seemingly due to oxidative inactivation as Cys-TrxR enzymes lose activity readily in the 
presence of oxidants, especially when heated, as was done in this experiment.  
It is not surprising that both Sec-TrxR enzymes were able to reverse acrolein 
inhibition while Cys-TrxR was not. Chemically, we would expect the S-C bond formed 
between Cys and acrolein to be much more stable than the corresponding Se-C bond 
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formed between Sec and acrolein. Because Se is much larger than S, the formed Se-C bond 
would be considerably longer, and therefore weaker, than the formed S-C bond. Hence, the 
Sec-acrolein adduct of mutant and WT mTrxR should break more readily than the Cys-
acrolein adduct of DmTrxR. Indeed, it is known that selenoxide elimination reactions occur 
at ~100 °C milder temperatures, and are 1x105 times as fast as related sulfoxide elimination 
reactions5, 239, 240. 
 Additionally, it has been previously reported that peptide Cys-acrolein adducts can 
be reversed through a Schiff base mechanism, if the formed Cys-acrolein adduct is in close 
proximity to the peptide amine.22 Notably, Lys side chain amines cannot catalyze this 
reversibility, and this chemistry was never tested in proteins. The authors also state ≤ 3% 
acrolein is reversed from Cys residues in the absence of a peptide amine, highlighting the 
inherent stability of a Cys-acrolein adduct.22 Combined with these previous reports, our 
findings strongly suggest that Cys-RES adducts are not chemically reversible and would 
require enzymatic mechanisms of reversal. As recently reviewed by Aye, RES-alkylation 
of Cys is generally irreversible.241 One notable exception to this is alkylation of Cys by 
nitro olefin fatty acids. This is due to the much lower pKa of the proton that is beta to the 
sulfur atom of the adduct (pKa ~17) in comparison to enals and enones that lack such an 
electron withdrawing group (pKa ~30).
241, 242 
 Our observation that TrxR activity can be recovered after alkylation with an enal 
like acrolein or other “Michael acceptor” can be explained in terms of the lability of certain 
types of C–Se bonds that are in close proximity to a carbonyl carbon. As depicted in Figure 
4.24, especially labile C–Se bonds that can be easily cleaved are ones in which the selenium 
atom is bonded: (i) directly to the carbonyl carbon, (ii) to the carbon alpha to the carbonyl 
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carbon or, (iii) to the carbon beta to the carbonyl carbon. It is well known that selenoesters, 
like thioesters, are highly labile due to the lack of π-bonding between the chalcogen and 
the carbonyl carbon.243 It is much less recognized that both α-thio and α-selenocarbonyl 
compounds can be reduced to the corresponding ketone by soft nucleophiles (middle panel 
of Figure 4.24)244, 245. As shown here, and is widely known in the literature, oxidation of 
a β-selenocarbonyl (β-syn selenoxide elimination - last panel of Figure 4.24) results in 
formation of the alkene with cleavage of the Cβ–Se bond.
236, 237 This last type of bond 
cleavage is the one needed to impart resistance to RES to a selenoenzyme. 
 
Figure 4.24: Lability of carbon-selenium bonds in relationship to a carbonyl 
carbon. (left panel) Cleavage of a selenoester by a thiolate. (middle panel) reduction of 
an α-selenoketone by a thiolate. (right panel) β-syn selenoxide elimination or reverse 
Michael reaction results in cleavage of the Cβ–Se bond. 
 
Though previous publications have found connections between a “protective 
function of selenoproteins” in the presence of RES26, none have explicitly showed that this 
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protective function is due to the reversibility of the RES adduct on Sec. In fact, many 
studies state that the adduction of Sec in proteins by RES is an irreversible modification19, 
235, 246-248. Others have observed the reversibility of RES inhibition but have not attributed 
this to Sec. One example comes from and Park and coworkers who show that low 
concentrations of acrolein rapidly inactivate TrxR both in vitro and in vivo which leads to 
a significant increase in intracellular peroxide levels after 1 hr24. They went on to determine 
that loss in TrxR activity is due to acrolein modification of the C-terminal Sec residue, and 
state that TrxR inactivation is irreversible in vitro, but do not provide data or methods 
detailing these reversibility experiments24. However, they also state: “interestingly, TrxR 
activity was restored without any treatment within 24 h in human endothelial cells 
(HUVEC). The restoration of TrxR activity in HUVEC is associated with increases in the 
levels of TrxR mRNA.” They go on to conclude that acrolein inhibition of TrxR is 
reversible by compensative TrxR gene induction24. While this may be partially correct, the 
authors did not discuss the possibility that the formed acrolein adduct on Sec could be 
reversible in vivo through a selenoxide elimination mechanism. A selenoxide elimination 
mechanism (as we propose herein) would undoubtably be feasible in their system since the 
authors show a significant increase in intracellular peroxide levels, and state that GSH (or 
other cellular acrolein scavengers) are present in HUVEC.  
Another example comes from Cassidy and coworkers who studied the interactions 
of electrophilic lipids with purified TrxR and used site directed Sec mutagenesis to 
characterize how RES affect tumor suppressor protein p5325. They observed that when 
TrxR was treated with 4-HNE, both Cys and Sec adducts were formed. The authors state: 
“This observation can be rationalized if one considers that the kinetically favored product 
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(the Sec adduct formed by reaction with the highly nucleophilic Sec anion) might give rise 
to the thermodynamically more stable Cys adduct if this system were to approach 
equilibrium.” Further evidence for 4-HNE-Sec adduct reversibility in this study comes 
from the fact that detection of tryptic peptides containing lipid adducts by MS analysis 
required reduction of the complex with sodium borohydride prior to digestion25. 
Ultimately, the authors conclude that selenium sufficiency both increases TrxR activity and 
spares p53 function in cells treated with electrophilic lipids, which provides a mechanism 
for how dietary selenium confers protection against cancer25. Though the authors elude to 
both the reversibility of protein-Michael adducts and a protective mechanism of selenium, 
they never connect these two concepts; the authors never explicitly pronounce that the 
ability of  Sec to reverse the formed adduct confers a gain of function to selenoproteins. 
Further support for our idea that electrophilic adduction on the Sec residue of TrxR 
can be reversed may possibly come from a misinterpreted result from the study of the 
inhibition of the selenoenzyme GPX with 4-hydroxynonenal by Romero and coworkers.249 
This study found that GPX could not be completely inhibited with a great excess of 4-
hydroxynonenal (1 mM), and GPX could regain 41% of its activity after inhibition with 
0.12 mM 4-hydroxynonenal by addition of 1 mM glutathione.249 The authors attribute the 
restoration in activity to reversing the alkylation of Lys92 catalyzed by glutathione. This 
conclusion was reached because it is known that a Schiff base that forms between a Lys 
side chain and an α,β-unsaturated carbonyl can be reversed by hydrolysis and they 
considered the alkylation of Sec to be irreversible.249 The authors did not consider the 
possibility of a β-syn selenoxide elimination despite the fact that H2O2 was used as the 
substrate in their assays. An alternative explanation is that the additional glutathione added 
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in their rescue experiment was needed to scavenge the 4-hydroxynonenal that was ejected 
from the β-syn selenoxide elimination. 
 In this report we have extended the original concept that selenoenzymes resist 
inactivation by ROS to a broader idea that selenoenzymes can resist electrophilic stress by 
RES as well. As we previously noted, oxygen and related ROS are just a specific subset of 
RES, though the mechanism through which the selenoenzyme recovers from each type of 
stress is different. In the case of recovery from ROS, a selenoenzyme can undergo fast 
reductive mediated repair by intracellular reducing agents such as glutathione or ascorbate.  
 
 
Figure 4.25: Repair pathways for a selenoenzyme after exposure to RES or ROS. 
Active enzyme is represented by the color green. Enzyme that is inactivated by repairable 
by a non-enzymatic reaction is represented by the color orange, red represents 
irreversible inactivation to the enzyme. The enzyme colored in magenta represents an 
enzyme that is repairable by an enzyme-mediated repair pathway. In this case, 
sulfiredoxin is capable of repairing Cys-enzymes that have been overoxidized to sulfinic 
acid in an ATP-dependent manner.250 The corresponding seleninic acid form of a 
selenoenzyme can be chemically reduced by GSH or ascorbate and does not need an 
enzyme catalyzed reaction for repair, highlighting a large advantage for Sec-enzymes 
compared to the Cys-ortholog. Likewise, Sec-enzymes that are alkylated by an enal or 
enone can undergo a non-enzymatic repair pathway, but this pathway involves oxidation 
instead of reduction. 
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In the case of recovery of recovery from RES, a selenoenzyme can undergo fast oxidative 
mediated repair via a β-syn selenoxide elimination. These concepts are illustrated in Figure 
4.25 and highlight the gain of function that selenium adds to an enzyme relative to sulfur.  
As mentioned in the introduction, the mechanistic work we present here strongly 
corresponds with a previous study from Randall and coworkers who provided in vivo 
evidence for the reversibility of mTrxR-acrolein adducts. In this study, the authors 
demonstrate that acrolein rapidly inactivates Sec-TrxR in human bronchiolar epithelial 
HBE1 cells, which recovered over 4–8 h by a mechanism depending on the presence of 
cellular GSH and Trx and corresponding with reversal of protein–acrolein adduction27. 
However, they do not provide mechanistic details of this reversal, and propose that their 
observed GSH-dependent restoration of mTrxR activity depends on glutathione S-
transferase (GST) activity27. While GST could be involved in the reversal at a cellular level, 




4.4 Conclusion and future work 
 
Herein, we reported the construction and characterization of a mutant enzyme: 
mTrxR-C(αMe)UG. Our mutant protein cannot undergo β-syn elimination with the peptide 
backbone (which would result in inactive DHA), due to the presence of an α-methyl group 
in place of the standard α-proton166. This unique property confers enhanced oxidative 
resistance to mTrxR-C(αMe)UG compared to the mTrxR-CUG WT enzyme. We utilized 
the ability of mTrxR-C(αMe)UG to resist oxidative stress to explore a new hypothesis: 
selenoproteins have evolved to resist electrophilic stress. To do this, we first inactivated 
mTrxR-C(αMe)UG with acrolein, then restored its Trx reductase activity using H2O2 and 
imidazole through a selenoxide elimination pathway. These conditions are consistent with 
the biological environment that is known to surround SecTRAPs208. Notably, we were also 
able to restore activity in the mTrxR-CUG WT, but not the Cys-TrxR ortholog, providing 
strong evidence that Sec-enzymes may have evolved to resist electrophilic stress. 
Importantly, our work ties up loose ends from previous studies on these topics. 
Randall and coworkers state: “rather than representing irreversible protein damage, protein 
alkylation by acrolein and other electrophiles may be an important reversible event in 
adaptive responses to electrophilic stress or function as electrophile-specific signaling 
mechanism analogous to protein S-nitrosylation or S-glutathionylation. A more complete 
understanding of such reversal mechanisms would not only offer better insight into the 
biological functions of electrophiles but may also contribute to improved strategies to 
manage chronic pulmonary diseases associated with environmental acrolein exposure or 
cigarette smoking.”27  
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Herein, we provide the mechanistic evidence that other studies are missing24-27, and 
we provide evidence to support a new hypothesis for why nature chose selenium. We 
anticipate that our work will provide a mechanistic foundation for numerous in vivo 
findings in the future.  
Going forward, we hope to find conditions for which more Sec-enzyme activity can 
be recovered upon reversing a Sec-RES adduct. This will likely require the finetuning of 
reaction conditions for both alkylation and reversal steps. Furthermore, reversal of other 
RES adducts, beyond acrolein, should be explored. It is possible that less reactive RES, 
such as curcumin or 4-HNE, would afford more recovered activity than acrolein due to 




4.5 Figures and tables 
 
          
 
Figure 4.4: Mass spectra of product from Fmoc-strategy solution phase synthesis 
of H-Cys-(αMe)Cys-Gly-OH. The spectra at the top shows the MS results from peptide 
submitted after the coupling step shown in Scheme 4.1. Notably, none of the desired 
tripeptide is observed (theoretical m/z = 1031.32). Instead, a mixture of (αMe)Cys-Gly 
dipeptide and (αMe)Cys-Gly-(αMe)Cys-Gly is observed. The larger peptide is the result 
of dipeptide self-coupling. The theoretical m/z for both of these observed products is 






Figure 4.5: Mass spectra of product from Moz-strategy solution phase synthesis of 
N-Cys-(αMe)Cys-Gly-OH. The spectra shows the MS results from peptide submitted 
after the final saponification step shown in Scheme 4.2. Notably, some of the desired 
tripeptide is observed! However, the desired tripeptide is observed as a mixture of 
products and HPLC purification results in very low final yield. The theoretical m/z for 









Figure 4.6: Mass spectra of tripeptide: H-Cys-(αMe)Cys-Gly-OH after cleavage 
from the resin. When synthesizing this peptide, we observed “over coupling” of Cys to 
the deprotected  (αMe)Cys-amine when using Fmoc-Cys(Mob)-OPfP (discussed in the 
main text). Here, there are 5 major species present (from left to right): (i.) truncated 
dipeptide H-(αMe)Cys-Gly-OH (theoretical m/z = 193.06), (ii.) desired tripeptide H-
Cys-(αMe)Cys-Gly-OH (theoretical m/z = 296.07), (iii.) double Cys coupled peptide H-
Cys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 399.08), (iv.) triple Cys coupled peptide 
H-Cys-Cys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 502.08), (v.) quadruple Cys 
coupled peptide H-Cys-Cys-Cys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 605.09). 
Note: the text eludes to this “over coupling” problem in the context of the H-Cys-
(αMe)Sec-Gly-OH peptide. We observed the same over coupling regardless of the 





Figure 4.7: 1H-NMR spectra for Boc-Cys(Mob)-OPfP. The crystalline solid after 
column purification was dissolved in deuterated chloroform, and spectrum taken with a 









Figure 4.8: 13C-NMR spectra for Boc-Cys(Mob)-OPfP. The crystalline solid after 
column purification was dissolved in deuterated chloroform, and spectrum taken with a 













Figure 4.9: Mass spectrum of tripeptide: H-Cys-(αMe)Sec-Gly-OH after cleavage 
from the resin with contaminant DTNP deprotection. For all, the peaks are labeled 
with the observed value above the highest point. (A) The m/z spectra, showing that two 
major species of the peptide are present: (i.) S-Se “bridge” (theoretical m/z = 342.00, 
displayed in chemical structure), and (ii.) the doubly (5-Npys) protected species 
(theoretical m/z = 651.99, displayed in chemical structure). (B and C) The Se isotope 














Figure 4.10: Mass spectrum of tripeptide: H-Cys-Sec-Gly-OH, after cleavage from 
the resin with contaminant DTNP deprotection. (A) The m/z spectra, showing three 
major species are present: (i.) S-Se “bridge” (theoretical m/z = 327.98), (ii.) peptide 
disulfide or diselenide with single (5-Npys) adduct (theoretical m/z+2 = 482.98), and (iii.) 
the doubly (5-Npys) protected species (theoretical m/z = 637.96). (B and C) High 
resolution Se isotope patterns for the major species are expanded. The structures 








Figure 4.11: Mass spectrum of mTrxR-CUG C-terminus redox center peptide. 
Sample was not reduced and alkylated prior to MS analysis, so Cys/Sec residues are in 
the selenosulfide bridge, as displayed in the structure provided. The theoretical m/z is 










Figure 4.12: Mass spectrum of mTrxR-C(αMe)UG C-terminus redox center 
peptide. Sample was not reduced and alkylated prior to MS analysis, so Cys/Sec residues 
are in the selenosulfide bridge, as displayed in the structure provided. The theoretical 










Figure 4.13: Mass spectrum of mTrxR N-terminus redox center peptide. Sample 
was not reduced and alkylated prior to MS analysis, so Cys residues are in the disulfide 
bridge, as displayed in the structure provided. The theoretical m/z is given as the exact 










Figure 4.14: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with Trx 









Figure 4.15: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with 









Figure 4.16: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with 














Figure 4.17: Michaelis–Menten kinetics 
of semi-synthetic mTrxR enzymes with 
DTNB substrate. (A). mTrxR-CUG (wild 
type), (B). mTrxR-C(αMe)UG (mutant), 
















Figure 4.18: Resistance to oxidative 
inactivation of mTrxR-CUG (red), 
mTrxR-C(αMe)UG (green), and 
DmTrxR-CCS (blue). Enzymes were 
incubated with varying [H2O2] for 25 min 
at 22 °C, in KP buffer pH 7. Enzyme 
activity was monitored spectro-
photometrically for substrates: (A) Trx 
substrate (130 µM Trx), (B) H2O2 substrate 
(250 mM), and (C) DTNB substrate (2mM 
DTNB). The activities represent the 
amount of activity remaining relative to the 
oxidant-untreated control. For (B), 
DmTrxR-CCS is not included as it lacks 
the selenium atom necessary to reduce 
peroxides. For plots (A-C), the error bars 
represent the standard deviation from three 
or more trials and are normalized to the 










Figure 4.20: Inhibition of TrxR enzymes by acrolein. (A) inhibition of mTrxR-CUG 
(WT) and mTrxR-C(αMe)UG (mutant) by acrolein after 10 min incubation in 100 mM 
potassium phosphate, 1 mM EDTA, pH 7 buffer at 22 °C. (B) Inhibition of DmTrxR-











Figure 4.21: Inhibition of mTrxR enzymes by 4-HNE and curcumin. (A) inhibition 
of mTrxR-CUG (WT) and mTrxR-C(αMe)UG (mutant) by 4-hydroxynonenal after 20 
min incubation in 100 mM potassium phosphate, 1 mM EDTA, pH 7 buffer at 22 °C. 
(B) inhibition of mTrxR-CUG (WT) and mTrxR-C(αMe)UG (mutant) by curcumin after 







Figure 4.22: Inhibition of TrxR by acrolein and subsequent reversal of acrolein 
inhibition using H2O2 and imidazole. For all, Trx reductase activity was monitored by 
depletion of NADPH spectrophotometrically at A340. mTrxR-CUG (red), mTrxR-
C(αMe)UG (green), and DmTrxR-CCS (blue) were inhibited by acrolein (condition 
1), and no reversal reaction was attempted for this condition. Next, acrolein adduction 
was reversed via one of the following: (condition 2) 5 mM imidazole; (condition 3) 
2 mM H2O2; or (condition 4) 2 mM H2O2 and 5 mM imidazole. All “reversal” reactions 
were conducted in 200 mM KP, 1 mM EDTA, pH 7, at 37 °C for 10 min. Condition 0 
(control) represents the normalized Trx reductase activity of all enzymes before acrolein 
inhibition or reversal, and all other bars represent the amount of activity remaining 







Figure 4.23: Adduction and 
reversal of mTrxR-CUG by 
acrolein and GSH. (Top): 
Experimental design for acrolein 
adduction of mTrxR-CUG at pH 
4.5, then reversal by addition of 
GSH at pH 6.4. Here, we did not 
add H2O2 and rely on the enzyme 
to produce its own oxidants. 
(Left): Absorbance at 340 nm 
over 5 min time with Trx 
substrate. A decrease of A340 
indicates consumption of 
NADPH. Each line is an average 
of 6 trials. The black line is the 
acrolein untreated (ethanol) 
control, representing 100% 
activity. Blue and green have been 
treated with acrolein and blue was 
subsequently subjected to reversal 





Table 4.1: Synthesis of H-Cys-(αMe)Cys-Gly-OH using SPPS and PyBrOP coupling 
agent. Each trial highlights a different synthesis where H2N-(αMe)Cys-Gly-resin was 
formed, and Fmoc-Cys(Trt)-OH is to be coupled to the dipeptide using 4-fold excess 
















Crude yield Comments 
1 0.05 
2x 
(22 °C, 3 h) 










(22 °C, 2 h) 
1x 
(22 °C, 12 h) 











(22 °C, 2 h) 
1x 
(22 °C, 12 h) 
 
No 
N/A (no desired peptide 
detected). 
Could not 




(22 °C, 2 h) 
1x 
(22 °C, 12 h) 




Not able to 
estimate due 









(22 °C, 2 h) 
1x 
(22 °C, 12 h) 











(37 °C, 2 h) 
2x 
(22 °C, 12 h) 
No 





peptide at all. 
7 0.1 
6x 
(37 °C, 2 h) 
2x 
(37 °C, 12 h) 
No 









Table 4.2: Full MS digest of mTrxR-CUG enzyme. 





Notes and modifications 
detected 
GGQQSFDLLVIGGGSGGLACAK 35-56 2092 N/A Cys54(CAM) 
EAAQLGK 57-63 716.39 716.39 
 
(K)VAVADYVEPSPR 65-76 1302.7 1430.8 
Only detected with N-term 
Lys missed cleave 
WGLGGTCVNVGCIPK 80-94 1617.8 1617.8 
N-term redox center, 
Cys86,91(CAM) 
(K)LMHQAALLGGMIR 96-108 1410.8 1538.9 
Only detected with N-term 
Lys missed cleave 
DAHHYGWEVAQPVQHNWK 109-126 2202 2202 
 
TMAEAVQNHVK 127-137 1227.6 1227.6 
 
SLNWGHR 138-144 869.44 869.44 
 
VQLQDR 145-150 758.42 758.42 
 
YFNIK 154-158 684.37 911.53 
 
ASFVDEHTVR 159-168 1160.6 1160.6 
 
ATLLSAEHIVIATGGRPR 176-193 1862.1 1862.1 
 
YPTQVK 194-199 735.4 735.4 
 
GALEYGITSDDIFWLK 200-215 1827.9 1827.9 
 
ESPGK 216-220 517.26 517.26 
 
TLVVGASYVALECAGFLTGIGLDTTVMMR-     
-(SIPLR) 
221-249 3045.5 3714.8 
Missed cleave fused with 
adjacent SIPLR; no CAM, 
2 phosph. detected 
SIPLR 250-254 585.37 585.37 
 
GFDQQMSSLVTEHMESHGTQFLK 255-277 2637.2 N/A 
 
GCVPSHIK 278-285 897.46 897.46 Cys279(CAM) 
LPTNQLQVTWEDHASGK 287-303 1924 1924 
 
EDTGTFDTVLWAIGR 304-318 1680.8 1680.8 
 
VPETR 319-323 601.33 601.33 
 
TLNLEK 324-329 717.41 717.41 
 
AGISTNPK 330-337 787.43 787.43 
 
IIVDAQEATSVPHIYAIGDVAEGRPELTPTAIK 341-373 3474.8 3474.8 
 




386-441 6349 N/A 
Cys407(CAM) 
DASQCYIK 442-449 984.45 984.45 Cys446(CAM) 
MVCMR 450-454 696.3 696.3 Cys452(CAM) 
EPPQLVLGLHFLGPNAGEVTQGFALGIK 455-482 2902.6 2902.6 
 
CGASYAQVMQTVGIHPTCSE EVVK 483-506 2651.2 2651.2 Cys483,500(CAM) 
LHISK 507-511 597.37 597.37 
 
SGLEPTVTGCUG 513-524 1285.5 1285.5 
C-term redox center, 
Cys522(CAM) Sec523(CAM) 
     




Table 4.3: Full MS digest of mTrxR-C(αMe)UG enzyme. 





Notes and modifications 
detected 
GGQQSFDLLVIGGGSGGLACAK 35-56 2,092.05 N/A Cys54(CAM) 
EAAQLGK 57-63 716.39 716.39373  
VAVADYVEPSPR 65-76 1,302.67 1302.668  
WGLGGTCVNVGCIPK 80-94 1,617.79 1617.787 
N-term redox center, 
Cys86,91(CAM) 
LMHQAALLGGMIR 96-108 1,410.77 1538.866 Missed Cleavage 
DAHHYGWEVAQPVQHNWK 109-126 2,202.03 2202.026  
TMAEAVQNHVK 127-137 1,227.62 1227.615  
SLNWGHR 138-144 869.44 869.4377  
VQLQDR 145-150 758.42 758.4155  
YFNIK 154-158 684.37 684.3715  
ASFVDEHTVR 159-168 1,160.57 1160.5694  
ATLLSAEHIVIATGGRPR 176-193 1,862.06 1862.0606  
YPTQVK 194-199 735.40 735.40357  
GALEYGITSDDIFWLK 200-215 1,827.92 1827.9163  
ESPGK 216-220 517.26 517.26165  
TLVVGASYVALECAGFLTGIGLDTTVMMR 221-249 3,045.55 3614.7191 
Missed Cleavage, 
Cys233(CAM) 
SIPLR 250-254 585.37 585.37187  
GFDQQMSSLVTEHMESHGTQFLK 255-277 2,637.21 2637.2072  
GCVPSHIK 278-285 897.46 897.4611 Cys279(CAM) 
LPTNQLQVTWEDHASGK 287-303 1,923.96 1923.9559  
EDTGTFDTVLWAIGR 304-318 1,680.82 N/A  
VPETR 319-323 601.33 601.3304  
TLNLEK 324-329 717.41 717.41413  
AGISTNPK 330-337 787.43 787.43084  
IIVDAQEATSVPHIYAIGDVAEGRPELTPTAIK 341-373 3,474.85 3474.8478  
LLAQR 377-381 600.38 600.38277  
SSTLMDYSNVPTTVFTPLEYGCVGLSEEEA-
-VALHGQEHVEVYHAYYKPLEFTVADR 
386-441 6,349.01 N/A Cys407(CAM) 
DASQCYIK 442-449 984.45 984.44551 Cys446(CAM) 
MVCMR 450-454 696.30 696.29898 Cys452(CAM) 
EPPQLVLGLHFLGPNAGEVTQGFALGIK 455-482 2,902.58 2902.5825  
CGASYAQVMQTVGIHPTCSE EVVK 483-506 2,651.23 2651.2262 Cys483,500(CAM) 
LHISK 507-511 597.37 597.37187  
SGLEPTVTGC(αMe)UG 513-524 1,299.48 1299.4788 
C-term redox center, 
Cys522(CAM), 
(αMe)Sec523(CAM) 
     





Table 4.4, (A): Kinetic parameters of mTrxR enzymes with E. coli Trx. 
Enzyme kcat (min-1) KM (M) kcat/KM (min
-1 M-1) kcat/KM(mutant) 
/kcat/KM(WT) 
mTrxR-CUG 1770  60 42  4.4 4.2 x107 – 
mTrxR-
C(Me)UG 
15  0.76 26  4.8 5.8 x105 0.0138 
mTrxR a NA NA NA – 
aThe truncated enzyme ends at glycine 487 and is missing the C-terminal tripeptide. 




Table 4.4, (B): Kinetic parameters of mTrxR enzymes with H2O2. 
Enzyme kcat (min-1) KM (mM) kcat/KM (min-1 M-1) kcat/KM(mutant) 
/kcat/KM(WT) 
mTrxR-CUG 1110  62 134  16 8.2 x103 – 
mTrxR-
C(Me)UG 
10.5  0.5 35  8.0 3.0 x102 0.037 
mTrxR a NA NA NA NA 
aThe truncated enzyme ends at glycine 487 and is missing the C-terminal tripeptide. 




Table 4.4, (C):  Kinetic parameters of mTrxR enzymes with DTNB. 
Enzyme kcat (min-1) KM (M) kcat/KM (min
-1 M-1) kcat/KM(mutant) 
/kcat/KM(WT) 
mTrxR-CUG 3170  450 3  0.7 1.1 x109 – 
mTrxR-
C(Me)UG 
1125  145 5  0.9 2.3 x108 0.209 
mTrxR a 2900  500 12  2.7 2.4 x108 0.218 




Table 4.4, (D): Kinetic parameters of mTrxR enzymes with selenocysteamine. 
Enzyme kcat (min-1) KM (M) kcat/KM (min
-1 M-1) kcat/KM(mutant) 
/kcat/KM(WT) 
mTrxR-CUG 3740  450 79  0.7 4.7 x107 – 
mTrxR-
C(Me)UG 
50  145 92  0.9 5.4 x105 0.011 





Table 4.5: Half maximal inhibitory concentration (IC50) of RES for TrxR enzymes. 
Enzyme RES IC50 
mTrxR-CUG  Acrolein 231 nM 
mTrxR-CUG 4-HNE 235 µM 
mTrxR-CUG Curcumin 34 µM 
mTrxR-CUG Cinnamaldehyde 225 µM 
mTrxR-CUG Dimethylfumarate >1 mM 
mTrxR-C(αMe)UG Acrolein 57 nM 
mTrxR-C(αMe)UG 4-HNE 118 µM 
mTrxR-C(αMe)UG Curcumin >100 µM 
mTrxR-C(αMe)UG Cinnamaldehyde 230 µM 
mTrxR-C(αMe)UG Dimethylfumarate >1 mM 
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